Anti-CLEC2D antibodies and methods of use thereof

Abstract

The present application disclosure relates to anti-CLEC2D ( CLEC2D encodes the gene for the Lectin Like Transcript-1 -LLT1- protein which is a functional ligand for the human NKR-P1A receptor) antibodies and related compositions and methods of use thereof. These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases.

Description

Related Application

[001] This application claims priority to and the benefit of Indian Provisional Patent Application No. 201941005395, filed on February 11, 2019, the entire contents of which are incorporated herein by reference. Incorporation-by-Reference of Sequence Listing

[0002] The contents of the text file named ZMTR-001 001WO Sequence Listing which was created on June 2, 2020, and is 3.43 megabytes in size, are incorporated herein by reference in their entirety. Technical Field

[003] The present disclosure relates to immunology, especially immune-oncology. Particularly, this disclosure relates to novel antibody molecules against CLEC2D antigen. This disclosure also relates to multiple formats and amino acid compositions of the disclosed antibody molecules, variable regions of the heavy and light chains of the antibody molecules, and CDR composition and length distribution against CLEC2D antigen. The compositions of this disclosure can be used either as monotherapies or in combination with other antibody molecules or any other therapeutic agents that are relevant for the treatment or prevention of diseases, such as cancer. Background

[004] Modulation of immune cell checkpoint receptors via antibody-based / directed therapeutic approaches has been gaining constant interest over the last decade. Many of these receptors are involved in T cell checkpoint modulation. However, B cell, natural killer (NK) cell, and myeloid cell checkpoint modulation is attracting attention.

[005] NK cells are part of the innate immunity which recognize and induce cytotoxicity against a wide range of target cells, such as tumor cells or virus infected cells. In addition, NK cells participate in the initiation and progress of the adaptive immune response through the production of various cytokines. Usually, these responses are regulated by the interaction of a wide array of activating and inhibitory receptors with ligands on the surface of the target cells and immune cells.

[006] The NK cell receptors are divided into two main structural classes: the immunoglobulin and C-type lectin-like (CTL) superfamilies. The NKR-P1 receptors (e.g., CD161) are a family of C-type lectin-like transmembrane molecules that are important immuno-regulatory genes and are expressed on various cell types, including spleen dendritic cells, subsets ofT cells and granulocytes. The Lectin-Like Transcript 1 (LLT1) or C-Type Lectin Domain Family 2 Member D (CLEC2D) or osteoclast inhibitory lectin (OCIL) molecule is a ligand for the CD161 receptor and this interaction differentially regulates the NK cell and T cell function. There are six splice variants of CLEC2D, isoform 1 being the canonical sequence which is expressed on NK cells, T cells, monocytes / 7macrophages, activated B cells and dendritic cells, and functions as a human NK cell activating receptor. The polypeptide chain of CLEC2D can be divided into the N-terminal cytoplasmic part, trans-membrane and stalk regions and C-terminal CTL ectodomain with two predicted N-glycosylation sites.

[007] CLEC2D and CD161 interaction leads to escape from the host defense in several disease scenarios, including various cancers. Such immune escape has been reported in human glioblastoma and other diseases. Moreover, CLEC2D expression on B cells is thought to regulate cross-talk between NK cells and antigen presenting cells (APC). Blocking CLEC2D-CD161 interaction therefore provides a new therapeutic option for the treatment of various cancers.

[008] The downstream signaling of CLEC2D-CD161 interactions is poorly understood. The interaction of CLEC2D / CD161 inhibits NK cell functions and stimulates T cell proliferation and secretion of cytokines. Hence, the effects of CLEC2D / CD161 interaction could be reversed by using monoclonal antibodies specifically binding to CLEC2D, and disrupting the interaction between CLEC2D and its known receptor CD161 or other unknown cellular mechanisms. Summary

[009] The disclosure provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises a sequence selected from the group consisting of: (a) a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 46, SEQ ID NO: 65, SEQ ID NO: 59, and SEQ ID NO: 99; (b) a sequence that is at least 80%, at least 81%, at least 82%, at least 83% , at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 57, SEQ ID NO: 91, SEQ ID NO: 98, SEQ ID NO: 84, SEQ ID NO: 58, SEQ ID NO: 88, SEQ ID NO: 96, SEQ ID NO: 47, SEQ ID NO: 17, and SEQ ID NO: 8; (c) a sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 93, SEQ ID NO: 53, SEQ ID NO: 95, SEQ ID NO: 23, SEQ ID NO: 103, and SEQ ID NO: 7; (d) a sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 45, SEQ ID NO: 15, SEQ ID NO: 51, SEQ ID NO: 44, SEQ ID NO: 73, SEQ ID NO: 36, SEQ ID NO: 77, SEQ ID NO: 50, and SEQ ID NO: 6; (e) a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identical or 100% identical to a sequence selected from SEQ ID NO: 97, SEQ ID NO: 16, SEQ ID NO: 76, SEQ ID NO: 9, SEQ ID NO: 89, SEQ ID NO: 107, SEQ ID NO: 68, SEQ ID NO: 29, SEQ ID NO: 67, SEQ ID NO: 74, SEQ ID NO: 32, SEQ ID NO:81, SEQ ID NO: 106, SEQ ID NO:31, SEQ ID NO: 62, SEQ ID NO: 48, SEQ ID NO: 75, SEQ ID NO: 12, SEQ ID NO: 102, SEQ ID NO: 54, SEQ ID NO: 80, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 92, SEQ ID NO: 108, and SEQ ID NO: 79; (f) a sequence that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identical or 100% identical to a sequence selected from SEQ ID NO: 105, SEQ IDNO:101, SEQ ID NO: 4, SEQ ID NO: 72, SEQ ID NO: 28, SEQ ID NO: 64, SEQ ID NO: 25, SEQ ID NO: 60, SEQ ID NO: 55, SEQ ID NO: 52, SEQ ID NO: 27, SEQ ID NO: 43, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 14, SEQ ID NO: 85, SEQ ID NO: 13, SEQ ID NO: 61, SEQ ID NO: 42, SEQ ID NO: 39, SEQ ID NO: 10, SEQ ID NO: 49, SEQ ID NO: 24, SEQ ID NO: 40, SEQ ID NO: 63, SEQ ID NO: 78, SEQ ID NO: 2, SEQ ID NO: 94, and SEQ ID NO: 5; (g) a sequence that is at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identical or 100% identical to a sequence selected from SEQ ID NO: 11, SEQ ID NO: 35, SEQ ID NO: 86, SEQ ID NO: 22, SEQ ID NO: 69, SEQ ID NO: 41, SEQ ID NO: 3, SEQ ID NO: 66, SEQ ID NO: 37, SEQ ID NO: 56, SEQ ID NO: 21, SEQ ID NO: 38, SEQ ID NO: 90, SEQ ID NO: 100, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 83, SEQ ID NO: 1, and SEQ ID NO: 19; and (h) a sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identical or 100% identical to a sequence selected from SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 87, SEQ ID NO: 82, and SEQ ID NO: 104, wherein the antibody or antigen-binding fragment thereofbinds to C-Type Lectin Domain Family 2 Member D (CLEC2D).

[010] The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the light chain comprises a sequence selected from the group consisting of: (a) sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 218, SEQ ID NO: 249, SEQ ID NO: 230, SEQ ID NO: 279, SEQ ID NO: 316, SEQ ID NO: 237, SEQ ID NO: 322, SEQ ID NO: 225, SEQ ID NO: 318, SEQ ID NO: 233, SEQ ID NO: 305, SEQ ID NO: 280, SEQ ID NO: 283, SEQ ID NO: 242, SEQ ID NO: 286, SEQ ID NO: 297, SEQ ID NO: 309, and SEQ ID NO: 246; (b) a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 222, SEQ ID NO: 258, SEQ ID NO: 219, SEQ ID NO: 313, SEQ ID NO: 294, SEQ ID NO: 303, SEQ ID NO: 317, SEQ ID NO: 273, SEQ ID NO: 266, SEQ ID NO: 315, SEQ ID NO: 257, SEQ ID NO: 288, SEQ ID NO: 301, SEQ ID NO: 221, SEQ ID NO: 240, SEQ ID NO: 299, SEQ ID NO: 247, SEQ ID NO: 263, and SEQ ID NO: 274; (c) a sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 231, SEQ ID NO: 250, SEQ ID NO: 260, SEQ ID NO: 226, SEQ ID NO: 271, SEQ ID NO: 256, SEQ ID NO: 272, SEQ ID NO: 278, SEQ ID NO: 302, SEQ ID NO: 320, SEQ ID NO: 295, SEQ ID NO: 292, SEQ ID NO: 229, SEQ ID NO: 264, SEQ ID NO: 252, SEQ ID NO: 267, SEQ ID NO: 304, SEQ ID NO: 300, SEQ IDNO:311, and SEQ ID NO: 324; (d) a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 259, SEQ ID NO: 239, SEQ ID NO: 281, SEQ ID NO: 228, SEQ ID NO: 217, SEQ ID NO: 227, and SEQ ID NO: 251; (e) a sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100%identical to a sequence selected from SEQ ID NO: 307, SEQ ID NO: 262, SEQ ID NO: 253, SEQ ID NO: 276, SEQ ID NO: 323, SEQ ID NO: 234, SEQ ID NO: 261, SEQ ID NO: 312, and SEQ ID NO: 290; (f) a sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 254, SEQ ID NO: 289, SEQ ID NO: 238, SEQ ID NO: 268, SEQ ID NO: 248, SEQ ID NO: 284, SEQ ID NO: 244, SEQ ID NO: 310, SEQ ID NO: 243, SEQ ID NO: 285, SEQ ID NO: 220, SEQ ID NO: 255, SEQ ID NO: 293, SEQ ID NO: 298, SEQ ID NO: 235, SEQ ID NO: 319, SEQ ID NO: 245, SEQ ID NO: 224, SEQ ID NO: 291, SEQ ID NO: 277, and SEQ ID NO: 232; and (g) a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 282, SEQ ID NO: 308, SEQ ID NO: 287, SEQ ID NO: 321, SEQ ID NO: 236, SEQ ID NO: 265, SEQ ID NO: 270, SEQ ID NO: 275, SEQ ID NO: 306, SEQ ID NO: 296, SEQ ID NO: 241, SEQ ID NO: 314, and SEQ ID NO: 223; wherein the antibody or antigen-binding fragment thereofbinds to CLEC2D. [OH] The disclosure provides isolated antibodies or antigen-binding fragments thereof, comprising: (a) a heavy chain comprising a sequence selected from: (i) a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 46, SEQ ID NO: 65, SEQ ID NO: 59, and SEQ ID NO: 99; (ii) a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 57, SEQ ID NO: 91, SEQ ID NO: 98, SEQ ID NO: 84, SEQ ID NO: 58, SEQ ID NO: 88, SEQ ID NO: 96, SEQ ID NO: 47, SEQ ID NO: 17, and SEQ ID NO: 8; (iii) a sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 93, SEQ ID NO: 53, SEQ ID NO: 95, SEQ ID NO: 23, SEQ ID NO: 103, and SEQ ID NO: 7; (iv) a sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 45, SEQ ID NO: 15, SEQ ID NO:51, SEQ ID NO: 44, SEQ ID NO: 73, SEQ ID NO: 36, SEQ ID NO: 77, SEQ ID NO: 50, and SEQ ID NO: 6; (v) a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 97, SEQ ID NO: 16, SEQ ID NO: 76, SEQ ID NO: 9, SEQ ID NO: 89, SEQ ID NO: 107, SEQ ID NO: 68, SEQ ID NO: 29, SEQ ID NO: 67, SEQ ID NO: 74, SEQ ID NO: 32, SEQ ID NO: 81, SEQ ID NO: 106, SEQ ID NO:31, SEQ ID NO: 62, SEQ ID NO: 48, SEQ ID NO: 75, SEQ ID NO: 12, SEQ ID NO: 102, SEQ ID NO: 54, SEQ ID NO: 80, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 92, SEQ ID NO: 108, and SEQ ID NO: 79; (vi) a sequence that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 105, SEQ IDNO:101, SEQ ID NO: 4, SEQ ID NO: 72, SEQ ID NO: 28, SEQ ID NO: 64, SEQ ID NO: 25, SEQ ID NO: 60, SEQ ID NO: 55, SEQ ID NO: 52, SEQ ID NO: 27, SEQ ID NO: 43, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 14, SEQ ID NO: 85, SEQ ID NO: 13, SEQ ID NO: 61, SEQ ID NO: 42, SEQ ID NO: 39, SEQ ID NO: 10, SEQ ID NO: 49, SEQ ID NO: 24, SEQ ID NO: 40, SEQ ID NO: 63, SEQ ID NO: 78, SEQ ID NO: 2, SEQ ID NO: 94, and SEQ ID NO: 5; (vii) a sequence that is at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO:11, SEQ ID NO: 35, SEQ ID NO: 86, SEQ ID NO: 22, SEQ ID NO: 69, SEQ ID NO: 41, SEQ ID NO: 3, SEQ ID NO: 66, SEQ ID NO: 37, SEQ ID NO: 56, SEQ ID NO: 21, SEQ ID NO: 38, SEQ ID NO: 90, SEQ ID NO: 100, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 83, SEQ ID NO: 1, and SEQ ID NO: 19; and (viii) a sequence that is at least 35%, at least 40%,a t least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 87, SEQ ID NO: 82, and SEQ ID NO: 104; and (b) a light chain comprising a sequence selected from: (i) a sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 218, SEQ ID NO: 249, SEQ ID NO: 230, SEQ ID NO: 279, SEQ ID NO: 316, SEQ ID NO: 237, SEQ ID NO: 322, SEQ ID NO: 225, SEQ ID NO: 318, SEQ ID NO: 233, SEQ ID NO: 305, SEQ ID NO: 280, SEQ ID NO: 283, SEQ ID NO: 242, SEQ ID NO: 286, SEQ ID NO: 297, SEQ ID NO: 309, and SEQ ID NO: 246; (ii) a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 222, SEQ ID NO: 258, SEQ ID NO: 219, SEQ ID NO: 313, SEQ ID NO: 294, SEQ ID NO: 303, SEQ ID NO: 317, SEQ ID NO: 273, SEQ ID NO: 266, SEQ ID NO: 315, SEQ ID NO: 257, SEQ ID NO: 288, SEQ ID NO: 301, SEQ ID NO: 221, SEQ ID NO: 240, SEQ ID NO: 299, SEQ ID NO: 247, SEQ ID NO: 263, and SEQ ID NO: 274; (iii) a sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 231, SEQ ID NO: 250, SEQ ID NO: 260, SEQ ID NO: 226, SEQ ID NO: 271, SEQ ID NO: 256, SEQ ID NO: 272, SEQ ID NO: 278, SEQ ID NO: 302, SEQ ID NO: 320, SEQ ID NO: 295, SEQ ID NO: 292, SEQ ID NO: 229, SEQ ID NO: 264, SEQ ID NO: 252, SEQ ID NO: 267, SEQ ID NO: 304, SEQ ID NO: 300, SEQ IDNO:311, and SEQ ID NO: 324; (iv) a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 259, SEQ ID NO: 239, SEQ ID NO: 281, SEQ ID NO: 228, SEQ ID NO: 217, SEQ ID NO: 227, and SEQ ID NO: 251; (v) a sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 307, SEQ ID NO: 262, SEQ ID NO: 253, SEQ ID NO: 276, SEQ ID NO: 323, SEQ ID NO: 234, SEQ ID NO: 261, SEQ ID NO: 312, and SEQ ID NO: 290; (vi.) a sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 254, SEQ ID NO: 289, SEQ ID NO: 238, SEQ ID NO: 268, SEQ ID NO: 248, SEQ ID NO: 284, SEQ ID NO: 244, SEQ ID NO: 310, SEQ ID NO: 243, SEQ ID NO: 285, SEQ ID NO: 220, SEQ ID NO: 255, SEQ ID NO: 293, SEQ ID NO: 298, SEQ ID NO: 235, SEQ ID NO: 319, SEQ ID NO: 245, SEQ ID NO: 224, SEQ ID NO: 291, SEQ ID NO: 277, and SEQ ID NO: 232; and (vii) a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 282, SEQ ID NO: 308, SEQ ID NO: 287, SEQ ID NO: 321, SEQ ID NO: 236, SEQ ID NO: 265, SEQ ID NO: 270, SEQ ID NO: 275, SEQ ID NO: 306, SEQ ID NO: 296, SEQ ID NO: 241, SEQ ID NO: 314, and SEQ ID NO: 223; wherein the antibody or antigen-binding fragment thereofbinds to CLEC2D.

[012] The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises a sequence selected from any one of SEQ ID NOs: 1-108.

[013] The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the light chain comprises a sequence selected from any one of SEQ ID NOs: 217-324.

[014] The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises a sequence selected from any one of SEQ ID NOs: 1-108, and the light chain comprises a sequence selected from any one of SEQ ID NOs: 217-324.

[015] The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises: (i) a heavy chain (HC) CDR1 comprising a sequence selected from SEQ ID NOs: 433-485; (ii) an HC CDR2 comprising a sequence selected from SEQ ID NOs: 486-546; and (iii) an HC CDR3 comprising a sequence selected from SEQ ID NOs: 547-653, wherein the antibody or antigen-binding fragment thereofbinds to CLEC2D.

[016] The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the light chain comprises: (i) a light chain (LC) CDR1 comprising a sequence selected from SEQ ID NOs: 654-726; (ii) an LC CDR2 comprising a sequence selected from SEQ ID NOs: 727-783; and (iii) an LC CDR3 comprising a sequence selected from SEQ ID NOs: 784-885; wherein the antibody or antigen-binding fragment thereofbinds to CLEC2D.

[017] The disclosure provides isolated antibodies or antigen-binding fragments thereof, comprising: a heavy chain comprising an HC CDR1 sequence selected from SEQ ID NOs: 433485, an HC CDR2 sequence selected from SEQ ID NOs: 486-546, and an HC CDR3 sequence selected from SEQ ID NOs: 547-653; a light chain comprising a LC CDR1 sequence selected from SEQ ID NOs: 654-726, a LC CDR2 sequence selected from SEQ ID NOs: 727-783, and a LC CDR3 sequence selected from SEQ ID NOs: 784-885; or a combination thereof.

[018] In some embodiments of the antibodies or antigen binding fragments thereof of the disclosure, the antibody or antigen-binding fragment thereofbinds to: a human CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 886-909; a human CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 930-1003; a cynomolgus CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 918-920; a mouse CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 911-915; arat CLEC2D polypeptide comprising a sequence of SEQ ID NO: 910; and / or a dog CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 916-917.

[019] The disclosure provides an isolated antibody or antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain complementarity determining region (CDRH) 1, CDRH2 and CDRH3 amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1,Y1, E2, I2 and L2, as disclosed in Table 9A, and wherein the light chain comprises a light chain complementarity determining region (CDRL)1, CDRL2 and CDRL3 amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1,Y1, E2, I2 and L2, as disclosed in Table 9A.

[020] The disclosure provides an isolated antibody or antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain comprises a variable heavy chain amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of: A1,B1,E1,P1,U1,Y1, E2, I2 and L2, as disclosed in Table 9A, and wherein the light chain comprises a variable light chain amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1,Y1, E2, I2 and L2, as disclosed in Table 9A.

[021] The disclosure provides an isolated antibody or antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain frame work region sequence of a Germline family of an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1,Y1, E2, I2 and L2, ofTable 9B, as disclosed herein, and wherein the light chain comprises a frame work region sequence of a light chain Germline family of an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1, Y1, E2, I2 and L2, ofTable 9B, as disclosed herein.

[022] In some embodiments of the antibodies or antigen binding fragments thereof of the disclosure, the antibody or antigen-binding fragment thereof is a monoclonal antibody.

[023] In some embodiments of the antibodies or antigen binding fragments thereof of the disclosure, the antibody or antigen-binding fragment thereofblocks binding of CLEC2D to a receptor. In some embodiments, the receptor comprises a CD161 receptor, and the CD161 receptor comprises a sequence selected from SEQ ID NOs: 921-929.

[024] In some embodiments of the antibodies or antigen binding fragments thereof of the disclosure, the antibody or antigen-binding fragment thereof is human, murine or chimeric. In some embodiments, the antigen-binding fragment is selected from the group consisting of Fv, Fav, F(ab’)2, Fab’, dsFv, scFv, sc(Fv)2, scFv-CH3, scFv-Fc, and diabody fragments. In some embodiments, the antibody or antigen-binding fragment thereofbinds to human CLEC2D with an affinity (KD) ofless than 100 nM.

[025] The disclosure provides pharmaceutical compositions comprising peptides (e.g., antibodies or antigen-binding fragments thereof) or nucleic acids described in the disclosure.

[026] The disclosure provides pharmaceutical compositions comprising antibodies or antigenbinding fragments thereof of the disclosure.

[027] The disclosure provides pharmaceutical compositions comprising nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

[028] In some embodiments of the pharmaceutical compositions of the disclosure, the pharamaceutical composition further comprises at least one of a buffer, a pharmaceutically acceptable diluent, a carrier, a solubilizer, an emulsifier, and a preservative.

[029] The disclosure provides isolated nucleic acids comprising a polynucleotide sequence that encodes an amino acid heavy chain sequence selected from SEQ ID NOs: 109-216.

[030] The disclosure provides isolated nucleic acids comprising a polynucleotide sequence that encodes an amino acid light chain sequence selected from SEQ ID NOs: 325-432.

[031] The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a heavy chain comprising a CDRH1, CDRH2 and CDRH3 amino acid sequence according to the CDRH1, CDRH2 and CDRH3 amino acid sequence respectively, of an anti-CLEC2D antibody selected from the group consisting of:A1,B1, E1,P1,U1,Y1, E2, I2 and L2, ofTable 9A, as disclosed herein.

[032] The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a light chain comprising a CDRL1, CDRL2 and CDRL3 amino acid sequence according to the CDRL1, CDRL2 and CDRL3 amino acid sequence respectively, of an anti- CLEC2D antibody selected from the group consisting of:A1,B1, E1,P1,U1,Y1, E2,12 and L2, ofTable 9A, as disclosed herein.

[033] The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a heavy chain amino acid sequence according to variable heavy chain amino acid sequence of an anti-CLEC2D antibody antibody selected from the group consisting of:A1,B1, E1,P1,U1,Y1, E2,12 and L2, ofTable 9A, as disclosed herein.

[034] The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a light chain amino acid sequence according to variable light chain amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1, U1,Y1, E2,12 and L2, ofTable 9A, as disclosed herein.

[035] The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a heavy chain comprising a framework region amino acid sequence according to heavy chain framework region amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1,Y1, E2,12 and L2, ofTable 9B, as disclosed herein.

[036] The disclosure provides an isolated nucleic acid comprising a polynucleotide sequence that encodes a light chain comprising a framework region amino acid sequence according to light chain framework region amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1,Y1, E2,12 and L2, ofTable 9B, as disclosed herein.

[037] The disclosure provides isolated nucleic acids comprising a polynucleotide sequence that encodes a heavy chain amino acid sequence of an antibody or antigen binding fragment thereof of the disclosure.

[038] The disclosure provides isolated nucleic acids comprising a polynucleotide sequence that encodes a light chain amino acid sequence of an antibody or antigen binding fragment thereof of the disclosure.

[039] The disclosure provides compositions comprising a first nucleic acid that encodes a polypeptide selected from SEQ ID NOs: 109-216 and a second nucleic acid that encodes a polypeptide selected from SEQ ID NOs: 325-432.

[040] The disclosure provides vectors comprising the nucleic acids of the disclosure.

[041] The disclosure provides cells comprising the nucleic acids, nucleic acid compositions or vectors of the disclosure. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is selected from the group consisting of a CHO cell, a 293 cell, an NSO cell, a PER.C6 cell, and a B cell. In some embodiments, the mammalian cell is a 293-6E cell or a DG44 cell. In some embodiments, the cells express the antibodies or antigen binding fragments thereof of the disclosure. In some embodiments, the cell is a germline cell.

[042] The disclosure provides cells producing the antibodies or antigen-binding fragments thereof of the disclosure

[043] The disclosure provides a method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments thereof of the disclosure.

[044] The disclosure provides a composition for use in treating a disease in a subject in need thereof, comprising a therapeutically effective amount of the antibodies or antigen-binding fragments thereof of the disclosure or the nucleic acids encoding the antibodies or antigenbinding fragments thereof of the disclosure.

[045] The disclosure provides a composition for use in the manufacture of a medicament for the prevention or treatment of a disease in a subject in need thereof, comprising a therapeutically effective amount of the antibodies or antigen-binding fragments thereof of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

[046] In some embodiments of the methods or compositions for use of the disclosure, the disease is rheumatoid arthritis. In some embodiments, the subject exhibits bone loss as a result of having rheumatoid arthritis. In some embodiments, administration of a therapeutically effective amount of the antibody or antigen-binding fragment thereof slows or reverses the bone loss in the subject.

[047] In some embodiments of the methods or compositions for use of the disclosure, the disease is a cancer. In some embodiments, the cancer is selected from the group consisting of breast cancer, prostate cancer, endometrial cancer, uterine cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, glioma, glioblastoma, myeloma, pheochromocytoma, paraganglioma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, cervical cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, gastric cancer, intestinal cancer, testicular cancer, skin cancer, thyroid cancer, thymoma, head and neck cancer, liver cancer, pharynx cancer, adrenocortical cancer, cholangiocarcinoma, mesothelioma, sarcoma, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma. In some embodiments, a cell of the cancer expresses CLEC2D on the cell surface. In some embodiments, administration of a therapeutically effective amount of the antibodies or antigen-binding fragments thereof results in an anti-tumor response in the subject.

[048] In some embodiments of the methods or compositions for use of the disclosure, the antibodies or antigen-binding fragments thereof are administered as a monotherapy. In some embodiments, the antibodies or antigen-binding fragments thereof are administered in combination with at least one ofaT cell targeted immunomodulatory agent, a second immunomodulatory agent, a cancer vaccine, an adoptive cell therapy, an oncolytic virus, a second antibody therapy, a radiotherapy, an antibody drug conjugate, a small interfering RNA, a chemotherapy, an immunotherapy, an immune checkpoint inhibitor, a mitotic inhibitor, or a combination thereof. In some embodiments, the adoptive cell therapy comprises a CAR-T therapy. In some embodiments, administration of a therapeutically effective amount of the antibody or antigen-binding fragment thereof alleviates a sign or a symptom of the disease.

[049] The disclosure provides an antibody library comprising at least about 108 unique monoclonal antibody clones, wherein at least about 80% of the antibody clones detectably and specifically bind a CLEC2D antigen.

[050] In some embodiments of the antibody library of the disclosure, the CLEC2D antigen comprises an amino acid sequence selected from SEQ ID NOs: 886-920 and SEQ ID NOs: 9301003. In some embodiments of the antibody library of the disclosure, the CLEC2D antigen comprises an amino acid sequence selected from SEQ ID NOs: 886-909 and SEQ ID NOs: 9301003. In some embodiments, the CLEC2D antigen comprises a CLEC2D antigen expressed on a tumor cell surface, a variant of the CLEC2D antigen, or a homolog of the CLEC2D antigen. In some embodiments, the variant of the CLEC2D antigen comprises a fragment of the CLEC2D protein. In some embodiments, the homolog of the CLEC2D antigen comprises a human, a mouse, a dog, a rat or a cynomolgus CLEC2D.

[051] The disclosure provides a method of modulating immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

[052] The disclosure provides a method of modulating (e.g., increasing) innate immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

[053] The disclosure provides a method of increasing the cytotoxicity of a natural killer cell in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments thereof of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

[054] The disclosure provides a method of modulating (e.g., increasing) adaptive immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

[055] The disclosure provides methods of screening a high diversity antibody gene library for antibodies that to a CLEC2D antibody comprising: (a) inserting a library of antibody genes into a phage protein gene and transforming a plurality of phages to produce a phage library, wherein the phages in the phage library display the library of antibody genes on the surface of the phage; (b) panning the phage library with a CLEC2D antigen for individual phages that bind to the CLEC2D antigen, thereby producing an enriched phage library that is enriched for antibody genes that encode antibodies that bind to the CLEC2D antigen; (c) repeating step (b) at least once or at least twice; (d) transferring the antibody genes from, the enriched phage library to a yeast surface display library; (e) isolating individual yeast cells that bind to the CLEC2D antigen from the yeast surface display library; (f) culturing the isolated individual yeast cells that bind to the CLEC2D antigen to produce yeast surface display library clones; and (g) sequencing the yeast surface display library clones; thereby isolating antibody genes that bind to the CLEC2D antigen.

[056] In some embodiments of the methods of screening of the disclosure, the panning step (b) comprises panning the phage library with CLEC2D coated magnetic beads. In some embodiments, the transferring step (d) comprises cloning the antibody genes into a yeast expression vector and transforming yeast cells. In some embodiments, the methods further comprise analyzing the surface expression of the antibody genes with a FLAG tag, a c-Myc tag, a polyhistidine tag or a V5 tag. In some embodiments, the testing step (e) comprises isolating yeast cells expressing antibody genes that bind to the CLEC2D antigen with flow cytometry. In some embodiments, the method further comprises repeating the flow cytometry isolation at least 1x, at least 2x, at least 3x, at least 4x or at least 5x. In some embodiments, the method further comprises cloning the antibody genes that bind to CLEC2D into a mammalian expression vector.

[057] The disclosure provides methods of making a composition comprising anti-CLEC2D antibodies or antigen binding fragments thereof, comprising (a) transforming mammalian cells with a vector comprising a sequence encoding a promoter and a sequence encoding an anti-CLEC2D antibody or antibody fragment, wherein the sequence encoding the promoter and the anti-CLEC2D antibody or antibody fragment are operably linked; (b) culturing the mammalian cells under conditions suitable for the expression of the anti-CLEC2D antibody or antibody fragment; (c) centrifuging the cultured mammalian cells to produce a supernatant; (d) filtering the supernatant; and (e) purifiying the filtered supernatant using liquid chromatography.

[058] In some embodiments of the methods of the disclosure, the filration step (d) comprises a 3 pm - 30 pm filter. In some embodiments, the filtration step (d) further comprises a 0.22 pm filter. In some embodiments, the purifying step (e) comprises a Protein A column. In some embodiments, the protein A column is treated with a high salt wash buffer to remove host cell proteins. In some embodiments, the ani-CLEC2D antibody of fragment thereof is eluted using 30 mM Phosphate buffer at pH.3.0-4.0. In some embodiments, the purifying step (e) further comprises an anion exchange chromatography (AEX) step. In some embodiments, the AEX step comprises a Q Sepharose column. In some embodiments, the Q Sepharose is pre-equilibrated in a pre-equilibration buffer comprising 10-100 mM Histidine. In some embodiments, the preequilibration buffer further comprises citrate, phosphate 2-(N-morpholino)ethanesulfonic acid (MES), acetate or a combination thereof. In some embodiments, the pre-equilibration buffer comprises a pH of 4.5-6.5. In some embodiments, the anti-CLEC2D antibody is eluted at step (e) with an elution buffer comprising 200-1000 mM NaCl, KCl or a combination thereof. In some embodiments, the elution buffer comprises a pH of4.5-6.5.

[059] In one aspect, this disclosure relates to the isolation of novel monoclonal antibodies that bind specifically to a CLEC2D antigen. The novel antibodies modulate (e.g., inhibit) the interaction of CD161 and CLEC2D to modifyNK cell / immune cell mediated cytotoxicity and / or cytokine production.

[060] In another aspect, this disclosure relates to cancer cells expressing CLEC2D are specifically recognized by these novel antibodies which may kill the tumor cells via ADCC (antibody dependent cellular cytotoxicity) and / or CDC (complement dependent cytotoxicity) and / or ADCP (antibody dependent cellular phagocytosis).

[061] In a related aspect, this disclosure relates to methods of making an anti-CLEC2D antibody, comprising selecting from a high diversity antibody gene library an anti-CLEC2D antibody. In one embodiment, the high diversity antibody gene library is displayed through phage and / or yeast surface display. In one embodiment, the phage- and / or yeast-displayed high diversity antibody gene library is selected using purified CLEC2D antigen as a target. In one embodiment, the selected anti-CLEC2D antibody genes are expressed in a mammalian cell (e.g., Chinese hamster ovary (CHO) cell). In one embodiment, a single cell clone expressing an anti-CLEC2D antibody is expanded into a cell line and verified for anti-CLEC2D antibody expression. In one embodiment, overexpression of selected antibody clones is achieved through defined culture media, supplements, and specific bioreactor processes cumulatively described herein as upstream process development. In one embodiment, the anti-CLEC2D antibodies expressed from the cell line are purified to homogeneity, for example, through various filtration and chromatography, referred to herein as downstream purification processes.

[062] The disclosure provides a method of treating a disease in a subject in need thereof, comprising: determining a level of CLEC2D protein in the subject; and administering a therapeutically effective amount of an anti-CLEC2D antibody to the subject.

[063] In some embodiments of the methods of the disclosure, the disease is a cancer. In some embodiments, the cancer comprises breast cancer, prostate cancer, endometrial cancer, uterine cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, glioma, glioblastoma, myeloma, pheochromocytoma, paraganglioma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, cervical cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, gastric cancer, intestinal cancer, testicular cancer, skin cancer, thyroid cancer, thymoma, head and neck cancer, liver cancer, pharynx cancer, adrenocortical cancer, cholangiocarcinoma, mesothelioma, sarcoma, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, pulmonary adenocarcinoma, adenocarcinoma, acinic cell adenocarcinoma, adrenal cortical carcinomas, alveoli cell carcinoma, anaplastic carcinoma, basaloid carcinoma, basal cell carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, renaladinol carcinoma, embryonal carcinoma, anometroid carcinoma, fibrolamolar liver cell carcinoma, follicular carcinomas, giant cell carcinomas, hepatocellular carcinoma, intraepidermal carcinoma, intraepithelial carcinoma, leptomanigio carcinoma, medullary carcinoma, melanotic carcinoma, menigual carcinoma, mesometonephric carcinoma, oat cell carcinoma, squamal cell carcinoma, sweat gland carcinoma, transitional cell carcinoma, tubular cell carcinoma, ameloblastic sarcoma, angiolithic sarcoma, botryoid sarcoma, endometrial stroma sarcoma, ewing sarcoma, fascicular sarcoma, giant cell sarcoma, granulositic sarcoma, immunoblastic sarcoma,juxaccordial osteogenic sarcoma, coppices sarcoma, leukocytic sarcoma (leukemia), lymphatic sarcoma (lympho sarcoma), medullary sarcoma, myeloid sarcoma (granulocitic sarcoma), austiogenci sarcoma, periosteal sarcoma, reticulum cell sarcoma (histiocytic lymphoma), round cell sarcoma, spindle cell sarcoma, synovial sarcoma, telangiectatic audiogenic sarcoma, Burkitt’s lymphoma, NPDL, NML, NH, diffuse lymphomas, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, B-cell lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma, acute myeloid lymphoma, chronic lymphocytic leukemia, chronic myeoloid leukemia, mantle cell lymphoma, and follicular lymphoma. In some embodiments, a cancer cell of the subject has an elevated level of CLEC2D protein when compared to a normal cell that does not have cancer. In some embodiments, an increased level of CLEC2D is associated with a poor prognostic outcome.

[064] In some embodiments of the methods of the disclosure, the disease is an autoimmune or inflammatory disorder. In some embodiments, the autoimmune or inflammatory disorder is type I diabetes, rheumatoid arthritis, lupus, inflammatory bowel diseases, celiac disease, Crohn disease, ulcerative Colitis, psoriasis, or multiple Sclerosis.

[065] In some embodiments of the methods of the disclosure, the disease is an autoimmune or inflammatory disorder. In some embodiments, the autoimmune disorder is type I diabetes, rheumatoid arthritis, lupus, inflammatory bowel diseases, celiac disease, Crohn disease, ulcerative Colitis, psoriasis, or multiple Sclerosis.

[066] In some embodiments of the methods of the disclosure, the disease is infectious disease. In some embodiments, the disease is HIV infection, human Cytomegalovirus infection, Hepatitis B infection, Hepatitis C infection, Ebola virus infection, Dengue, Yellow fever, Listeriosis, Tuberculosis, Cholera, Malaria, Leishmaniasis, or Trypanosoma infection.

[067] In another aspect, multiple in vitro and in vivo assays are used to characterize the novel antibodies produced from CHO cell lines which include, various biophysical parameters, antigen recognition, tumor cell surface binding, tumor cell death, production of cytokines, and analysis of downstream genes to define mode of action. These monoclonal antibodies are also tested for long term stability, various formulations relevant for therapeutic, prognostic and diagnostic uses in cancer, infectious diseases, autoimmune and chronic diseases. In another aspect, in vivo tumor suppression assays are carried out to establish anti-tumor activity of selected antibodies as monotherapy or in combination with other therapeutic products.

[068] In one aspect, this disclosure further relates to the isolation of novel and unique monoclonal antibodies that bind specifically to CLEC2D antigen. In some aspect, the novel antibodies influence the interaction of CD161 and CLEC2D to modify immune cell (e.g., NK cell, B-cell, or T-cell) mediated cytotoxicity and / or cytokine production. In some aspects, various cancer cells, expressing CLEC2D, are recognized by these novel antibodies and have revealed cytotoxic effects through various means including, ADCC (antibody dependent cellular cytotoxicity) and / or CDC (Complement dependent cytotoxicity and / or ADCP (Antibody dependent cellular phagocytosis). In one aspect, the disclosure provides emphasis and postulates on the role of CLEC2D in cross-talk between lymphocytes and immune tolerance. In another aspect, in the realm of approved therapeutics or those in pre-clinical or clinical testing, the methods for identifying novel antibody molecules and related compositions provided herein comprise pharmaceutical features amenable to manufacturability / developability.

[069] In one aspect, this disclosure relates to a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof of, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of:A1,B1, E1,P1,U1,Y1, E2, I2 and L2, ofTable 9A and B, as disclosed herein.

[070] In one aspect, this disclosure relates to a method of modulating immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1,Y1, E2, I2 and L2, ofTable 9A and B, as disclosed herein.

[071] In one aspect, this disclosure relates to a method of modulating (e.g., increasing) innate immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of:A1,B1, E1,P1,U1,Y1, E2, I2 and L2, ofTable 9A and B, as disclosed herein.

[072] In one aspect, this disclosure relates to a method of modulating (e.g., increasing) adaptive immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of:A1,B1, E1,P1,U1,Y1, E2, I2 and L2, ofTable 9A and B, as disclosed herein.

[073] In one aspect, this disclosure relates to a method of increasing the cytotoxicity of a natural killer cell in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of:A1,B1,E1,P1,U1, Y1, E2, I2 and L2, ofTable 9A and B, as disclosed herein. Brief Description of the Figures

[074] The features of the present disclosure will become fully apparent from the following description taken in conjunction with the accompanying figures. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee. With the understanding that the figures depict only several embodiments in accordance with the disclosure and are not to be considered limiting its scope, the disclosure will be described further through use of the accompanying figures.

[075] FIGS. 1A-1C illustrate present disclosure in a schematic format in: FIG. 1A, scenario wherein CLEC2D and CD161 interacts resulting in tumor cells escaping immune cells; FIG. 1B, scenario wherein interaction between CLEC2D and CD161 is blocked using an anti-CLEC2D antibody, resulting in lysis signal followed by killing of tumor cells; and FIG. 1C, scenario wherein ligation of CLEC2D antigen with anti-CLEC2D antibody resulting in activation ofNK cell and in elevation of cytokine expression followed by enhanced target cell clearance either by direct killing or by involving other immune cells

[076] FIGS. 2 A-2F illustrate expression and purification of CLEC2D antigen in mammalian cell in: FIG. 2A, generation of mammalian expression plasmids to express CLEC2D ecto-domain as soluble antigen. The construct was generated through gene synthesis followed by confirmation through restriction digestion and Sanger sequencing; FIG. 2B, IMAC chromatography profile displaying purification of a soluble CLEC2D (Q72-V191), with inset showing elution profile of the CLEC2D antigen; FIG. 2C, SDS-PAGE profile ofload, wash and final eluted CLEC2D protein, demonstrating that the purified CLEC2D protein was homogenous and pure, and suitable for further downstream experimentation; FIG. 2D, western blot of the purified CLEC2D protein, probed with a commercially available antibody against CLEC2D antigen; FIG. 2E, ELISA assay showing the binding specificity of a commercial antibody against different concentrations of the purified CLEC2D antigen; and FIG. 2F, SDS-PAGE analysis of the purified CLEC2D antigen incubated with PNGase enzyme under reducing conditions for 3 hrs or 6 hrs revealed deglycosylation of CLEC2D antigen.

[077] FIG.3 illustrates a schematic depiction of an antibody library screening strategy: the naive antibody library screened against the target CLEC2D antigen using phage and yeast surface display systems.

[078] FIGS. 4A-4E illustrate phage panning of antibody library with CLEC2D antigen coated on magnetic beads in: FIG. 4A, estimation of magnetic bead conjugation efficiency by flow cytometry; FIG. 4B, restriction enzyme digestion of independent heavy chain clones after panning ofFab library; FIG. 4C, restriction enzyme digestion of independent kappa light chain clones after panning ofFab library; FIG. 4D, restriction enzyme digestion of independent heavy chain clones after panning of ScFv library; and FIG. 4E, restriction enzyme digestion of independent kappa light chain clones after panning of ScFv library.

[079] FIGS. 5A-5H illustrate screening of antibody against CLEC2D using yeast surface display in: FIG. 5A, plate images depicting yeast colony towards generation of ScFv antibody library through electroporation; FIG. 5B, plate images depicting generation ofhaploid heavy and light chain antibody libraries; FIG. 5C, plate images showing mating efficiency ofhaploid yeast strains containing heavy or light chain antibody libraries, wherein mating efficiency was estimated to be ~29% ; FIG. 5D, representative flow cytometric analysis ofbinding of antibody molecules expressed on the yeast cell surface with CLEC2D antigen, the ScFv libraries were sorted multiple times to enrich high affinity yeast clones; FIG. 5E, representative flow cytometric analysis ofbinding of antibody molecules expressed on the yeast cell surface with CLEC2D antigen, the Fab libraries were sorted multiple times to enrich high affinity yeast clones; FIG. 5F, representative data on enrichment of yeast clones after multiple rounds of sorting, both in terms of expression and antigen recognition; FIG. 5G, the individual yeast clones were separated and tested with CLEC2D antigen to identify yeast cell lines expressing high affinity antibody clones; and FIG. 5H, representative flow cytometry data to show the percentage binding of a soluble CLEC2D antigen with monoclonal antibody clones. At least about 80% of the clones detectably and specifically bound to the CLEC2D antigen.

[080] FIGS. 6A-6D illustrate the peer group sequence analysis of clones screened through yeast display platform in: FIG. 6A, bar graph showing the CDRH3 length distribution of selected molecules; FIG. 6B, bar graph displaying relative amino acid frequency distribution for heavy chain CDRH3 (Kabat nomenclature); FIG. 6C, pie chart exhibiting heavy chain consensus family distribution; and FIG. 6D, pie chart exhibiting light chain consensus family distribution.

[081] FIGS. 7A-7B illustrate the mammalian expression constructs used to generate full-length monoclonal antibody in: FIG. 7A, the vector designed to clone selected antibody variable heavy chain genes after screening through phage and yeast display platforms; and FIG. 7B, the vector designed to clone selected antibody variable light chain (kappa) genes after screening through phage and yeast display platforms. Constructs were generated through gene synthesis followed by confirmation through restriction digestion and Sanger sequencing.

[082] FIGS. 8A-8C illustrate mammalian expression system to express full-length CLEC2D on the cell surface, as shown in: FIG. 8A, CLEC2D gene expression construct was generated through gene synthesis followed by confirmation through restriction digestion and Sanger sequencing; and FIG. 8B, flow cytometry with commercially available anti-CLEC2D antibody (4C7) showing expression of CLEC2D on transfected CHO cell surface (C4548); and FIG. 8C, the surface expression of CLEC2D as monitored with anti-CLEC2D (4C7) antibody on fixed and non-permeabilized cells by confocal microscopy (60X). Binding of anti-CLEC2D antibody was observed on C4548 cells whereas no binding was observed in un-transfected CHO cells. The nucleus was counterstained with DAPI (blue). Scale bar is 10pm.

[083] FIGS. 9A-9C illustrate anti-CLEC2D monoclonal antibody clones purified from transiently transfected CHO cell. Antibody was purified using protein A column chromatography, as shown in: FIG. 9A, SDS -PAGE profile of representative Anti-CLEC2D antibodies. The purified antibodies were subjected to SDS-PAGE analysis in both non-reducing and reducing conditions. Anti-CLEC2D Antibody clone purified from C3566 was shown in lane 9, upper panel of reducing and non-reducing gels. All clones from lower panels, except clone in lane 4 revealed good profiles in reducing and non-reducing gels. Clones showing degraded products were not considered for further studies. Similar criteria was employed for other clones as described in example section; FIG. 9B, the interaction of purified anti-CLEC2D antibody with CLEC2D antigen expressed on CHO cell surface through flow cytometry; Representative antibody clones, as exemplified by, C4577, C2907, C3566, C5582, C5397, were evaluated for CLEC2D binding on CHO cell lines either untransfected or transfected with full length CLEC2D construct. Shift in MFI towards right indicated binding of respective clones towards surface expressed CLEC2D antigen; and FIG. 9C, representative images of interaction of anti-CLEC2D antibodies with CLEC2D antigen expressed on PC3 tumor cells. As shown in Table 22 a qualitative rating ofbinding was carried out, “+” indicating low binding to “+++” indicating very high binding. As exemplified, surface binding was not detected with antibody C4252, whereas with antibody C0610, low binding was observed thereby rated as (+) while other clones have showed differential yet significant surface binding. The nucleus was counterstained with DAPI (violet). Scale bar is 10pm.

[084] FIGS. 10A-10E illustrate stable CHO cell line development expressing Anti-CLEC2D antibody, as shown in: FIG. 10A, the binding studies carried out with surface expressed CLEC2D as monitored using supernatant obtained from CHO mini-pool samples transfected with Anti-CLEC2D antibody expression plasmid, using flow cytometry. Histogram represents extent ofbinding against surface CLEC2D antigen expressed on C4548 cell, as observed for various clones. Fold change in MFI has been plotted against individual mini-pools binding. Higher fold change indicating higher binding of anti-CLEC2D antibody to CLEC2D antigen; FIG. 10B, single cell clone screening - Anti CLED2D antibody expressed from single cell clonal lines was purified and used for flow cytometry experiments. Higher fold change in fluorescence signal indicates stronger binding of anti-CLEC2D antibody binding to CLEC2D antigen; FIG. 10C, flow cytometric analysis of monoclonal antibody producing stable CHO cell lines - anti- CLED2D antibody expressed from single cell clonal lines was purified and used for flow cytometry experiments. Multiple monoclonal cell lines expressing the Anti-CLEC2D antibodies were (such as C4608, C5093, C5511, C6481, C6726, C7720, C9103, C5848 and C3452) were tested for binding to CHO cell surface expressed CLEC2D antigen by flow cytometry. Fold increase in median fluorescence intensity was estimated and was observed to be in the range of 3-10 fold for multiple stable clones; FIG. 10D, representative images of interaction of anti-CLED2D monoclonal antibodies produced from clonal CHO cell lines with the CLEC2D antigen expressed on PC3 tumor cell line. As depicted herein, various anti-CLEC2D antibodies showed differential yet significant surface binding to CLEC2D antigen on PC3 cell surface. The nucleus was counterstained with DAPI (violet). Scale bar is 10pm; and FIG. 10E, quantitative RT PCR performed on of anti-CLEC2D antibody- stable cell clones C4608 and C5511 to confirm stable integration of antibody heavy chain and light chain genes. GAPDH house-keeping gene was used as internal normalizer. The study was carried out for 60 generations of CHO monoclonal lines expressing the Anti-CLEC2D antibodies.

[085] FIGS. 11A-11F illustrate functional characterization of monoclonal anti-CLEC2D antibodies, as shown in: FIG. 11A, the binding of anti-CLEC2D antibodies, C4608, C5511, C6481, C2438, C3452, C0949 on surface expressed CLEC2D on prostate cancer cell line, PC3. Shift in MFI towards right indicated binding of antibody to surface expressed CLEC2D antigen on PC3 cell line; and FIG. 11B, representative flow cytometric analysis of cytotoxicity assay performed on PC3 target cells using PBMC as effector cells, at a ratio of1:5 at a fixed concentration of 100ug / mL of Anti-CLEC2D antibodies. Clones assessed for functionality herein were C5511, C4608 and C6481 with PBMC from Donor 1, while antibodies purified from clones C5392 and C3452 were tested with PBMC from Donor 2. The percentage ofPC3 live cells is indicated by APC (eFluor 670) positive cells and dead cells indicates Sytox green-positive cells. Respective single cell clones have been labelled against each plot; FIG. 11C, representative flow cytometry analysis of cytotoxicity assay performed on PC3 target cells using PBMC as effector cells (1:5), with increasing concentrations of anti-CLEC2D antibody (C5511) from 10 pg / mL to 200 ug / mL revealed increased dose dependent tumor cell cytotoxicity; FIG. 11D, representative flow cytometric analysis of cytotoxicity assay performed on PC3 target cells using PBMC as effector cells at fixed concentration of anti-CLEC2D antibody C5511. The tumor to effector cell ratio (T:E) was increased from 1:5to 1:10. The data revealed with increasing proportion of effector cells leads to higher levels of tumor cell cytotoxicity; and FIG. 11E, end point cytotoxicity assay revealed significant cytotoxicity of tumor cells at10 pg / mL. The assay also determines optimum concentration of anti-CLEC2D antibody to kill target cells using confocal microscopy. Upper panel indicates all control treatments where no cytotoxicity was observed as expected, and lower panel indicates the enhanced PC3 tumour cell death when treated with increasing the concentration of anti-CLEC2D antibody (C6726) in presence ofPBMC (T:E = 1:5). The maximum cell death were observed at concentration of 50ug / ml of Anti-CLEC2D antibody. PC3 tumor cells - Green; PBMC - red; Dead cells - Blue; and Fig. 11F, end point cytotoxicity assay using selected anti-CLEC2D antibody to kill target cells using confocal microscopy. No cytotoxicity observed in control treatments like PC3 tumor cell alone, PBMC alone, PBMC with isotype human IgG1 antibody. PC3 tumor cell cytotoxicity was observed when Anti-CLEC2D antibody (C6726, C5848, C4608, C5511 and C6481) clones were used. Size enhanced images revealed PC3 tumor cells were surrounded by effector cells inducing tumor cell death. PC3 tumor cells - Green; PBMC - red; Dead cells - Blue.

[086] FIGS. 12A-12D illustrate NK cell mediated cytotoxicity of tumor cells with anti-CLEC2D antibody, a shown in: FIG. 12A, cytotoxicity ofPC3 tumor cells when treated with purifiedNK cells and anti-CLEC2D antibodies (C6481 & C5511) at 100ug / ml. The data revealed 86% NK cell mediated cytotoxicity of PC3 tumor cells atT:Eof1:1. The percentage of PC3 dead cells indicates Sytox green-positive cells; FIG. 12B, no target cell death was observed when incubated with either isotype control (human IgG1 antibody) or with only NK cells increasing T:E ratio starting from 1:0.5 to 1:10; Scale bar is 10pm and FIG. 12C, anti-CLEC2D antibody alone cannot induce cytotoxicity ofPC3 tumor cell; Scale bar is 10pm and FIG. 12D anti-CLEC2D antibody C5511 (at 50ug / mL) revealed increasing PC3 tumor cell death with increasing T:E ratio starting from 1:0.5, 1:5 and 1:10 C5511. Scale bar is 10pm.

[087] FIG. 13 illustrates cytotoxicity ofPC3 tumor cells treated with isolated T cells and anti-CLEC2D antibodies (C5511 & C6481) at 100ug / ml. The percentage of dead PC3 tumor cells indicated by Sytox green-positive cells.

[088] FIGS. 14A-14B illustrate live cell imaging with Anti-CLEC2D antibody dependent cytotoxicity ofPC3 tumor cells, a shown in: FIG. 14A, live cell imaging revealed cytotoxicity of PC3 tumor cells over a period of incubation with human PBMC cells and Anti-CLEC2D antibody at 200pg / ml. The assay was carried out for 20hrs in a humidifier maintained at 37°C and 5% CO2 during the image acquisition. On the contrary, incubation with Control human IgG1 antibody (200pg / ml) did not cause tumor cell cytotoxicity. Live PC3 tumor cells - Green; PBMC - Red; Dead cells - Blue; Scale bar is 20pm and FIG. 14B, live cell imaging revealed cytotoxicity of PC3 tumor cells over a period of incubation with human NK cells and Anti-CLEC2D antibody at 200pg / ml. The assay was carried out for 20hrs in a humidifier maintained at 37°C and 5% CO2 during the image acquisition. On the contrary, incubation with Control human IgG1 antibody (200pg / ml) did not cause tumor cell cytotoxicity. Live PC3 tumor cells -Green; NK cells - Red; Dead cells - Blue. Scale bar is 20pm.

[089] FIGS. 15A-15G illustrate predictive models of anti-CLEC2D antibodies, as shown in: FIG. 15A, cartoon representation of epitope recognition (Chain A - Dark Blue, Chain B - Cyan) &CD161 (Chain C - Orange red, Chain D - Purple) complex PDB ID 5MGT; FIG. 15B, the red selections denote residues within 6A ofNKR-P1’s chains; FIG. 15C, ribbon representation of refined anti-CLEC2D antibody structures; respective clones for specific anti-CLEC2D monoclonal antibodies have been labelled appropriately. Variable light chain is depicted in darker shade while heavy chain variable region is shown in white; FIG. 15D, represents selected conformations following PIZSA scoring and conformation clustering principle, belonging to C4608, contributed to one of the clusters interacting against CLEC2D (darker shade); FIG. 15E, a visualization of the residues selected for mutation to determine if the G00001-G00004-G00007-G00010-G00015 cluster combination from C4608 contains the binding site towards CLEC2D antigen; FIG. 15F, represents selected conformations following PIZSA scoring and conformation clustering principle, belonging to C5511, contributed to one of the clusters interacting against CLEC2D (darker shade); and FIG. 15G, a visualization of the residues selected for mutation to determine if the G00001-G00005-G00011-G00019-G00020 cluster combination from C5511 contains the binding site towards CLEC2D antigen.

[090] FIGS. 16A-16G illustrate on identified epitope patch on CLEC2D antigen against anti-CLEC2D antibody clones C4608 and C5511; FIG. 16A, surface representation of anti-CLEC2D antibody C4608 contact points on CLEC2D antigen; FIG. 16B, anti-CLEC2D antibody C4608 contact points on CLEC2D antigen that are overlapping with CD161 binding regions on CLEC2D; FIG. 16C, surface representation of anti-CLEC2D antibody C5511 contact points on CLEC2D antigen; FIG. 16D, anti-CLEC2D antibody C5511 contact points with CLEC2D antigen that are overlapping with CD161 binding regions on CLEC2D; In all depictions darker shade indicates the interacting residue locations on CLEC2D antigen; FIG. 16E, anti-CLEC2D antibody mediated disruption of CLEC2D and CD161 interaction- monitoring of CLEC2D antigen bead conjugation efficiency check; FIG. 16F, binding of CD161-FC to CLEC2D antigen was observed on magnetic beads in concentration depend manner; FIG. 16G, flow cytometric monitoring of CD161 binding in the absence and presence of Anti-CLEC2D antibody as compared with control, as a measure of disruption of CD161 and CLEC2D binding, as indicated by the solid black arrow.

[091] FIGS. 17A-17B illustrate NK cell activation with anti-CLEC2D antibody, as shown in: FIG. 17A, anti-CLE2D antibody C5511 induces CD69 expression indicating NK cell activation towards becoming cytotoxic. Respective experimental conditions have been mentioned against each plot. IL2 treatment was carried out as positive control of CD69 overexpression; and FIG. 17B, anti-CLEC2D antibody mediated CD69 expression is higher compared to PC3 cell primed CD69 expression level onNK cells.

[092] FIGS. 18A-18D illustrate effects of anti-CLEC2D antibody C5511 on cytokine expression by effector cells, as shown in: FIG. 18A, anti-CLEC2D antibody C5511 was used at concentrations of 10pg / mL and 100pg / mL to monitor elevation in IFNy expression level; FIG. 18B, anti-CLEC2D antibody C5511 was used at concentration of 100ug / mL in the presence or absence ofPC3 cells (E:T = 10:1). IFNy expression was monitored in the CD3+ve gated population; FIG. 18C, anti-CLEC2D antibody C5511 was used at concentration of 100ug / mL in the presence or absence ofPC3 cells (E:T = 10:1). IFNy expression was monitored in the CD3-ve gated population; and FIG. 18D, anti-CLEC2D antibody C5511 was used as at concentrations of 100pg / mL in the presence or absence of isolated NK cell. IFNy overexpression was observed with anti-CLEC2D antibody C5511.

[093] FIGS. 19A-19G illustrate mammalian expression constructs used to generate full-length monoclonal antibody. Constructs were generated through gene synthesis followed by confirmation through restriction digestion and Sanger sequencing, as shown in: FIG. 19A, vector designed to clone selected antibody variable heavy chain genes in IgG4 backbone; FIG. 19B, vector designed to clone selected antibody variable heavy chain genes in IgG1 NtoA backbone; FIG. 19C, flow cytometric analysis ofbinding of Anti-CLEC2D antibody with IgG4 isotype backbone (C3256 and C3276) to CLEC2D antigen expressed on surface of CHO cells. Binding was compared with un-transfected CHO cells, as estimated from peak shift towards right; FIG. 19D, cytotoxicity of Anti-CLEC2D antibody using various antibody isotypes. IgG1 isotype (C3452 & C4608) and IgG4 isotype (C3256 & C3276) Anti-CLEC2D antibodies exhibited significant cytotoxicity when incubated with freshly isolated PBMC and PC3 tumor cells; FIG. 19E, anti-CLEC2D antibody produced as afucosylated monoclonal antibodies C0613, C1301, C6268, C1699, C2437, C9832, C8900 and C7749 revealed binding to CHO cell surface expressed CLEC2D antigen by flow cytometry; FIG. 19F, NK cell-mediated cytotoxicity ofPC3 tumor cells with the afucosylated anti-CLEC2D antibody (C7749, C8800,C9832) used at 5X lesser concentration than C5511. The data revealed afucosylated Anti-CLEC2D antibodies achieved nearly equal cell death at 5 times less concentration, indicating afucosylated Anti-CLEC2D antibodies are more cytotoxic; and FIG. 19G, CDC mediated cytotoxicity was measured for anti-CLEC2D antibody C5511 using Ramos and PC3 tumor cell lines. Rituximab was used as positive control.

[094] FIGS. 20A-20K illustrate anti-tumor effects in cancer xenograft mouse model. HuNOG-EXL mice were used for PC3 xenograft and the tumor bearing animals were randomized and used for injecting Anti-CLEC2D antibody product, as shown in: FIG. 20A, tumor volume vs. time plot demonstrating significant anti tumor effects observed with Anti-CLEC2D antibody alone or in combination with anti-PDL1 antibody; FIG. 20B, images displaying immune cell infiltration through staining of CD3+ T cells in the tumor micro environment; FIG. 20C, images of mice with the xenograft showing Alexa 647 labelled anti-CLEC2D antibody injected into the tumor over a 96-hour period; FIG. 20D, effect of test compounds on tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 36). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version 8.3.0). ** p<0.01 statistically significant (Day 36) when C5511 mAb group was compared with Vehicle control IgG1 group; FIG. 20E, effect of test compounds on tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 24). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version 8.3.0).*** p<0.001 and * p<0.05 statistically significant (Day 24) when C5511 mAb group and C6481 mAb group, respectively were compared to Vehicle control IgG1 group; FIG. 20F, effect of test compounds on delta tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 36). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version 8.3.0). ** p<0.01 statistically significant (Day 36) when C5511 mAb group was compared to Vehicle control IgG1 group; FIG. 20G, effect of test compounds on delta tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 24). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version.8.3.0). *** p<0.001 and * p<0.05 statistically significant (Day 24) when C5511 mAb group and C6481 mAb group, respectively were compared to Vehicle control IgG1 group; FIG. 20H, effect of test compounds on relative tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 36). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version 8.3.0). * p<0.05 statistically significant (Day 36) when C5511 mAb group was compared to Vehicle control IgG1 group; FIG. 20I, effect of test compounds on relative tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 24) . Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version.8.3.0). *** p<0.001 and * p<0.05 statistically significant (Day 24) when C5511 mAb group and C6481 mAb group, respectively were compared to Vehicle control IgG1 group; FIG. 20J, effect of test compounds on delta relative tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 36). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version.8.3.0). * p<0.05; and statistically significant (Day 36) when C5511 mAb group was compared to Vehicle control IgG1 group; and FIG. 20K, effect of test compounds on delta relative tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 24). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version.8.3.0). *** p<0.001 and * p<0.05 statistically significant (Day 24) when C5511 mAb group and C6481 mAb group, respectively were compared to Vehicle control IgG1 group.

[095] FIGS. 21A-21I illustrate characterization of purified Anti-CLEC2D antibody product, as shown in: FIG. 21A, SDS-PAGE analysis of purified C5511 antibody in non reducing and reducing conditions; FIG. 21B, TIC chromatogram from Intact Mass spectrometry analysis of Anti-CLEC2D antibody (3 replicates); FIG. 21C, WCX chromatogram analysis of Anti-CLEC2D antibody; FIG. 21D, Size Exclusion chromatogram of Anti-CLEC2D antibody; FIG. 21E, ELISA assay development of Anti-CLEC2D antibody against CLEC2D purified biotinylated antigen. The data was fit to one site binding model to calculate Kd of Anti-CLEC2D antibody; FIGS. 21E and 21F, CLEC2D antigen affinity based binding studies of representative Anti-CLEC2D antibody. FIG. G, Purified CLEC2D antigen ecto-domain was used as source of antigen in BIACORE studies; Response monitored has been plotted against time; FIG. 21H, affinity based binding studies of representative Anti-CLEC2D antibody molecules with FcRn at pH 5.9; and FIG. 21I, affinity based binding studies of representative Anti-CLEC2D antibody molecules with FcRn at at pH 7.4.

[096] FIGS. 22A-22C illustrate that anti-CLEC2D antibody for plausible diagnostic and prognostic applications, as shown in: FIG. 22A, selection of Anti-CLEC2D antibody (C0949) based on binding characteristics. Four Anti-CLEC2D antibodies were evaluated (C2779, C2438, C0949 and C2543) for CLEC2D binding on PC3 target cells. C0949 showed excellent binding and peak median shift; FIG. 22B, anti-CLEC2D antibody C0949 recognizes CLEC2D antigen on multiple prostate cancer cell lines; and FIG. 22C, anti-CLEC2D antibody C0949 recognizes CLEC2D antigen on multiple tumor cell lines. Specific binding and fold change in mean fluorescence was calculated by ratio of mean FITC fluorescence between test and control.

[097] FIGS. 23A-23D illustrate that anti-CLEC2D antibody recognize CLEC2D antigen on prostate cancer tumor cells, as shown in: FIG. 23A, expression level of CLEC2D antigen on prostate cancer disease stage after TCGA data analysis; FIG. 23B, expression level of CLEC2D antigen on prostate cancer cell lines PC3, DU145, 22RV1 and LnCap; FIG. 23C, expression level of CLEC2D antigen on prostate cancer cell lines PC3, LnCap, 22RV1, and DU145 with induction using LPS, Poly I:C, IFN-y, PBMC supernatant, PBMC cells, NK cells and T cells. Upper panel with anti-CLEC2D antibody, lower panel representing the merged image; and FIG. 23D, human tissue microarray slides stained with anti-CLEC2D antibody C2685 showing staining of tumor cells in malignant prostate cancer tissue.

[098] FIGS. 24A-24D illustrate that anti-CLEC2D antibody recognize CLEC2D antigen on various other tumor cells, as shown in: FIG. 24A, TCGA data analysis for CLEC2D antigen expression in various cancers; FIG. 24B, expression level of CLEC2D antigen on various tumor cell lines HepG2 (liver cancer), LN229 (Glioblastoma), SKOV3 (Ovary cancer), BT474 (Breast cancer), NCI-H929 (Myeloma), and Ramos (Lymphoma); FIG. 24C, expression level of CLEC2D antigen on BT474 (Breast cancer), SKOV3 (Ovary cancer), LN229 (Glioblastoma), Ramos (Lymphoma), NCI-H929 (Myeloma) and HepG2 (liver cancer), upon induction with LPS, Poly I:C, IFNy; FIG. 24D, anti-CLEC2D antibody C5511 mediated cytotoxicity observed on SKOV3 (ovary cancer) at 100pg / ml; and anti-CLEC2D antibodies C5511 and C6481 mediated cytotoxicity observed on HepG2 (liver cancer) cell lines at 100pg / ml. The percentage of dead cells indicated by Sytox green-positive cells.

[099] FIGS. 25A-25E illustrate lymphocyte proliferation assay with anti-CLEC2D antibody using flow cytometry analysis, as shown in: FIG. 25A, Antibody wet-coating protocol; FIG. 25B, Air dried antibody coating protocol; FIG. 25C, High density pre-culture protocol; FIG. 25D, measurement of IFNy cytokine secretion from effector cells when PBMC are incubated with Anti-CLEC2D antibodies (C5511, C4608, C6481) for extended period. Treatment with OKT3 antibody was used as a positive control; and FIG. 25E, measurement ofIL2 cytokine secretion from effector cells when PBMC are incubated with Anti-CLEC2D antibodies (C5511, C4608, C6481) for extended period. Treatment with OKT3 antibody was used as a positive control. PBMCs were treated with anti CD3 antibody OKT3 (1pg / ml), Anti-CLEC2D antibody C4608, C5511 and C6481 (1pg / ml, 10ug ml, 50gg / ml & 100gg / ml) and incubated for four days. The fluorescent proliferation dye status was monitored using flow cytometer. Untreated PBMC was used as a control.

[100] FIG. 26 illustrates histogram overlay showing binding of anti-CLEC2D antibodies (C3566 and C5511) against CLEC2D antigen homologs from Rat, Mouse and cynomolgus monkey, expressed on CHO cell surface, using flow cytometric analysis. Detailed Description

[101] Modulation of immune cell checkpoint receptors via antibody-based / directed therapeutic approaches has been gaining constant interests over the past few years. The largest efforts have been centered on T cell checkpoint modulation. However, there is an increasing attention in B cell, NK cell, and myeloid cell checkpoint modulation as well. The innate immune system includes natural killer (NK) cells, which possess the ability to recognize and induce the cytotoxicity of a wide range of target cells, such as, tumor cells or virus infected cells. NK cells do not need any prior antigen sensitization. Apart from direct cytotoxicity, NK cells also participate in the initiation and progress of the adaptive immune response through the production and secretion of cytokines. Usually, these responses are regulated by adequate balance of signals induced by the interaction of a wide array of surface-activating and surface-inhibitory receptors with ligands on the surface of target cells. Modulation ofNK cell numbers and / or its relevant function through a variety of agents such as monoclonal antibodies, cytokines may result in enhanced anti-tumor activity. These agents can be offered either alone or in combination as potential therapeutics. Therefore, anti-cancer activity ofNK cell can be unleashed through harnessing surface receptors, both activating and / or inhibitory kinds.

[102] Blocking these interactions may be a new therapeutic option for treatment of several cancers. However, the finding, understanding and designs need to be tuned and therapeutic treatment needs to be further tailored for specific receptor as targets against various cancers, which is still unmet.

[103] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include the plural and plural terms shall include the singular as is considered appropriate to the context and / or application. The various singular / plural permutations may be expressly set forth herein for the sake of clarity. Generally, nomenclatures used in connection with, and techniques ofbiotechnology, immunology, molecular and cellular biology, recombinant DNA technology described herein are those well known and commonly used in the art. Certain references and other documents cited herein are expressly incorporated herein by reference. In case of conflict, the present specification, including definitions, will control. The materials, methods, figures and examples are illustrative only and not intended to be limiting.

[104] Furthermore, the methods, preparation and use of the antibody naive library disclosed employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, computational chemistry, cell culture, recombinant DNA technology, Polymerase Chain Reaction (PCR) and related fields. These techniques, their principles, and requirements are explained in the literature and known to a person skilled in the art.

[105] Before the method of generating the antibody naive library and the nucleic acids which encode the antibody naive library and other embodiments of the present disclosure are disclosed and described, it is to be understood that the terminologies used herein are for the purpose of describing particular embodiments only and are not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

[106] In one embodiment, the terms “library” and “libraries” are used interchangeably within this disclosure, which relate to the product of the disclosure. In one embodiment, it refers to a collection or pool of nucleic acid sequences. In one embodiment, it refers to a collection or pool of amino acid sequences. In some embodiments, it refers to a collection or pool of organisms that comprise a collection or pool of amino acid sequences or nucleic acid sequences. In some embodiments, the organisms are bacteriophages (phages) or yeast (e.g., Saccharomyces cerevisiae).

[107] In one embodiment, the terms ‘pooling’, ‘pooled’, ‘pool’, and ‘pools’ in the context of the instant disclosure means combining the samples / nucleic acid sequences / nucleic acid fragments / gene clones / amplified product / antibodies obtained by employing the method of the instant disclosure from multiple donors i.e., more than one donor.

[108] In one embodiment, the term “PBMC” refers to any peripheral blood cell having a round nucleus consisting of lymphocytes (T cells, B cells, NK cells) and monocytes, erythrocytes, platelet, and granulocytes (neutrophils, basophils, and eosinophils).

[109] Antigens

[110] As used herein, the terms “antigen” or “immunogen” refer to any foreign substance which induces an immune response in the body. In one embodiment, an antigen is a cellular protein. In one embodiment, an antigen is a cell surface protein.

[111] The antigen may be isolated or derived from any species. Representative species include, but are not limited to Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris and Cynomolgus macaca fascicularis. In some embodiments, the antigen is a fragment of a wild type protein isolated or derived from Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris or Cynomolgus macaca fascicularis. In some embodiments, the antigen is a mutant variant of a protein from Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris or Cynomolgus macaca fascicularis. In some embodiments, antigens can be mutated to increase the solubility and / or stability of the antigen. For example, a CLEC2D antigens can include a mutation atH176Cto introduce an additional disulphide bridge with the Cys163 amino acid to increase the stability and homogeneity of the expressed protein.

[112] In some embodiments, the antigen includes an epitope tag at either the N orC terminus of the polypeptide. Exemplary tags include, but are not limited to polyHistidine tags and FLAG tags. Any epitope tag known in the art is envisaged as within the scope of the disclosure.

[113] C-type lectin domain family 2 member D (CLEC2D), also referred to as CLAX, Lectin Like Transcript-1 (LLT1) and OCIL, is a member of the natural killer cell receptor C-type lectin family. CLEC2D binds to Killer Cell Lectin Like Receptor B1 (KLRB1). KLRB1 is also known asCD161, CLEC5B, NKR, NKR-P1, NKR-P1A, NKRP1A and hNKR-P1A. All orthologs and isoforms of CLEC2D and CD161 are considered to be within the scope of the present disclosure.

[114] In some embodiments, a C-type lectin domain family 2 member D (CLEC2D) protein or any of its aliases or homologs, known in the art, whether from humans or other species, represents a target antigen of an antibody produced by the methods described herein.

[115] In some embodiments, the antigen is a CLEC2D antigen that has at least 85%, at least 90%, at least 95%, at least 96%, at least 97% at least 98%, at least 99% or 100% identity to a CLEC2D sequence isolated or derived from Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris and Cynomolgus macaca fascicularis.

[116] In some embodiments, a CD161 protein or any of its aliases or homologs, known in the art, whether from humans or other species, represents a target antigen of an antibody produced by the methods described herein.

[117] In some embodiments, the CD161 antigen has at least 85%, at least 90%, at least 95%, at least 96%, at least 97% at least 98%, at least 99% or 100% identity to a CD161 sequence isolated or derived from Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris and Cynomolgus macaca fascicularis.

[118] Exemplary antigens are shown in Table 1 below. Table 1. Representative CLEC2D and CD161 Polypeptide Sequences SEQID Description Amino Acid Sequence SEQID 886 Human (Homo sapiens) CLEC2D construct 1 MHDSNNVEKDITPSELPANPGCLHSKEHSIKATLIWRLFFLIMFLTIIVCGMVAALSAIRANCHQ EPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGP SDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARHYTERKWICSKSDI HV SEQID 887 Human (Homo sapiens) CLEC2D construct 2 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARHYTERKWICSKSDIHVHHH HHHHH SEQID 888 Human (Homo sapiens) CLEC2D construct 3 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHVHHH HHHHHG SEQID 889 Human (Homo sapiens) CLEC2D construct 4 MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARH YTERKWICSKSDIHVHHHHHHHH SEQID 890 Human (Homo sapiens) CLEC2D construct 5 MMSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQV ESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAR CYTERKWICSKSDIHVHHHHHHHHG SEQID 891 Human (Homo sapiens) CLEC2D construct 6 MMSFVSLLLVGILFHATQAHHHHHHHHDDDDKQAACPESWIGFQRKCFYFSDDTKNWTSS QRFCDSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGA GECAYLNDKGASSARCYTERKWICSKSDIHV SEQID 892 Human (Homo sapiens) CLEC2D construct 7 HHHHHHHHDDDDKQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQE LNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARCYTER KWICSKSDIHV SEQID 893 Human (Homo sapiens) CLEC2D construct 8 MMSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQV ESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAA CAAAAAWICSKSDIHVHHHHHHHH SEQID 894 Human (Homo sapiens) CLEC2D construct 9 MQLLRCFSIFSVIASVLAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESF QELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAACA AAAAWICSKSDIHVEFEQKLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQE LTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYV F SEQID 895 Human (Homo sapiens) CLEC2D construct 10 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAACAAAAAWICSKSDIHVEFE QKLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQELTTICEQIPSPTLESTPYS LSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYVF SEQID 896 Human (Homo sapiens) CLEC2D construct 11 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAACAAAAAWICSKSDIHVHHH HHHHH SEQID 897 Human (Homo sapiens) CLEC2D construct 12 MMSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQV ESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAALADKGASSAR CYTERKWICSKSDIHVHHHHHHHH SEQID 898 Human (Homo sapiens) CLEC2D construct 13 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGECAALADKGASSARCYTERKWICSKSDIHVHHH HHHHH SEQID 899 Human (Homo sapiens) CLEC2D construct 14 MQLLRCFSIFSVIASVLAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESF QELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAALADKGASSARCY TERKWICSKSDIHVEFEQKLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQE LTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYV F SEQID 900 Human (Homo sapiens) CLEC2D construct 15 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGECAALADKGASSARCYTERKWICSKSDIHVEFEQ KLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQELTTICEQIPSPTLESTPYSL STTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYVF SEQID 901 Human (Homo sapiens) CLEC2D construct 16 MMSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQV ESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDAGAASA RCYTERKWICSKSDIHVHHHHHHHH SEQID 902 Human (Homo sapiens) CLEC2D construct 17 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDAGAASARCYTERKWICSKSDIHVHHH HHHHH SEQID 903 Human (Homo sapiens) CLEC2D construct 18 MQLLRCFSIFSVIASVLAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESF QELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDAGAASARCY TERKWICSKSDIHVEFEQKLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQE LTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYV F SEQID 904 Human (Homo sapiens) CLEC2D construct 19 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDAGAASARCYTERKWICSKSDIHVEFEQ KLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQELTTICEQIPSPTLESTPYSL STTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYVF SEQID 905 Human (Homo sapiens) CLEC2D construct 20 MHDSNNVEKDITPSELPANPGCLHSKEHSIKATLIWRLFFLIMFLTIIVCGMVAALSAIRANCHQ EPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGP SDHWIGLSREQGQPWKWINGTEWTRQLVMKEDGANLYVAKVSQVPRMNPRPVMVSYPG SRRVCLFE SEQID 906 Human (Homo sapiens) CLEC2D construct 21 MHDSNNVEKDITPSELPANPGCLHSKEHSIKATLIWRLFFLIMFLTIIVCGMVAALSAIRANCHQ EPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGP SDHWIGLSREQGQPWKWINGTEWTRQ SEQID 907 Human (Homo sapiens) CLEC2D construct 22 MHDSNNVEKDITPSELPANPGCLHSKEHSIKATLIWRLFFLIMFLTIIVCGMVAALSAIRANCHQ EPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELVSYPGSRR VCLFE SEQID 908 Human (Homo sapiens) CLEC2D construct 23 MHDSNNVEKDITPSELPANPAIRANCHQEPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSS QRFCDSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGA GECAYLNDKGASSARHYTERKWICSKSDIHV SEQID 909 Human (Homo sapiens) CLEC2D construct 24 MHDSNNVEKDITPSELPANPAIRANCHQEPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSS QRFCDSQDADLAQVESFQELVSYPGSRRVCLFE SEQID 910 Rat (Rattus norvegicus) CLEC2D construct 1 MPSSAHLQDPPPLLSRTLTQNEGQTSLRQSSSCGPSAASASESLSGSTESRIPHSKMLQGKLPR NIPLEYPAGLYCCYVVIIVLSVAVVALSVALSVKKTAQISTINTYAACPRNWIGVGNKCFYFNEIP SNWTLSQTLCKEQGAELARFDTEEELNFLRRYKGSSGYWFGLHRESSAHPWKWTDNTEYNN SVSIGGDEKHGFLSDNGFSSGRGYIVRKSICRKPNSYTSQCL SEQID 911 Mouse (Mus Musculus) CLEC2D construct 1 MCVTKASLPMLSPTGSPQEVEVGKILQGKRHGTISPESCAKLYCYYGVIMVLTVAVIALSVALS ATKTEQIPVNKTYAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFDNQDELN FLMRYKANFDSWIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTRIYSLRM WICSKLNSYSLHCQTPFFPS SEQID 912 Mouse (Mus Musculus) CLEC2D construct 2 MSFVSLLLVGILFHATQAYAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFD NQDELNFLMRYKANFDSWIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTRI YSLRMWICSKLNSYSLHCQTPFFPSHHHHHHHH SEQID 913 Mouse (Mus Musculus) CLEC2D construct 3 YAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFDNQDELNFLMRYKANFDS WIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTRIYSLRMWICSKLNSYSLHC QTPFFPSHHHHHHHH SEQID 914 Mouse (Mus Musculus) CLEC2D construct 4 MSFVSLLLVGILFHATQAYAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFD NQDELNFLMRYKANFDSWIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTR CYSLRMWICSKLNSYSLHCQTPFFPSHHHHHHHH SEQID 915 Mouse (Mus Musculus) CLEC2D construct 5 YAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFDNQDELNFLMRYKANFDS WIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTRCYSLRMWICSKLNSYSLH CQTPFFPSHHHHHHHH SEQID 916 Dog (Canis lupus familiaris ) CLEC2D construct 1 MSFVSLLLVGILFHATQAEAACPESWIGFQRKCFYFSDDIKNWTFSQRFCDSYGADLVQIETLL ELNFLLRYKGPYDHWIGLSRDLGQPWKWVNGTEWTNCFPIRGGGECAYLNDKGASSARRYT ERKWICSKPDIYAQIKRQNSIHHHHHHHH SEQID 917 Dog (Canis lupus familiaris ) CLEC2D construct 2 EAACPESWIGFQRKCFYFSDDIKNWTFSQRFCDSYGADLVQIETLLELNFLLRYKGPYDHWIGL SRDLGQPWKWVNGTEWTNCFPIRGGGECAYLNDKGASSARRYTERKWICSKPDIYAQIKRQ NSIHHHHHHHH SEQID 918 Cynomolgus (Macaca fascicularis) CLEC2D construct 1 MVTGSKMHDSNNVEKDIAPSELPANPGYRHSKQHSGKATLIWPLFFLIMFLTIIVCGMVVALS AIRANCHQKPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDAALAQVESFQEL NFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGEYAYLNDKGASSARYYTERK WICSKPDTYVQMVQQSPN SEQID 919 Cynomolgus (Macaca fascicularis) CLEC2D construct 2 MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDAALAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGEYAYLNDKGASSARYY TERKWICSKPDTYVQMVQQSPNHHHHHHHH SEQID 920 Cynomolgus (Macaca fascicularis) CLEC2D construct 3 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDAALAQVESFQELNFLLRYKGPSDHWI GLSREQGQPWKWINGTEWTRQFPILGAGEYAYLNDKGASSARYYTERKWICSKPDTYVQMV QQSPNHHHHHHHH SEQID 921 Human (Homo sapiens) CD161 construct 1 MDQQAIYAELNLPTDSGPESSSPSSLPRDVCQGSPWHQFALKLSCAGIILLVLVVTGLSVSVTSL IQKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLL LIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDLEIRGDAKENSCISISQTS VYSEYCSTEIRWICQKELTPVRNKVYPDS SEQID 922 Human (Homo sapiens) CD161 construct 2 MSFVSLLLVGILFHATQAQKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVN PWNNSLADCSTKESSLLLIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDL EIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDSHHHHHHHH SEQID 923 Human (Homo sapiens) CD161 construct 3 QKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLLL IRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNW KWINGSFLNSNDLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDSHHHHH HHH SEQID 924 Dog( Canis lupus familiaris) CD161 construct 1 MSFVSLLLVGILFHATQAQNSSIEECRVDVQVNGNETTEKPNLLQCPVHWHLLQEKCLFFSHA SNTWKDSLTDCSAKESSLLLIQDQEELRLIRGLIYKKEILFWIGLNLTLSEKKWKWINGSFLNSNIL QIAGYNKESSCVYISLTGIVSENCDAENQWICQKELKPDRNKICSKFHHHHHHHH SEQID 925 Dog( Canis lupus familiaris) CD161 construct 2 QNSSIEECRVDVQVNGNETTEKPNLLQCPVHWHLLQEKCLFFSHASNTWKDSLTDCSAKESSL LLIQDQEELRLIRGLIYKKEILFWIGLNLTLSEKKWKWINGSFLNSNILQIAGYNKESSCVYISLTGI VSENCDAENQWICQKELKPDRNKICSKFHHHHHHHH SEQID 926 Cynomolgus (Macaca fascicularis) CD161 construct 1 MSFVSLLLVGILFHATQAQKPSIGKCSVDIQQNRTKTTERPDLLNCPIYWQQVQEKCLLFSHTV NPWNNSLADCSTKESSLLLIQDKDELTRTQNLIHDKAISFWIGLNFSLSEKNWKWINGSFLSSN DLKITGDAKENSCVYISQTSVYSEYCSTEMKWICQKELTLVRNKVSPDSWLHHHHHHHH SEQID 927 Cynomolgus (Macaca fascicularis) CD161 construct 2 QKPSIGKCSVDIQQNRTKTTERPDLLNCPIYWQQVQEKCLLFSHTVNPWNNSLADCSTKESSL LLIQDKDELTRTQNLIHDKAISFWIGLNFSLSEKNWKWINGSFLSSNDLKITGDAKENSCVYISQ TSVYSEYCSTEMKWICQKELTLVRNKVSPDSWLHHHHHHHH SEQID 928 Mouse (Mus Musculus) CD161 construct 1 MSFVSLLLVGILFHATQAQKPSREKCCVFIQENLNKTTDCSVNLECPQDWLLHRDKCFHVSQV SNTWEEGQADCGRKGATLLLIQDQEELRFLLDSIKEKYNSFWIGLRFTLPDMNWKWINGTTF NSDVLKITGVTENGSCASILGDKVTPESCASDNRWICQKELNHETPSNDSHHHHHHHH SEQID 929 Mouse (Mus Musculus) CD161 construct 2 QKPSREKCCVFIQENLNKTTDCSVNLECPQDWLLHRDKCFHVSQVSNTWEEGQADCGRKGA TLLLIQDQEELRFLLDSIKEKYNSFWIGLRFTLPDMNWKWINGTTFNSDVLKITGVTENGSCASI LGDKVTPESCASDNRWICQKELNHETPSNDSHHHHHHHH SEQID 930 Human (Homo sapiens) CLEC2D construct 25 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGaSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 931 Human (Homo sapiens) CLEC2D construct 26 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGaSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 932 Human (Homo sapiens) CLEC2D construct 27 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPaDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 933 Human (Homo sapiens) CLEC2D construct 28 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPaDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 934 Human (Homo sapiens) CLEC2D construct 29 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSaHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 935 Human (Homo sapiens) CLEC2D construct 30 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSaHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 936 Human (Homo sapiens) CLEC2D construct 31 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREaGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 937 Human (Homo sapiens) CLEC2D construct 32 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREaGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 938 Human (Homo sapiens) CLEC2D construct 33 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGaCAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 939 Human (Homo sapiens) CLEC2D construct 34 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGaCAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 940 Human (Homo sapiens) CLEC2D construct 35 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAaLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 941 Human (Homo sapiens) CLEC2D construct 36 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAaLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 942 Human (Homo sapiens) CLEC2D construct 37 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDaGASSARCYTERKWICSKSDIHV HHHHHHHH SEQID 943 Human (Homo sapiens) CLEC2D construct 38 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDaGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 944 Human (Homo sapiens) CLEC2D construct 39 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASaARCYTERKWICSKSDIH VHHHHHHHH SEQID 945 Human (Homo sapiens) CLEC2D construct 40 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASaARCYTERKWICSKSDIHVHHHHHHHH SEQID 946 Human (Homo sapiens) CLEC2D construct 41 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSAaCYTERKWICSKSDIHV HHHHHHHH SEQID 947 Human (Homo sapiens) CLEC2D construct 42 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSAaCYTERKWICSKSDIHVHHHHHHHH SEQID 948 Human (Homo sapiens) CLEC2D construct 43 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCaTERKWICSKSDIH VHHHHHHHH SEQID 949 Human (Homo sapiens) CLEC2D construct 44 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCaTERKWICSKSDIHVHHHHHHHH SEQID 950 Human (Homo sapiens) CLEC2D construct 45 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYaERKWICSKSDIH VHHHHHHHH SEQID 951 Human (Homo sapiens) CLEC2D construct 46 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYaERKWICSKSDIHVHHHHHHHH SEQID 952 Human (Homo sapiens) CLEC2D construct 47 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTaRKWICSKSDIH VHHHHHHHH SEQID 953 Human (Homo sapiens) CLEC2D construct 48 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTaRKWICSKSDIHVHHHHHHHH SEQID 954 Human (Homo sapiens) CLEC2D construct 49 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTEaKWICSKSDIHV HHHHHHHH SEQID 955 Human (Homo sapiens) CLEC2D construct 50 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTEaKWICSKSDIHVHHHHHHHH SEQID 956 Human (Homo sapiens) CLEC2D construct 51 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERaWICSKSDIHV HHHHHHHH SEQID 957 Human (Homo sapiens) CLEC2D construct 52 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERaWICSKSDIHVHHHHHHHH SEQID 958 Human (Homo sapiens) CLEC2D construct 53 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAALADaGAaSARCYTERKWICSKSDIH VHHHHHHH SEQID 959 Human (Homo sapiens) CLEC2D construct 54 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAALADaGAaSARCYTERKWICSKSDIHVHHHHHHH SEQID 960 Human (Homo sapiens) CLEC2D construct 55 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAaLaDAGAASARCYTERKWICSKSDIH VHHHHHHH SEQID 961 Human (Homo sapiens) CLEC2D construct 56 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAaLaDAGAASARCYTERKWICSKSDIHVHHHHHHH SEQID 962 Human (Homo sapiens) CLEC2D construct 57 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQaFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 963 Human (Homo sapiens) CLEC2D construct 58 QAACPESWIGFQRKCFYFSDDTKNWTSSQaFCDSQDADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG AGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 964 Human (Homo sapiens) CLEC2D construct 59 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGaPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 965 Human (Homo sapiens) CLEC2D construct 60 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGaPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 966 Human (Homo sapiens) CLEC2D construct 61 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTaQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV HHHHHHHH SEQID 967 Human (Homo sapiens) CLEC2D construct 62 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTaQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 968 Human (Homo sapiens) CLEC2D construct 63 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKaDIH VHHHHHHHH SEQID 969 Human (Homo sapiens) CLEC2D construct 64 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERKWICSKaDIHVHHHHHHHH SEQID 970 Human (Homo sapiens) CLEC2D construct 65 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIaV HHHHHHHH SEQID 971 Human (Homo sapiens) CLEC2D construct 66 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIaVHHHHHHHH SEQID 972 Human (Homo sapiens) CLEC2D construct 67 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSAaCaTaRKWICSKSDIHV HHHHHHHH SEQID 973 Human (Homo sapiens) CLEC2D construct 68 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSAaCaTaRKWICSKSDIHVHHHHHHHH SEQID 974 Human (Homo sapiens) CLEC2D construct 69 MSFVSLLLVGILFHATQAQ AACPESWIGFQaKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIaV HHHHHHHH SEQID 975 Human (Homo sapiens) CLEC2D construct 70 QAACPESWIGFQaKCFYFSDDTKNWTSSQRFCDSQDADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG AGECAYLNDKGASSARCYTERKWICSKSDIaVHHHHHHHH SEQID 976 Human (Homo sapiens) CLEC2D construct 71 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTaWaaaFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV HHHHHHHH SEQID 977 Human (Homo sapiens) CLEC2D construct 72 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTaWaaaFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 978 Human (Homo sapiens) CLEC2D construct 73 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQaFC DaQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 979 Human (Homo sapiens) CLEC2D construct 74 QAACPESWIGFQRKCFYFSDDTKNWTSSQaFCDaQDADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG AGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 980 Human (Homo sapiens) CLEC2D construct 75 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQaADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIaV HHHHHHHH SEQID 981 Human (Homo sapiens) CLEC2D construct 76 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQaADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG AGECAYLNDKGASSARCYTERKWICSKSDIaVHHHHHHHH SEQID 982 Human (Homo sapiens) CLEC2D construct 77 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGaPWKWI NGTEWTaQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV HHHHHHHH SEQID 983 Human (Homo sapiens) CLEC2D construct 78 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGaPWKWINGTEWTaQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 984 Human (Homo sapiens) CLEC2D construct 79 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDaaaNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 985 Human (Homo sapiens) CLEC2D construct 80 QAACPESWIGFQRKCFYFSDaaaNWTSSQRFCDSQDADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG AGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 986 Human (Homo sapiens) CLEC2D construct 81 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGaPWaWIN GTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV HHHHHHHH SEQID 987 Human (Homo sapiens) CLEC2D construct 82 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGaPWaWINGTEWTRQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 988 Human (Homo sapiens) CLEC2D construct 83 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSRaQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARaYTERKWICSKSDIHV HHHHHHHH SEQID 989 Human (Homo sapiens) CLEC2D construct 84 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSRaQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARaYTERKWICSKSDIHVHHHHHHHH SEQID 990 Human (Homo sapiens) CLEC2D construct 85 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSRaaGaPWKWIN GTEWTRQFPILGAGECAYLNDKGASSAaCYTERKWICSKSDIHVH HHHHHHH SEQID 991 Human (Homo sapiens) CLEC2D construct 86 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSRaaGaPWKWINGTEWTRQFPIL GAGECAYLNDKGASSAaCYTERKWICSKSDIHVHHHHHHHH SEQID 992 Human (Homo sapiens) CLEC2D construct 87 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDaTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCaTERaWICSKSDIHV HHHHHHHH SEQID 993 Human (Homo sapiens) CLEC2D construct 88 QAACPESWIGFQRKCFYFSDaTKNWTSSQRFCDSQDADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG AGECAYLNDKGASSARCaTERaWICSKSDIHVHHHHHHHH SEQID 994 Human (Homo sapiens) CLEC2D construct 89 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESaQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTaQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV HHHHHHHH SEQID 995 Human (Homo sapiens) CLEC2D construct 90 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SaQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTaQFPIL GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 996 Human (Homo sapiens) CLEC2D construct 91 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDaKaWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH VHHHHHHHH SEQID 997 Human (Homo sapiens) CLEC2D construct 92 QAACPESWIGFQRKCFYFSDDaKaWTSSQRFCDSQDADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG AGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH SEQID 998 Human (Homo sapiens) CLEC2D construct 93 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDaKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCaTaRKWICSKSDIH VHHHHHHHH SEQID 999 Human (Homo sapiens) CLEC2D construct 94 QAACPESWIGFQRKCFYFSDDaKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSARCaTaRKWICSKSDIHVHHHHHHHH SEQID 1000 Human (Homo sapiens) CLEC2D construct 95 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTaNWTSSQaFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSARCYTaRKWICSKSDIH VHHHHHHHH SEQID 1001 Human (Homo sapiens) CLEC2D construct 96 QAACPESWIGFQRKCFYFSDDTaNWTSSQaFCDSQDADLAQVES FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG AGECAYLNDKGASSARCYTaRKWICSKSDIHVHHHHHHHH SEQID 1002 Human (Homo sapiens) CLEC2D construct 97 MSFVSLLLVGILFHATQAQ AACPESWIGFQRKCFYFSDDTKNWTSSQRFC DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI NGTEWTRQFPILGAGECAYLNDKGASSAaCaTEaKWICSKSDIHV HHHHHHHH SEQID 1003 Human (Homo sapiens) CLEC2D construct 98 QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL GAGECAYLNDKGASSAaCaTEaKWICSKSDIHVHHHHHHHH

[119] Antibodies

[120] In one embodiment, the term "antibody" refers to an immunoglobulin, which may be derived from natural sources or synthetically produced, in whole or in part. The terms "antibody" and "immunoglobulin" are used synonymously throughout the specification unless otherwise stated.

[121] In one embodiment, the term “antibody” includes both polyclonal and monoclonal antibody preparations and also includes the following: chimeric antibody molecules, F(ab’)2 and F(ab) fragments, Fv molecules, single chain Fv molecules (ScFv), dimeric and trimeric antibody fragments, bispecific antibody, minibodies, humanized monoclonal antibody molecules, human antibodies, fusion proteins comprising Fc region of antibody and any functional fragments arising out of these molecules, where derivative molecules retain immunological functionality of the parent antibody molecule. The antibody according to this disclosure is a human antibody, humanized antibody, chimeric antibody, or further genetically engineered antibody as long as the characteristic properties according to this disclosure are retained.

[122] "Native antibodies and immunoglobulins" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavychain variable domains (Clothia et al., J. Mol. Biol. 186:651 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. U.S.A. 82:4592 (1985)).

[123] The term "antigen-binding site," or "binding portion" refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains, referred to as "hypervariable regions," are interposed between more conserved flanking stretches known as "framework regions," or "FRs". Thus, the term "FR" refers to amino acid sequences which are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs."

[124] The term "variable" refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a P-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the P-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences ofProteins ofImmunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

[125] "Antibody fragments" comprise a portion of a full length antibody, preferably the variable domain thereof, or at least the antigen binding site thereof. scFv antibodies are, e.g., described in Huston, J.S., Methods in Enzymol. 203 (1991) 46-88. In one embodiment, “antibody fragment" is a portion of a whole antibody which retains the ability to exhibit antigen binding activity. In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain binding to the respective antigen being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the properties of an antibody according to this disclosure.

[126] Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab’)2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

[127] "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH -VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

[128] A single chain Fv ("scFv") polypeptide molecule is a covalently linked VH:VL heterodimer, which can be expressed from a gene fusion including VH- and VL-encoding genes linked by a peptide-encoding linker. A number of methods have been described to discern chemical structures for converting the naturally aggregated, but chemically separated, light and heavy polypeptide chains from an antibody V region into an scFv molecule, which will fold into a three dimensional structure substantially similar to the structure of an antigen-binding site. See, e.g.,U.S.PatentNos. 5,091,513;5,132,405;and4,946,778.

[129] The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab’ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab’-SH is the designation herein for Fab’ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab’)2 antibody fragments originally were produced as pairs of Fab’ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[130] The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (k) and lambda (l), based on the amino acid sequences of their constant domains.

[131] As used herein, the terms "immunological binding" and "immunological binding properties" refer to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (Kd) of the interaction, wherein a smaller Kd represents a greater affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen-binding site / antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions. Thus, both the "on rate constant" (Kon) and the "off rate constant" (Koff) can be determined by calculation of the concentrations and the actual rates of association and dissociation. The ratio of Koff / Kon enables the cancellation of all parameters not related to affinity, and is equal to the dissociation constant Kd. In some embodiments, an antibody of the present disclosure binds to CLEC2D at a Kd <10 uM. preferably < 1 uM. more preferably <100 nM, for example, < 90 nM, < 80 nM, < 70 nM, < 60 nM, < 50 nM, < 40 nM, < 30 nM, < 20 nM, <10 nM, < 5 nM, or < 1 nM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art. In some embodiment, the binding affinity of the antibody of this disclosure is within the range of 10-5M to 10-12 M. For example, the binding affinity of the antibody of this disclosure is from 10-6 M to 10-12 M, from 10-7 M to 10-12 M, from 10-8 M to 10-12 M, from 10-9 M to 10-12 M, from 10-5 M to 10-11 M, from 10-6 M to 10-11 M, from 10-7 M to 10-11 M, from 10-8 M to 10-11 M, from 10-9 M to 10-11 M, from 10-10 M to 10-11 M, from 10-5 M to 10-10 M, from 10-6 M to 10-10, from 10-7 M to 10-10 M, from 10-8 M to 10-10, from 10-9 M to 10-10 M, from 10-5 M to 10-9 M, from 10-6 M to 10-9 M, from 10-7 M to 10-9 M, from 10-8 M to 10-9 M, from 10-5 M to 10-8 M, from 10-6 M to 10-8 M, from 10-7 M to 10-8 M, from 10-5 M to 10-7 M, from 10-6 M to 10-7 M or from 10-5 M to 10-6 M.

[132] The present disclosure also features antibodies that have a specified percentage identity or similarity to the amino acid or nucleotide sequences of the CLEC2D antibodies described herein. For example, the antibodies may have at least 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the CLEC2D antibodies described herein. Preferably, the antibodies may have at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the CLEC2D antibodies described herein. More preferably, the antibodies may have at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the CLEC2D antibodies described herein. Even more preferably, the antibodies may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the CLEC2D antibodies described herein. Sequence identity or similarity to the nucleic acids and proteins of the present disclosure can be determined by sequence comparison and / or alignment by methods known in the art. For example, sequence comparison algorithms (i.e., BLAST or BLAST 2.0), manual alignment or visual inspection can be utilized to determine percent sequence identity or similarity for the nucleic acids and proteins of the present disclosure.

[133] As to amino acid sequences, one of skill in the art will readily recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds, deletes, or substitutes a single amino acid or a small percentage of amino acids in the encoded sequence is collectively referred to herein as a “conservatively modified variant”. In some embodiments, the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.

[134] Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called a, 5, s, y, and u, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

[135] In one embodiment, a humanized antibody may be used in the compositions and methods provided herein. In some embodiments, the term "humanized antibody" or "humanized version of an antibody" refers to antibodies in which the framework or "complementarity determining regions" (CDR) have been modified to comprise the CDR of an immunoglobulin of different specificity as compared to that of the parent immunoglobulin. In other embodiments, the CDRs of the VH and VL are grafted into the framework region ofhuman antibody to prepare the "humanized antibody." See e.g., Riechmann, L., et al, Nature 332 (1988) 323-327; and Neuberger, M.S., et al, Nature 314 (1985) 268-270. The heavy and light chain variable framework regions can be derived from the same or different human antibody sequences. The human antibody sequences can be the sequences of naturally occurring human antibodies. Human heavy and light chain variable framework regions are listed e.g., in Lefranc, M.-P., Current Protocols in Immunology (2000) - Appendix IP A.1P.1-A.1P.37 and are accessible via IMGT, the international ImMunoGeneTics information system® (http: / / imgt.cines.fr) or via http: / / vbase.mrc-cpe.cam.ac.uk. Optionally the framework region can be modified by further mutations. Particularly preferred CDRs correspond to those representing sequences recognizing the antigens noted above for chimeric antibodies. The term "humanized antibody" as used herein also comprises such antibodies which are modified in the constant region to generate the properties according to this disclosure, especially in regard to Clq binding and / or FcR binding, e.g., by "class switching" i.e., change or mutation ofFc parts (e.g., from IgGl to IgG4 and / or IgGl / IgG4 mutation). The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germ line immunoglobulin sequences. Human antibodies are well-known in the state of the art (van Dijk, M.A., and van de Winkel, J.G., Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire or a selection ofhuman antibodies in the absence of endogenous immunoglobulin production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production ofhuman antibodies upon antigen challenge (see, e.g., Jakobovits, A., et al, Proc. Natl. Acad. Sci. USA 90 (1993) 2551-2555; Jakobovits, A., et al, Nature 362 (1993) 255-258; Brueggemann, M.D., et al., Year Immunol. 7 (1993) 33-40). Human antibodies can also be produced in phage display libraries (Hoogenboom, H.R., and Winter, G., J. Mol. Biol. 227 (1992) 381-388; Marks, J.D., et al, J. Mol. Biol. 222 (1991) 581- 597). The techniques of Cole, A., et al. and Boerner, P., et al. are also available for the preparation of human monoclonal antibodies (Cole, A., et al., Monoclonal Antibodies and Cancer Therapy, Liss, A.L., p. 77 (1985); and Boerner, P., et al, J. Immunol. 147 (1991) 86-95). As already mentioned for humanized antibodies according to this disclosure the term "human antibody" as used herein also comprises such antibodies which are modified in the constant region to generate the properties according to this disclosure.

[136] In one embodiment, the term "monoclonal antibody" refers to an antibody composition having a homogeneous antibody population. The antibody is not limited to the species or source of the antibody or by the manner in which it is made. In another embodiment, the term encompasses whole immunoglobulins as well as fragments such as Fab, F(ab’)2, Fv, and other fragments, as well as chimeric and humanized homogeneous antibody populations that exhibit immunological binding properties of the parent monoclonal antibody molecule. In another embodiment, the terms "monoclonal antibody" or "monoclonal antibody composition" as used herein refer to a preparation of antibody molecules of a single amino acid composition. In another embodiment, the terms Fab or ScFv are used as antibody fragments with specific mention.

[137] In some embodiments, a chimeric antibody may be used in the compositions and methods provided herein. In one embodiment, the term "chimeric antibody" refers to a monoclonal antibody comprising a variable region, i.e., binding region, from one species (e.g., a mouse or rat) and at least a portion of a constant region derived from a different source or species (e.g., human), usually prepared by recombinant DNA techniques. Chimeric antibodies comprising a mouse variable region and a human constant region are especially preferred. Such chimeric antibodies are the product of expressed immunoglobulin genes comprising DNA segments encoding immunoglobulin variable regions from one species and DNA segments encoding immunoglobulin constant regions for a different species. Other forms of "chimeric antibodies" encompassed by the present disclosure are those in which the class or subclass has been modified or changed from that of the original antibody. Such "chimeric" antibodies are also referred to as "class-switched antibodies." Methods for producing chimeric antibodies involve conventional recombinant DNA and gene transfection techniques now well known in the art. See, e.g., Morrison, S.L., et al, Proc. Natl. Acad Sci. USA 81 (1984) 6851-6855; US 5,202,238 andUS 5,204,244.

[138] In one embodiment, “antibody display library” refers to a platform(s) expressing antibodies on the surface of a cell or cell-free suited for a screening methodology against target antigens. Herein, phage display library and yeast display library are used with accurate specification unless indicated otherwise.

[139] In one embodiment, the term “naive library” refers to a collection of nucleic acid sequences encoding a naturally occurring VH repertoire from a non-immunized source.

[140] In one embodiment, the term "VH" refers to the single heavy chain variable domain of antibody of the type that can be found in mammals which are naturally devoid oflight chains or parts of the same; Naive VH can be understood accordingly.

[141] In one embodiment, the term “VL” refers to single light chain variable domain of the antibody; they are found in two types based on the constant domain sequence. Vk (with kappa constant region) and Vl (lambda constant region) are understood accordingly.

[142] In one embodiment, the term "CDR" refers to complementary determining region of the antibody structure.

[143] In one embodiment, the term "repertoire," means a collection, indicating genetic diversity.

[144] In one embodiment, the term "framework region" is used herein to refer to the nucleic acid sequence regions of an antibody molecule that encode the structural elements of the molecule.

[145] In another embodiment, the term "vector" refers to a DNA related to a cloning or expression system to accommodate antibody genes in specific designated restriction sites. Phagemid vectors (applicable to phage display systems) or yeast vectors (applicable to yeast display systems) are understood accordingly or mammalian expression vectors (applicable to mammalian expression systems).

[146] The disclosure provides antibodies and antibody fragments that bind to a CLEC2D antigen of the disclosure.

[147] The disclosure provides VH and VL domains of antibodies or antibody fragments that bind to a CLEC2D antigen or an epitope of CLEC2D as described in the disclosure.

[148] The disclosure provides sequences of CDR1, CDR2 and CDR3 of the VH domain and CDR1, CDR2 and CD3 of the VL domain of antibodies that bind to a CLEC2D antigen or an epitope of CLEC2D as described in the disclosure.

[149] Any combinations ofVH and VL sequences of the disclosure are considered within the scope of this disclosure. Any combinations of the CDR1, CDR2 and CDR3 sequences of the VH domains, or the CDR1, CDR2 and CD3 sequences of the VL domains are considered within the scope of this disclosure.

[150] Those skilled in the art will recognize that it is possible to determine, without undue experimentation, if a monoclonal antibody has the same specificity as a monoclonal antibody of the disclosure by ascertaining whether the former prevents the latter from binding to CLEC2D. If the monoclonal antibody being tested competes with the monoclonal antibody of the disclosure, as shown by a decrease in binding by the monoclonal antibody of the disclosure, then it is likely that the two monoclonal antibodies bind to the same, or to a closely related, epitope.

[151] Another way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the disclosure is to pre-incubate the monoclonal antibody of the disclosure with the CLEC2D protein, with which it is normally reactive, and then add the monoclonal antibody being tested to determine if the monoclonal antibody being tested is inhibited in its ability to bind CLEC2D. If the monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic specificity as the monoclonal antibody of the disclosure. Screening of monoclonal antibodies of the disclosure can be also carried out by utilizing CLEC2D and determining whether the test monoclonal antibody is able to neutralize CLEC2D.

[152] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the disclosure, or against derivatives, fragments, analogs homologs or orthologs thereof. (See, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference).

[153] Antibodies can be purified by well-known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

[154] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

[155] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth ofHGPRT-deficient cells.

[156] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. (See Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., NewYork, (1987) pp. 51-63)).

[157] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis ofMunson and Pollard, Anal. Biochem., 107:220 (1980). Moreover, in therapeutic applications of monoclonal antibodies, it is important to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

[158] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. (See Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Suitable culture media for this purpose include, for example, Dulbecco’s Modified Eagle’s Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

[159] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[160] Monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the disclosure can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable ofbinding specifically to genes encoding the heavy and light chains of murine antibodies). In some embodiments, the hybridoma cells of the disclosure serve as a source of such DNA. In some embodiments, antibody gene sequences are isolated and cloned using the methods of the disclosure (e.g., phage and yeast library display), and serve as the source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (see U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalentlyjoining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the disclosure, or can be substituted for the variable domains of one antigen-combining site of an antibody of the disclosure to create a chimeric bivalent antibody.

[161] All cell lines suitable for the expression and purification of antibodies or antibody fragments are considered to be within the scope of the disclosure. In some embodiments, the cell line is a mammalian cell line. Cell lines can be isolated or derived from any source, including human, mouse and hamster. Suitable cell lines include, but are not limited to, Chinese Hamster Ovary (CHO) cells, HEK 293 cells, HEK293T cells, BHK21 cells, NSO cells, PER.C6 cells, B cells, HEK 293-6E cells, Sp2 / 0-Ag14 cells and DG44 cells. In some embodiments, the cell line is a hybridoma cell line.

[162] The antibody can be expressed by a vector containing a DNA segment encoding the single chain antibody described herein.

[163] These can include vectors, liposomes, naked DNA, adjuvant-assisted DNA, gene gun, catheters, etc. Vectors include chemical conjugates such as described in WO 93 / 64701, which has targeting moiety (e.g., a ligand to a cellular surface receptor), and a nucleic acid binding moiety (e.g., polylysine), viral vector (e.g., a DNA or RNA viral vector), fusion proteins such as described in PCT / US 95 / 02140 (WO 95 / 22618) which is a fusion protein containing a target moiety (e.g., an antibody specific for a target cell) and a nucleic acid binding moiety (e.g., a protamine), plasmids, phage, etc. The vectors can be chromosomal, non-chromosomal or synthetic.

[164] Preferred vectors include viral vectors, fusion proteins and chemical conjugates. Retroviral vectors include moloney murine leukemia viruses. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector (see Geller, A. I. et al., J. Neurochem, 64:487 (1995); Lim, F., et al., in DNA Cloning: Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995); Geller, A. I. et al., Proc Natl. Acad. Sci.: U.S.A. 90:7603 (1993); Geller, A. I., et al., Proc Natl. Acad. Sci USA 87:1149 (1990), Adenovirus Vectors (see LeGal LaSalle et al., Science, 259:988 (1993); Davidson, et al., Nat. Genet 3:219 (1993); Yang, et al., J. Virol. 69:2004 (1995) and Adeno-associated Virus Vectors (see Kaplitt, M. G.. et al., Nat. Genet. 8:148 (1994).

[165] Pox viral vectors introduce the gene into the cells cytoplasm. Avipox virus vectors result in only a short term expression of the nucleic acid. Adenovirus vectors, adeno-associated virus vectors and herpes simplex virus (HSV) vectors are preferred for introducing the nucleic acid into neural cells. The adenovirus vector results in a shorter term expression (about 2 months) than adeno-associated virus (about 4 months), which in turn is shorter than HSV vectors. The particular vector chosen will depend upon the target cell and the condition being treated. The introduction can be by standard techniques, e.g., infection, transfection, transduction or transformation. Examples of modes of gene transfer include e.g., naked DNA, CaPO4 precipitation, DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection, and viral vectors.

[166] Exemplary VH amino acid sequences of CLEC2D antibodies of the disclosure are shown in Table 2 below. VH amino acid sequences having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100 % identity to the sequences listed in Table 2 are considered within the scope of the disclosure. Table 2. VH Amino Acid Sequences SEQID VH Amino Acid Sequence SEQID 1 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTI TRDTSASTAYMELSSLRSEDTAVYYCARGSLSRSGWYAGLFDYWGQGTLVTVSS SEQID 2 QITLKESGGGVVQPGRSLRLSCAASGFTFSSYSMNWVRQAPGKGLQWVAIISDDGSKSYYADSVQGRFTISRD NSRNTVFLQMNSLRAEDTAMYYCARDRGTKWNQLNDVFDMWGQGTMVTVSS SEQID 3 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMT RDTSTSTVYMELSSLRSEDTAVYYCARGRGYSSSRLYYFDYWGQGTLVTVSS SEQID 4 QVTLKESGGGLVRPGGSLRLSCEASGFTFSDPYMDWVRQAPGKGLEWVGRITNKRTGYATTYAASVKDRFTIS RDDSRKSVYLQMNSLKTEDTAVYYCATDVSGSFAAYGGQGTLVTVSS SEQID 5 EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTI TRDTSASTAYMELSSLRSEDTAVYYCAGEGGAVAGTVYWGQGTLVTVSS SEQID 6 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFT ISRDDSKNTLYLQMNSLKTEDTAVYYCTTDEYFYWGQGTLVTVSS SEQID 7 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS KNQFSLKLSSVTAADTAVYYCARVNPGSYTREVSNFDYWGQGTLVTVSS SEQID 8 QVQLQQSGPELVKPSQTLTLTCGISGDSVSSNSVTWNWVRQSPSRGLEWLGRTYYRSQWYYNYAVSVKSRITI SPDTSKNQFSLQLNSVTPEDTAVYYCATRGHNYGVDYWGPGTTVTVSS SEQID 9 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVCRIKSKTDGETTDYAAPVKGRFTI SRDDSKNTLYLQMNSLKTEDTAVYHCTTGVGWSPFQYWGQGTLVTVSS SEQID 10 EVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS RDDSKSIAYLQMNSLKTEDTAVYYCTRDDKIAAAGFTYWYFDLWGRGTLVTVSS SEQID 11 QVQLVQSGAEVKKPGASVKVSCKASGYTFAAYYLHWVRQAPGQGLEWMGRISPGNGVTSYAQKFQGRVTM TGDTSINTVYMQLNNLISGDTAVYYCAREAADDPFDHWGQGALVTVSS SEQID 12 EVQLVQSGGGVVQPGRSLTLSCAASGFTFSSHLMHWVRQAPG KGLEWVAVISYDGTSKYYGDSVKGRFTISRD NSKNTLYLQMNSLRAEDTAIYYCAKADYKYDWGQGTLVTVSS SEQID 13 EVQLVQSGGGLVKPGGSLRLSCTASGFTFGDYAMSWVRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS RDDSKSIAYLQMNSLKTEDTAVYYCTTHRRPIYDILTGFDYWGQGTLVTVSS SEQID 14 QLQLQESGGGLVQPGRSLRLSCTASGFTFGDYAMSWVRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS RDDSKSIAYLQMNSLKTEDTAVYYCTREDTMVRGVIPWGQGTLVTVSS SEQID 15 QLQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGYIYHSGSTYYNPSLKSRVTISVDRS KNQFSLKLSSVTAADTAVYYCARDRRYYDSSGYYPAYYFDYWGQGTLVTVSS SEQID 16 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSGSYTNYADSVKGRFTISRD NAKNSLYLQINSLRAEDTAIYYCARDGGYDSSGFHFDYWGQGTLVTVSS SEQID 17 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSNNRAAWNWIRQSPSRGLEWLGRTYYRSKWYNEYAVSVKSRITI NPDTSKNQFSLQLNSMTPEDSAVYYCAILPSSGYLQDHHYYGMDVWGQGTTVTVSS SEQID 18 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTM TTDTSTSTAYMELSSLRSEDTAVYYCARAAVGDGYSYGRLDWGQGTLVTVSS SEQID 19 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISAD KSISTAYLQWSSLKASDTAMYYCARLPSYYYDSSGYFTWYFDLWGRGTLVTVSS SEQID 20 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWIIPIFGIANYAQKFQGRVTITAD KSTSTAYMELSSLRSEDTAVYYCARELYNYGSKDYFDYWGQGTLVTVSS SEQID 21 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISAD KSISTAYLQWSSLKASDTAMYYCARGGTWDTAMVTGFDYWGQGTLVTVSS SEQID 22 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIAWVRQMPGKGLEWMGVIYPGDSDTRYSPSFQGQVTISAD KSINTAYLQWSSLKASDTAMYYCARPHYDILTGSRAPFDYWGQGTLVTVSS SEQID 23 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS KNQFSLKLSSVTAADTAVYYCARARVESKDGYFDYWGQGTLVTVSS SEQID 24 EVQLVESGGGVVQPGRSLRLSCAASGFTFTDAWMNWVRQAPGKGLEWIGRVKNKADGETTDYAAPVKGRIT ISRDDAKNTLYVQMNSLKTEDTAVYYCTADLRLSTWDAYDFWGQGTMVTVSS SEQID 25 QITLKESGGGLVQPGGSLRLSCTVSGFTFSNNWMTWVRQTPGKGLEWVANIKQDGTEKHYVDSVKGRFTISR DNAENSLYLQMNSLRGEDTAVYYCARNSQRSFDYWGQGTLVTVSS SEQID 26 QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISR DNSKNTLYLQMNSLRAEDTAVYYCAKDLGDPRGGILNYWGQGTLVTVSS SEQID 27 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCARSSPWGELSLYQGAFDIWGQGTMVTVSS SEQID 28 QITLKESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCAKDNDFWSGKVFDYWGQGTLVTVSS SEQID 29 EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSTSSTIYYADSVKGRFTISRDN SKNMLFLQMNSLRAEDTAVYYCAKEGGSGWRHYFDYWGQGTLVTVSS SEQID 30 QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCARDYCSSTSCQNWFDPWGQGTLVTVSS SEQID 31 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSNYVMSWVRQAPGKGLEWVSAISGIGDTTYYADSVKGRFTISRD NAKNTLYLQMNSLRAEDTAVYYCARGRVAGDAFDIWGQGTMVTVSS SEQID 32 QLQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCAKDQGAAAGTLGYFDYWGQGTLVTVSS SEQID 33 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVT MTRNTSISTAYMELSSLRSEDTAVYYCTRGIYDSSGSSNPFDSWGQGTLVTVSS SEQID 34 EVQLVQSGAEVKKPGASVKISCEASGYTFTDYAIHWVRQAPGQRLEWMGWINAGDGGTKSSREFQGRVTITR DTSATTAYMEVSSLRSEDTAVYYCARGYCSGGSCPGTDFDYWGQGTLVTVSS SEQID 35 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTM TRDTSTSTVYMELSSLRSEDTAVYYCARDGVGGRDGYNFDYWGQGTLVTVSS SEQID 36 EVQLVQSGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARAPLAADGYFDYWGQGTLVTVSS SEQID 37 EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITAD ESTSTAYMELSSLRSEDTAVYYCARARGLQYLIWYFDLWGRGTLVTVSS SEQID 38 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTM TRDTSTSTVYMELSSLRSEDTAVYYCASPGMVRGVITAPLDYWGQGTLVTVSS SEQID 39 EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYAISWVRQAPGQGLEWMGGIIPMYGTANYAQKFQGRVTITA DESTSTAYMELSSLRSEDTALYYCAREAKWGMYYFDYWGQGTLVTVSS SEQ ID 40 EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAIHWVRQAPGKGLEWVAIISDDGSKSYYADSVQGRFTISRDN SRNTVYLQMNSLRAEDTAMYYCARDRGTKWNQLNDVFDMWGQGTMVTVSS SEQID41 QMQLVQSGAEVKKPGASVKVSCTASGYTFTSSDINWVRQATGQGLEWMGWMNPNSGNTGYAEKFQGRVT MTSDSSISTAYMELRSLTTEDTAVYYCARGGGASYTDSWGQGTLVTVSS SEQID42 QVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS RDDSKSIAYLQMNSLKTEDTAVYYCTAKGGYVGYSYGPFGGYWGQGTLVTVSS SEQID43 QVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS RDDSKSIAYLQMNSLKTEDTAVYYCTRGGTMVRGFGFNYWGQGTLVTVSS SEQ ID 44 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS KNQFSLKLSSVTAADTAVYYCARARRAMIGPLPRLVGYFDLWGRGTLVTVSS SEQID45 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS KNQFSLKLSSVTAADTAVYYCARGRPAPSWVKTRNWFDPWGQGTLVTVSS SEQID46 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITI NPDTSKNQFSLQLNSVTPEDTAVYYCAREASSGWNWGQGTLVTVSS SEQID47 QVQLQESGPGLVKPSQTLSLTCAISGDSVSSNNAAWNWIRQSPSRGLEWLGRTFYRSKWYNDYAVSVKSRLTV NPDTSKNQFSLRLNSVSPEDTAVYYCARGGRYTKGGYFDDWGQGTLVTVSS SEQID48 QVTLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTS KNQVVLTMTNMDPVDTATYYCAHRLDSSGRGGYFDYWGQGTLVTVSS SEQID49 EVQLVESGGGVVQPGRSLRLSCTASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCAKELVGTSSPYYYYYYGMDVWGQGTMVTVSS SEQID50 QLQLQESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDYYYGSGSSPWGQGTLVTVSS SEQID51 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS KNQFSLKLSSVTAADTAVYYCARGRPYCSSTSCYPEWFDPWGQGTLVTVSS SEQID52 QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISR DNSKNTLYLQMNSLRAEDTAVYYCAKLRGIDYYDSSGYQRGFDYWGQGTLVTVSS SEQID53 QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYTGSTNYNPSLKSRVTISVDTSKN QFSLKLSSVTTADTAVYYCARGGRGDGAAFDIWGQGTMVTVSS SEQID54 QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSSAMHWVRQAPGKGLEWVAMIWHDESKKYYADSVKGRFTIS RDNSKNTLYLQMNSLRAEDTAVYYCARPPDGGNSGRWYFDLWGRGTLVTVSS SEQID55 QMQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISR DNSKNTLYLQMNSLRAEDTAVYYCAKDKNVRKHDYGDHPYGGYFDYWGQGTLVTVSS SEQID56 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTI TRDTSASTAYMELSSLRSEDTAVYYCARVAGATSLWYWGQGTLVTVSS SEQID57 QVQLQQSGPGLVKPSQSLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITIK PDTSKNQFSLQLNSVTPEDTAVYYCTRLANSDGVDVWGQGTMVTVSS SEQID58 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSDSAVWTWIRQSPSRGLEWLGRTYYKSKWYNDYAASVKSRITIN PDTSKNQFSLHLNSVTPEDTAVYYCARGVTRTFDYWGQGTTVTVSS SEQID59 QLQLQESGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITIN PDTSKNQFSLQLNSVTPEDTAVYYCAEGNGPFDPWGQGTLVTVSS SEQ ID 60 QITLKESGGGVVQPGRSLRLSCVASGFTFSTYPMHWVRQAPGKGLEWVAVISYDGRNEYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCATRDTPLVGVSIYWGQGTLVTVSS SEQID61 QMQLVQSGGGLVKAGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVSAISSNGGSTYYADSVKGRFTISRD NSKNTLYLQMSSLRAEDTAVYYCVNRAGYGDYRHFQHWGQGTLVTVSS SEQID62 EVQLVQSGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFISYDGSNKYYADSVKGRFTISR DNSKNTLYLQMNSLRAEDTAVYYCATTGDRFQEFDYWGQGTLVTVSS SEQID63 QMQLVQSGGVLLQPGRSLRLSCTASGFTFAAYNINWFRQGPGGGLEWVGFIRANADSGTTEYAASVKGRFFIS RDDSRSTAYLQMTSLKTEDTAVYYCARDDRGRGDDFDYWGQGTLVTVSS SEQ ID 64 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYGMTWVRQAPGKGLEWVSTISGNGVGTYYPDSVKDRFTISR DSSKNTVYLQMNSLRAEDTAVYYCVKHGRAGINWYFDLWGRGTLVTVSS SEQID65 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITI NPDTSKNQFSLQLNSVTPEDTAVYYCARGGGLWAFDIWGQGTTVTVSS SEQID66 EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVT MTRDTSISTAYMELSRLRSDDTAVYYCARDKIGSCPYWGQGTLVTVSS SEQID67 QVTLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTS KNQVVLTMTNMDPVDTATYYCAHRPDSSSQCFDYWGQGTLVTVSS SEQID68 QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCARSSGWSLPEDYWGQGTLVTVSS SEQID69 QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTM TEDTSTDTAYMELSSLRSEDTAVYYCATDVNPELLGAGFDYWGQGTLVTVSS SEQID70 QVTLKESGGGLVQPGGSLRLSCAASGFTFSDQYMDWVRQAPGKGLEWVGRVRNKANSYTTEYAASVKGRFTI SRDDSKNSLYLQMNSLNTEDTAMYFCASSLNSGGYRCFHHWGQGTLVTVSS SEQID71 QVQLVQSGGGLVQPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVSAISSNGGSTYYADSVKGRFTISRD NSKNTLYLQMSSLRAEDTAVYYCVKAPRGVVPAAMRGGYWGQGTLVTVSS SEQID72 QVQLQESGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS RDDSKSIAYLQMNSLKTEDTAVYYCTRLVGNSGSYYPFGYWGQGTLVTVSS SEQID73 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS KNQFSLKLSSVTAADTAVYYCARGRSLPYRGLAPRSFGGYYFDYWGQGTLVTVSS SEQID74 QVQLQESGGGLVRPGGSLRLSCGDSGFNFSGYEMNWVRQAPGKGLEWVSYVSTSGSTRYYADSVKGRFTISR DNAKNTLYLQMNSLRVEDTAVYYCARGRTHWGPQDFDYWGQGTLVTVSS SEQID75 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCAKGGMYYYGSGSSYFDYWGQGTLVTVSS SEQID76 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGSTYYADSVKGRFTISR DNSKNMLFLQMNSPRAEDTAVYYCAKKIAAAGKQPVDYWGQGTLVTVSS SEQID77 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS KNQFSLKLSSVTAADTAVYYCARRKVYDYVWGSYRLPGSVSYYFDYWGQGTLVTVSS SEQID78 QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISAD KSISTAYLQWSSLKASDTAMYYCARLPGRAARPDYWGQGTLVTVSS SEQID79 QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCARGPGAVAGTKPKYYFDYWGQGTLVTVSS SEQID80 EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISR DNSKNTLYLQMNSLRAEDTAVYYCARATYYYDSSGYRFDYWGQGTLVTVSS SEQID81 EVQLVQSGGGLVEPGGSLRLSCAASRFTFSDAWMSWVRQAPGKGLEWVGRIKSKISGGTTDYAAPVQGRFTI SRDDSKNTLYLQMDSLKTEDTAVYYCANRNLGYWGQGTLVTVSS SEQID82 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVT MTTDTSTSTAYMELRSLRSDDTAVYYCARARYYDSSGYIAPSGYFDYWGQGTLVTVSS SEQID83 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVT ITRDTSASTAYMELSSLRSEDTAVYYCARDGPAVDGAEYFQHWGQGTLVTVSS SEQID84 QLQLQESGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSLKSRITIN PDTSKNQFSLQLNSVTPEDTAVYYCASLASGSPPPGDYWGQGTLVTVSS SEQID85 QVTLKESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVALISYDGSKKYYANSVKGRFTISRD NSKNTLYLQMKSLRAEDTAMYYCAKGPIVGATMDYWGQGALVTVSS SEQID86 EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTM TTDTSTSTAYMELRSLRSDDTAVYYCARWYGDYGLDYWGQGTLVTVSS SEQID87 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLAWMGWINAGNGNTKYSEKFEGRVTI TRDTSASTAYMELSSLRSEDTAVYYCARVAKYYYESGGYRASNWFDPWGQGTLVTVSS SEQID88 QVQLQESGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITIN PDTSKNQFSLQLNSVTPEDTAVYYCARAPPPTVGWYAPVFDYWGQGTLVTVSS SEQID89 QLQLQESGGGLVQPGGSLRLSCSASGISFRDYWMHWIRQTPGKGLVWVSRINPDGSSTSYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCAKVTGRRVGAHDYWGQGTLVTVSS SEQID90 QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVT MTRDTSISTAYMELSRLRSDDTAVYYCAFAQPGAETLNFDLWGRGTLVTVSS SEQID91 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSKSAAWNWIRQSPSRGLEWLGRTYYRSKWNNDYALSVKSRITI NPDTSKNQFSLQLKSVTPEDTALYYCVRQVAGGMDVWGQGTTVTVSS SEQID92 QVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISR DNSKNTLYLQMNSLRAEDTAVYYCAKGSVYSGSYYMLIDYWGQGTLVTVSS SEQID93 QVQLQQSGPGLVRPSQTLSLTCVISGDSVSSGSAAWNWIRQSPSRGLEWLGRTYYRAKWYNEYAGSVKSRITIS PDTSKNQFSLQLNSVTPEDTAVYFCTRQDKDNTRYSGLGVWGQGTTVTVSS SEQID94 EVQLVETGGGLVQPGGSLRLSCAASEFTLRNYGVSWVRQAPGKGLEWVSGMSGSGYSTYYADSVKGRFTISR DSSKNTLFLQMDSLRAEDTAIYYCARGPRMWSSGIDAFDIWGHGTMVTVSS SEQID95 QVQLQQWGAGLLKPSETLSLTCAVYGGSVSGYYWSWIRQPPGKGLEWMGEIHHSGSTNYNPSLKSRVTISLDT PKNQFSLKLSSVTAADTAVYYCARRDWAGKRVWGQGTLVTVSS SEQID96 QVQLQQSGPGLLKPSQTLSLTCAISGDSVSSNTATWNWIRQSPSRGLEWLGRTYYRSKWYKDNALSVKSRITIN PDTSKNQFSLQLNSVTPEDTAVYYCAGGRAGIAAFDIWGQGTTVTVSS SEQID97 QVQLVQSGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSLIYSDGRTNYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKGALQGEWRRFDYWGQGTLVTVSS SEQID98 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITI NPDTSKNQFSLQLNSVTPEDTAVYYCTRTNQGYGGNSGVFDYWGQGTLVTVSS SEQID99 QVQLQQSGPGLVKPSQTLSLTCAISGDSVSGNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITI NPDTSKNQFSLQLNSVTPEDTAVYYCARIVGGAVDCWGQGTLVTVSS SEQ ID 100 EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTI TRDTSASTAYMELSSLRSEDTAVYYCARVRVGATTVYDSWFDPWGQGTLVTVSS SEQ ID 101 QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD NSKNTLYLQMNSLRAEDTAVYYCAKDGGSSPYYDSSGLLPWYFDLWGRGTLVTVSS SEQ ID 102 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEYVSAISSNGGSTYYANSVKGRFTISRD NSKNTLYLQMGSLRAEDMAVYYCARAKFWTYYFDYWGQGTLVTVSS SEQ ID 103 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS KNQFSLKLSSVTAADTAVYYCARGGGSGSYYKRFFDYWGQGTLVTVSS SEQ ID 104 EVQLVQSGAEVRKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGWISAYDGNTNYAQKLQGRVTM TTDTSTSTAYMEVRSLRSDDTAVYYCARDGTVRRVVGATTPGNFDYRGQGTLVTVSS SEQ ID 105 EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTIS RDNSKNTLYLQMNSLRAEDTAVYYCARDLNRGYCSGGSCFGYWGQGTLVTVSS SEQ ID 106 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYISSSGTTIYYADSVKGRFTVSRD NAKNSLYLQMNSLRAEDTAVYYCARDYSSSGECFDYWGQGTLVTVSS SEQ ID 107 EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTIS RDNSKNTLYLQMNSLRAEDTAVYYCARDQAAMVGYFDYWGQGTLVTVSS SEQ ID 108 QVTLKESGGGVVQPGRSLRLSCAASGFIFSNYAIHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARTFAGYSSKLGYFDLWGRGTLVTVSS

[167] A VH amino acid sequence of the disclosure may be encoded by a polynucleotide shown in Table 3 below. Table 3. VH DNA Sequences SEQ ID VH DNA Sequence SEQ ID 109 GAAGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG TTTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGG CCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAA ATATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAG CCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGA GGCTCCTTGTCCCGAAGTGGCTGGTACGCCGGACTCTTTGACTACTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCA SEQ ID 110 CAGATCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTATAGCATGAACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGCAGTGGGTGGCAATTATATCAGATGATGGAAGTAAGAGTTACT ACGCAGACTCCGTGCAGGGCCGATTCACCATCTCCAGAGACAATTCGAGGAACACAGTA TTTCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTATGTATTACTGTGCGAGAGA CAGGGGAACTAAATGGAACCAATTGAATGATGTTTTTGATATGTGGGGCCAAGGGACAA TGGTCACCGTCTCTTCA SEQ ID 111 GAAGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG TTTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGG CCCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGC TACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAG TCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGA GGCCGAGGGTATAGCAGCAGTCGGCTCTACTACTTTGACTACTGGGGCCAGGGAACCCT GGTCACCGTCTCCTCA SEQ ID 112 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCTTGGTCCGGCCTGGAGGGTCCCTGAGACT CTCCTGTGAAGCCTCTGGATTCACCTTCAGTGACCCCTACATGGACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTTGGCCGAATTACAAATAAGCGTACCGGTTACGCCA CAACATATGCCGCGTCTGTGAAGGACAGATTCACCATCTCAAGAGATGATTCAAGGAAG TCAGTATATCTGCAAATGAACAGCCTGAAGACCGAGGACACGGCCGTATATTATTGTGC AACAGATGTCAGTGGGTCCTTCGCGGCCTACGGGGGCCAGGGCACCCTGGTCACCGTCT CCTCA SEQ ID 113 GAGGTCCAGCTGGTACAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGCTATGCATTGGGTGCGCCAGGC CCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAA TATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGC CTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGGGAG AGGGCGGAGCAGTGGCTGGTACTGTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCC TCA SEQ ID 114 CAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACT CTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGCAAAACTGATGGTGGGACA ACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAA CACGCTGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTA CCACAGACGAGTATTTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 115 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGTAA ATCCGGGGAGTTATACGAGGGAGGTGAGCAACTTTGACTACTGGGGCCAGGGAACCCTG GTGACCGTCTCCTCA SEQ ID 116 CAGGTACAGCTGCAGCAGTCAGGTCCAGAATTGGTGAAGCCCTCGCAGACCCTCACACT CACCTGTGGCATCTCCGGGGACAGTGTCTCTAGCAACAGTGTTACTTGGAACTGGGTCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACTTACTACCGGTCCCAGTGG TATTATAATTATGCGGTGTCTGTGAAAAGTCGAATAACCATCAGCCCAGACACATCCAA GAACCAGTTCTCCCTGCAGTTGAATTCTGTGACTCCCGAGGACACGGCTGTCTATTACTG TGCAACCAGGGGACATAACTACGGTGTAGATTACTGGGGCCCGGGGACCACGGTCACCG TCTCCTCA SEQ ID 117 CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACT CTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTTTGCCGTATTAAAAGCAAAACTGATGGTGAGACA ACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAA CACGCTGTATCTGCAAATGAACAGCCTGAAAACTGAGGACACAGCCGTGTATCACTGTA CCACAGGGGTGGGATGGTCGCCCTTCCAATACTGGGGCCAGGGCACCCTGGTCACCGTC TCCTCA SEQ ID 118 GAGGTCCAGCTGGTACAGTCTGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC TAGAGACGACAAAATAGCAGCAGCTGGATTCACATACTGGTACTTCGATCTCTGGGGCC GTGGCACCCTGGTCACCGTCTCCTCA SEQ ID 119 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT CTCCTGCAAGGCTTCTGGATACACCTTCGCCGCCTATTATTTACACTGGGTGCGACAGGC CCCTGGACAAGGCCTTGAGTGGATGGGGCGGATCAGCCCTGGTAACGGTGTCACAAGTT ATGCACAGAAATTTCAGGGCAGAGTCACCATGACCGGGGACACGTCCATTAACACAGTC TACATGCAACTGAACAATTTGATTTCTGGCGACACGGCCGTATATTACTGTGCGAGAGA GGCTGCCGACGACCCGTTTGACCATTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA SEQ ID 120 GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGACACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTTCCCATCTTATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAACTAGTAAATATT ACGGAGACTCCGTGAAGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACGTTG TATCTGCAAATGAACAGCCTGCGAGCTGAAGACACGGCTATATATTACTGTGCGAAAGC AGATTATAAATATGACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 121 GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACT CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC TACTCATAGACGCCCAATTTACGATATTTTGACTGGTTTTGACTACTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCA SEQ ID 122 CAGCTGCAGCTGCAGGAGTCCGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC TAGAGAGGATACTATGGTTCGGGGAGTTATTCCCTGGGGCCAGGGAACCCTGGTCACCG TCTCCTCA SEQ ID 123 CAGCTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCT CACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTCCTGGAGCTGGATCCG GCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATCATAGTGGGAGCACCT ACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAGGTCCAAGAACCAG TTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGA GATCGGCGTTACTATGATAGTAGTGGTTATTATCCCGCCTACTACTTTGACTACTGGGGC CAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 124 GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTTACACAAACT ACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTG TATCTGCAAATAAACAGCCTGAGAGCCGAGGACACGGCCATTTATTACTGTGCGAGAGA CGGGGGCTATGATAGTAGTGGTTTTCACTTTGACTACTGGGGCCAGGGAACCCTGGTCA CCGTCTCCTCA SEQ ID 125 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAACAACAGGGCTGCTTGGAACTGGATCA GGCAGTCGCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG TATAATGAATATGCAGTCTCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAACTCTATGACTCCCGAGGACTCGGCTGTGTATTACTG TGCAATTTTGCCTAGTAGTGGTTATCTACAGGACCACCACTACTACGGTATGGACGTCTG GGGCCAAGGGACCACGGTCACCGTCTCCTCA SEQ ID 126 GAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG TCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTACGGTATCAGCTGGGTGCGACAGG CCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAAC TATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAG CCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGA GCCGCGGTGGGGGATGGATACAGCTATGGTCGGCTCGATTGGGGCCAGGGAACCCTGGT CACCGTCTCCTCA SEQ ID 127 GAGGTCCAGCTGGTACAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGA TCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGA TGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGA TACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGC CTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAC TCCCCTCGTATTACTATGATAGTAGTGGTTACTTTACCTGGTACTTCGATCTCTGGGGCCG TGGCACCCTGGTGACCGTCTCTTCA SEQ ID 128 GAGGTCCAGCTGGTACAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT CTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGC CCCTGGACAAGGGCTTGAGTGGATGGGATGGATCATCCCTATCTTTGGTATAGCAAACT ACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGC CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAG AACTATACAACTATGGTTCAAAGGACTACTTTGACTACTGGGGCCAGGGAACCCTGGTC ACCGTCTCCTCA SEQ ID 129 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGA TCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGA TGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGA TACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGC CTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGG GCGGTACTTGGGATACAGCTATGGTTACGGGCTTTGACTACTGGGGCCAGGGAACCCTG GTCACCGTCTCCTCA SEQ ID 130 GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGA TCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGCCTGGGTGCGCCAGA TGCCCGGGAAAGGCCTGGAGTGGATGGGGGTCATCTATCCTGGTGACTCTGATACCAGA TACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAATACCGC CTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAC CCCATTACGATATTTTGACTGGTTCCCGGGCGCCCTTTGACTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCTCA SEQ ID 131 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGCCC GAGTGGAATCCAAGGATGGGTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC TCCTCA SEQ ID 132 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACTTTCACTGATGCCTGGATGAACTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGATTGGCCGTGTTAAAAACAAAGCTGATGGTGAGACA ACGGACTACGCTGCACCCGTCAAAGGCAGAATCACCATCTCAAGAGATGATGCAAAGA ACACTCTGTATGTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTATTGT ACCGCTGACCTGCGACTTTCTACGTGGGATGCTTATGATTTCTGGGGCCAAGGGACAATG GTCACCGTCTCTTCA SEQ ID 133 CAGATCACCTTGAAGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTAAGACT CTCTTGTACAGTCTCAGGATTCACCTTTAGTAACAATTGGATGACCTGGGTCCGCCAGAC TCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAACTGAGAAACAC TATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCGAGAACTCACT GTATCTGCAGATGAACAGCCTGAGAGGTGAGGACACGGCCGTGTATTATTGTGCGAGAA ACAGTCAACGTTCGTTTGACTACTGGGGCCAGGGCACCCTGGTGACCGTCTCCTCA SEQ ID 134 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA TTTAGGGGATCCCCGGGGTGGTATTTTGAACTACTGGGGCCAGGGCACCCTGGTCACCG TCTCCTCA SEQ ID 135 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCCCGGTC GAGCCCCTGGGGGGAGTTATCGTTATACCAGGGGGCTTTTGATATCTGGGGCCAAGGGA CAATGGTCACCGTCTCTTCA SEQ ID 136 CAGATCACCTTGAAGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA TAACGATTTTTGGAGTGGGAAAGTCTTTGACTACTGGGGCCAGGGCACCCTGGTCACCG TCTCCTCA SEQ ID 137 GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTATAGCATGAACTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTTTCATACATCAGTAGTACTAGTAGTACCATATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAATATGCTG TTTCTACAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA AGGGGGCAGTGGCTGGCGCCACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG TCTCCTCA SEQ ID 138 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT GTCCTGTGCAGCCTCTGGATTCACCTTCAGCAGCTATGCTATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGA TTATTGTAGTAGTACCAGCTGCCAGAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGG TCACCGTCTCCTCA SEQ ID 139 CAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAACTATGTCATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTATTGGTGATACTACATACT ACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACGCTG TATCTGCAAATGAACAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCAAGAGG GCGCGTGGCGGGGGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTGACCGTCTCTT CA SEQ ID 140 CAGCTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA TCAAGGGGCAGCAGCTGGTACCCTGGGGTACTTTGACTACTGGGGCCAGGGAACCCTGG TGACCGTCTCCTCA SEQ ID 141 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT CTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAACTGGGTGCGACAGGC CACTGGACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTAACACAGGCT ATGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACAGCC TACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTACGAGAGG AATCTATGATAGTAGTGGTTCTTCCAATCCCTTTGACTCCTGGGGCCAGGGAACCCTGGT GACCGTCTCCTCA SEQ ID 142 GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGA TTTCCTGCGAGGCTTCTGGATACACCTTCACTGATTATGCTATACATTGGGTGCGCCAGG CCCCCGGACAAAGACTTGAGTGGATGGGATGGATCAACGCTGGCGATGGTGGCACAAA AAGTTCACGGGAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGACCACAG CCTACATGGAGGTGAGCAGTCTGAGATCTGAAGACACGGCTGTCTATTACTGTGCGAGA GGATATTGTAGTGGTGGTAGCTGCCCAGGAACGGATTTTGACTACTGGGGCCAGGGAAC CCTGGTCACCGTCTCCTCA SEQ ID 143 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT TTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGC CCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCT ACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGT CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAG ATGGTGTAGGAGGGAGAGATGGCTACAATTTTGACTACTGGGGCCAGGGAACCCTGGTC ACCGTCTCCTCA SEQ ID 144 GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACG CAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT CTTCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCCC CCTAGCAGCAGATGGCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC A SEQ ID 145 GAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGG CCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAAC TACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAG CCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGA GCCCGGGGGCTACAGTACCTAATCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTG ACCGTCTCCTCA SEQ ID 146 CAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT TTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGC CCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCT ACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGT CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGCC CGGGTATGGTTCGGGGAGTTATTACTGCCCCGCTTGACTACTGGGGCCAGGGCACCCTG GTCACCGTCTCCTCA SEQ ID 147 GAGGTCCAGCTGGTACAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGC CCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATGTATGGTACAGCAAACT ACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGC CTACATGGAACTGAGCAGCCTGAGATCTGAGGACACGGCCCTCTATTACTGTGCGAGAG AAGCTAAGTGGGGAATGTACTACTTTGACTACTGGGGCCAGGGCACCCTGGTCACCGTC TCCTCA SEQ ID 148 GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATACACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAATTATATCAGATGATGGAAGTAAGAGTTACT ACGCAGACTCCGTGCAGGGCCGATTCACCATCTCCAGAGACAATTCGAGGAACACAGTA TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTATGTATTACTGTGCGAGAGA CAGGGGAACTAAATGGAACCAATTGAATGATGTTTTTGATATGTGGGGCCAAGGGACAA TGGTCACCGTCTCTTCA SEQ ID 149 CAGATGCAGCTGGTGCAATCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT CTCCTGCACGGCTTCTGGATACACCTTCACCAGTTCTGATATCAACTGGGTGCGACAGGC CACTGGACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTAACACCGGCT ATGCAGAGAAGTTCCAGGGCAGGGTCACCATGACCAGCGACTCCTCCATAAGCACCGCC TACATGGAGTTGAGAAGCCTGACCACTGAGGACACGGCCGTATATTACTGTGCGAGAGG TGGGGGTGCGAGCTATACTGACTCCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA SEQ ID 150 CAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC CGCTAAGGGGGGCTACGTCGGATACAGCTATGGACCTTTTGGGGGCTACTGGGGCCAGG GAACCCTGGTCACCGTCTCCTCA SEQ ID 151 CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC TAGAGGGGGGACTATGGTTCGGGGTTTCGGATTTAACTACTGGGGCCAGGGAACCCTGG TCACCGTCTCCTCA SEQ ID 152 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGCCC GGCGGGCTATGATAGGGCCGCTTCCGCGACTTGTCGGGTACTTCGATCTCTGGGGCCGTG GAACCCTGGTCACCGTCTCCTCA SEQ ID 153 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGCC GCCCCGCCCCATCCTGGGTTAAAACCCGTAACTGGTTCGACCCCTGGGGCCAGGGAACC CTGGTCACCGTCTCCTCA SEQ ID 154 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG TGCAAGAGAGGCTAGCAGTGGCTGGAACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT CA SEQ ID 155 CAGGTGCAGCTGCAGGAGTCCGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAATGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATTCTACAGGTCCAAGTGG TATAATGACTATGCAGTTTCTGTGAAAAGTCGACTAACCGTCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCGGTTGAACTCTGTGAGTCCCGAGGACACGGCTGTGTATTACTG TGCAAGAGGGGGAAGATATACCAAGGGAGGGTACTTTGACGACTGGGGCCAGGGAACC CTGGTGACCGTCTCCTCA SEQ ID 156 CAGGTCACCTTGAAGGAGTCTGGTCCTACGCTGGTGAAACCCACACAGACCCTCACGCT GACCTGCACCTTCTCTGGGTTCTCACTCAGCACTAGTGGAGTGGGTGTGGGCTGGATCCG TCAGCCCCCAGGAAAGGCCCTGGAGTGGCTTGCACTCATTTATTGGGATGATGATAAGC GCTACAGCCCATCTCTGAAGAGCAGGCTCACCATCACCAAGGACACCTCCAAAAACCAG GTGGTCCTTACAATGACCAACATGGACCCTGTGGACACAGCCACATATTACTGTGCACA CAGATTGGATAGCAGTGGCCGTGGTGGTTACTTTGACTACTGGGGCCAGGGCACCCTGG TCACCGTCTCCTCA SEQ ID 157 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTACAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA GTTGGTGGGTACCAGCTCTCCTTATTACTACTACTACTACGGTATGGACGTCTGGGGCCA AGGGACAATGGTCACCGTCTCTTCA SEQ ID 158 CAGCTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACG CAGACTCCGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT CTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTA TTACTATGGTTCGGGGAGTTCTCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 159 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGCC GGCCATATTGTAGTAGTACCAGCTGCTACCCAGAGTGGTTCGACCCCTGGGGCCAGGGA ACCCTGGTCACCGTCTCCTCA SEQ ID 160 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAATT AAGGGGTATAGATTACTATGATAGTAGTGGTTACCAACGGGGGTTTGACTACTGGGGCC AGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 161 CAGGTGCAGCTGCAGGAGTCCGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGGATCCGGCAGCC CCCAGGGAAGGGACTGGAGTGGATTGGCTATATCTATTACACTGGGAGCACCAACTACA ACCCCTCCCTCAAGAGCCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCC CTGAAGCTGAGCTCTGTGACCACTGCGGACACGGCCGTGTATTACTGTGCGAGAGGTGG GAGGGGGGATGGGGCCGCTTTTGACATCTGGGGCCAAGGGACAATGGTCACCGTCTCTT CA SEQ ID 162 CAGGTGCAGCTGGTGCAATCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCGTCTGGATTCACCTTCAGCAGCTCTGCCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGACTGGAGTGGGTGGCAATGATTTGGCATGATGAGAGTAAGAAATACT ATGCAGACTCCGTGAAGGGCCGATTCACTATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGACC CCCCGACGGTGGTAACTCCGGTCGCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGT CACCGTCTCCTCA SEQ ID 163 CAGATGCAGCTGGTGCAATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA CAAGAACGTCCGAAAACATGACTACGGTGACCACCCCTACGGGGGGTACTTTGACTACT GGGGCCAGGGCACCCTGGTGACCGTCTCCTCA SEQ ID 164 GAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT TTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGC CCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAA TATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGC CTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGAG TGGCGGGAGCTACTTCCCTATGGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA SEQ ID 165 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGAGCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG TATAATGATTATGCAGTATCTGTGAAGAGTCGAATAACCATCAAACCAGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG TACAAGGCTAGCTAATTCCGACGGTGTGGACGTCTGGGGCCAAGGGACAATGGTCACCG TCTCCTCA SEQ ID 166 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCGACAGTGCTGTTTGGACCTGGATCAG GCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAAGTCGAAGTGGT ATAATGATTATGCAGCATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAG AACCAGTTCTCCCTGCACCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGT GCAAGAGGTGTAACCCGGACCTTTGACTACTGGGGCCAGGGGACCACGGTCACCGTCTC CTCA SEQ ID 167 CAGCTGCAGCTGCAGGAGTCGGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG TGCAGAAGGCAATGGGCCGTTCGACCCCTGGGGCCAGGGAACCCTGGTGACCGTCTCCT CA SEQ ID 168 CAGATCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGTAGCCTCTGGATTCACCTTCAGTACCTATCCCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGACGTAATGAATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAAAACACGCTG TATCTGCAAATGAACAGTCTGCGAGCTGAAGACACGGCTGTCTATTATTGTGCGACTCG GGATACACCTTTGGTTGGGGTTTCGATATACTGGGGCCAGGGCACCCTGGTCACCGTCTC CTCA SEQ ID 169 CAGATGCAGCTGGTGCAATCTGGGGGAGGCCTGGTCAAGGCTGGGGGGTCCCTGAGACT CTCCTGTTCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC TCCAGGGAAGGGACTGGAATATGTTTCAGCTATTAGTAGTAATGGGGGTAGCACATACT ACGCAGACTCAGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTTCAAATGAGCAGTCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGTGAATCG GGCGGGTTACGGTGACTACAGACACTTCCAGCACTGGGGCCAGGGCACCCTGGTCACCG TCTCCTCA SEQ ID 170 GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATGATGGAAGTAATAAATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGACAAC AGGGGACCGCTTCCAAGAGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT CA SEQ ID 171 CAGATGCAGCTGGTGCAGTCTGGGGGAGTCTTGCTTCAGCCAGGGCGGTCCCTGAGACT CTCCTGTACAGCTTCTGGATTCACCTTTGCTGCTTATAATATCAACTGGTTCCGCCAGGGT CCTGGGGGGGGGCTGGAGTGGGTAGGTTTCATTAGAGCCAACGCTGATAGTGGGACAAC AGAGTACGCCGCGTCTGTGAAAGGCAGATTCTTCATCTCAAGAGATGATTCCAGAAGCA CCGCCTACCTGCAAATGACTAGCCTTAAAACCGAGGACACAGCCGTTTATTACTGTGCC AGAGATGATCGGGGTCGGGGAGATGACTTTGACTACTGGGGCCAGGGCACCCTGGTCAC CGTCTCCTCA SEQ ID 172 CAGGTGCAGCTGGTGCAATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGGCATGACGTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTAGTGGTAATGGTGTTGGCACATACT ACCCAGACTCCGTGAAGGACCGGTTCACCATCTCCAGAGACAGTTCCAAGAACACGGTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGTGAAACA TGGTAGGGCCGGAATAAACTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTGACCG TCTCCTCA SEQ ID 173 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG TGCAAGAGGGGGAGGGCTTTGGGCTTTTGATATCTGGGGCCAAGGGACCACGGTCACCG TCTCCTCA SEQ ID 174 GAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT CTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGC CCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACAAACT ATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCC TACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGA CAAGATCGGCAGCTGTCCTTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 175 CAGGTCACCTTGAAGGAGTCTGGTCCTACGCTGGTGAAACCCACACAGACCCTCACGCT GACCTGCACCTTCTCTGGGTTCTCACTCAGCACTAGTGGAGTGGGTGTGGGCTGGATCCG TCAGCCCCCAGGAAAGGCCCTGGAGTGGCTTGCACTCATTTATTGGGATGATGATAAGC GCTACAGCCCATCTCTGAAGAGCAGGCTCACCATCACCAAGGACACCTCCAAAAACCAG GTGGTCCTTACAATGACCAACATGGACCCTGTGGACACAGCCACATATTACTGTGCACA CAGACCGGATAGCAGCAGTCAATGTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG TCTCCTCA SEQ ID 176 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAAG CAGTGGCTGGTCACTGCCTGAAGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT CA SEQ ID 177 CAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT CTCCTGCAAGGTTTCCGGATACACCCTCACTGAATTATCCATGCACTGGGTGCGACAGGC TCCTGGAAAAGGGCTTGAGTGGATGGGAGGTTTTGATCCTGAAGATGGTGAAACAATCT ACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCGAGGACACATCTACAGACACAGC CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCAACGG ATGTGAACCCGGAGCTACTGGGGGCGGGATTTGACTACTGGGGCCAGGGCACCCTGGTC ACCGTCTCCTCA SEQ ID 178 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGAGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACCAGTACATGGACTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTGTTAGAAACAAAGCTAACAGTTACACCA CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAGAAC TCACTGTATCTGCAAATGAATAGTCTGAACACCGAGGACACGGCCATGTATTTCTGTGCT AGTAGTCTCAATAGTGGGGGCTACCGATGCTTCCATCACTGGGGCCAGGGCACCCTGGT GACCGTCTCCTCA SEQ ID 179 CAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT CTCCTGTTCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC TCCAGGGAAGGGACTGGAATATGTTTCAGCTATTAGTAGTAATGGGGGTAGCACATACT ACGCAGACTCAGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTTCAAATGAGCAGTCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGTGAAAGC GCCGAGGGGTGTAGTACCAGCTGCTATGCGGGGGGGCTACTGGGGCCAGGGAACCCTG GTCACCGTCTCCTCA SEQ ID 180 CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGAC TCTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGG CTCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACA ACAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAG CATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTA CTAGATTGGTGGGCAATAGTGGGAGCTACTATCCGTTTGGGTACTGGGGCCAGGGAACC CTGGTGACCGTCTCCTCA SEQ ID 181 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC CCTGAAGCTGAGCTCGGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGCC GGTCCCTTCCCTACCGGGGGTTGGCTCCTAGATCTTTCGGAGGATACTACTTTGACTACT GGGGCCAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 182 CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTACGGCCTGGAGGGTCCCTGAGACT CTCCTGTGGAGACTCTGGATTCAACTTCAGTGGATATGAAATGAACTGGGTCCGCCAGG CTCCAGGGAAGGGGCTGGAGTGGGTTTCATACGTCAGTACTAGTGGTAGTACCAGATAC TACGCAGACTCTGTGAAGGGCCGATTTACCATCTCCAGAGACAACGCCAAGAACACCCT GTATTTGCAAATGAACAGTCTGAGAGTCGAGGACACGGCTGTGTATTACTGTGCAAGAG GACGGACTCACTGGGGCCCCCAGGACTTTGACTACTGGGGCCAGGGAACCCTGGTCACC GTCTCCTCA SEQ ID 183 CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGG AGGAATGTATTACTATGGTTCGGGGAGCTCGTACTTTGACTACTGGGGCCAGGGAACCC TGGTGACCGTCTCCTCA SEQ ID 184 CAGGTGCAGCTGGTGCAATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAATGGGTCTCAGGTATTAGTGGTAGTGGTGGTAGCACATACT ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACATGCTG TTTCTGCAAATGAACAGCCCGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAGAA AATAGCAGCAGCTGGTAAGCAACCTGTTGACTACTGGGGCCAGGGAACCCTGGTCACCG TCTCCTCA SEQ ID 185 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAAGGA AGGTGTATGATTACGTTTGGGGGAGTTATCGCCTCCCCGGGTCGGTATCGTACTACTTTG ACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 186 CAGGTCCAGCTGGTACAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGA TCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGA TGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGA TACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGC CTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAC TCCCGGGGAGAGCAGCTCGTCCAGACTACTGGGGCCAGGGCACCCTGGTCACCGTCTCC TCA SEQ ID 187 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGG CCCCGGGGCAGTGGCTGGTACTAAGCCAAAGTACTACTTTGACTACTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCA SEQ ID 188 GAGGTCCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGGGC CACGTATTACTATGATAGTAGTGGTTATAGGTTTGACTACTGGGGCCAGGGAACCCTGGT CACCGTCTCCTCA SEQ ID 189 GAGGTCCAGCTGGTACAGTCTGGGGGAGGCTTGGTAGAACCGGGGGGGTCCCTTAGACT CTCCTGTGCAGCCTCTCGATTCACTTTCAGTGACGCCTGGATGAGCTGGGTCCGCCAGGC TCCAGGTAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGCAAAATAAGTGGTGGGACA ACAGACTACGCTGCACCCGTGCAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAA CACGCTGTATCTGCAAATGGACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTG CGAACCGAAACTTAGGCTACTGGGGCCAGGGCACCCTGGTGACCGTCTCCTCA SEQ ID 190 GAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT TTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGC CCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAA TATTCACAGAAGTTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGC CTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAG CTCGTTACTATGATAGTAGTGGTTATATTGCCCCATCGGGTTACTTTGACTACTGGGGCC AGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 191 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT TTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGC CCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAA TATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGC CTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGAG ATGGCCCCGCCGTTGATGGTGCTGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTC ACCGTCTCCTCA SEQ ID 192 CAGCTGCAGCTGCAGGAGTCGGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGCGAGGCCTTGAGTGGCTGGGAAGGACTTACTACAGGTCCAAGTGG TATAATGATTATGCAGTATCTCTGAAAAGTCGAATAACCATCAACCCGGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTATATTACTG TGCAAGTTTGGCGAGTGGTTCCCCCCCTCCGGGGGACTACTGGGGCCAGGGAACCCTGG TGACCGTCTCCTCA SEQ ID 193 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTACCTATGGCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCACTTATATCATATGATGGAAGTAAAAAATACT ATGCAAACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGTTG TATCTGCAAATGAAAAGTCTGAGAGCTGAGGACACGGCTATGTATTACTGTGCGAAAGG CCCTATAGTGGGAGCGACTATGGACTACTGGGGCCAGGGAGCCCTGGTCACCGTCTCCT CA SEQ ID 194 GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGG CCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAAC TATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAG CCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGA TGGTACGGTGACTACGGCCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC A SEQ ID 195 GAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT TTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGC CCCCGGACAAAGGCTTGCGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAAT ATTCAGAGAAGTTCGAAGGCAGAGTCACCATCACCAGGGACACATCCGCGAGCACAGC CTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGGG TCGCCAAATATTATTACGAGAGTGGTGGTTATCGGGCCTCCAACTGGTTCGACCCCTGGG GCCAGGGCACCCTGGTCACCGTCTCCTCA SEQ ID 196 CAGGTGCAGCTGCAGGAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG TGCAAGAGCGCCCCCTCCGACTGTTGGCTGGTACGCCCCCGTCTTTGACTACTGGGGCCA GGGAACCCTGGTCACCGTCTCCTCA SEQ ID 197 CAGCTGCAGCTGCAGGAGTCCGGGGGAGGCTTAGTTCAGCCGGGGGGGTCCCTGAGACT CTCCTGCTCAGCCTCTGGAATCAGCTTCAGAGATTACTGGATGCACTGGATCCGCCAAAC TCCAGGGAAGGGGCTGGTGTGGGTCTCACGTATTAATCCTGATGGGAGTAGCACAAGCT ACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGT TACGGGACGGAGAGTGGGAGCCCATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCT CCTCA SEQ ID 198 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT CTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGC CCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACAAACT ATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCC TACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCCTTTGC CCAGCCGGGCGCTGAGACGTTGAACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCG TCTCCTCA SEQ ID 199 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAAAAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAATGG AATAATGATTATGCATTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAAGTCTGTGACTCCCGAGGACACGGCTCTGTATTACTG TGTAAGACAAGTCGCGGGCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCT CCTCA SEQ ID 200 CAGGTGCAGCTGGTGCAATCTGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGG ATCGGTATATAGTGGGAGCTACTATATGCTCATTGACTACTGGGGCCAGGGCACCCTGG TCACCGTCTCCTCA SEQ ID 201 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAGGCCCTCGCAGACCCTCTCACT CACCTGTGTCATCTCCGGGGACAGTGTCTCTAGCGGCAGTGCTGCTTGGAACTGGATCAG GCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATATTATAGGGCCAAGTGGT ATAATGAATATGCAGGGTCTGTGAAAAGCCGAATAACCATCAGTCCGGACACATCCAAG AACCAGTTCTCCCTGCAACTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGT ACAAGACAAGACAAAGACAACACGAGATATTCCGGTTTGGGCGTCTGGGGCCAAGGGA CCACGGTGACCGTCTCCTCA SEQ ID 202 GAGGTGCAGCTGGTGGAGACCGGGGGAGGCTTAGTTCAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGAATTCACCCTTAGGAACTATGGCGTGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTATGAGTGGTAGTGGTTATAGTACATACT ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAGTTCCAAGAACACGCTG TTTCTGCAAATGGACAGCCTGAGAGCCGAGGACACGGCCATATATTACTGTGCGAGAGG GCCCCGAATGTGGAGCAGTGGCATTGATGCTTTTGATATCTGGGGCCACGGGACAATGG TGACCGTCTCTTCA SEQ ID 203 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCGTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATGGGGGAAATCCATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCACTAGACACGCCCAAGAACCAGTTCTC CCTGAAGCTAAGCTCTGTGACCGCCGCGGACACGGCTGTATATTACTGTGCGAGACGGG ATTGGGCAGGAAAAAGGGTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 204 CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTATTAAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACACTGCTACTTGGAACTGGATCAG GCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGT ATAAGGATAATGCACTGTCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAG AACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGT GCAGGAGGTCGGGCTGGTATTGCCGCTTTTGATATCTGGGGCCAAGGGACCACGGTCAC CGTCTCCTCA SEQ ID 205 CAGGTGCAGCTGGTGCAATCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAATGGGTCTCACTTATTTATAGTGATGGTCGCACAAACTATG CAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAGGGGG CCCTACAGGGCGAATGGCGGAGATTTGACTACTGGGGCCAGGGCACCCTGGTCACCGTC TCCTCA SEQ ID 206 CAGGTGCAGCTACAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATATTACAGGTCCAAGTGG TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG TACAAGAACCAACCAGGGATACGGTGGTAACTCCGGGGTATTTGACTACTGGGGCCAGG GAACCCTGGTCACCGTCTCCTCA SEQ ID 207 CAGGTGCAGCTACAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT CACCTGTGCCATCTCCGGGGACAGTGTCTCTGGCAACAGTGCTGCTTGGAACTGGATCA GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA GAACCAGTTCTCCCTGCAGTTGAATTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG TGCGAGGATAGTGGGAGGTGCCGTTGACTGCTGGGGCCAGGGAACCCTGGTGACCGTCT CCTCA SEQ ID 208 GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG TTTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGG CCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAA ATATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAG CCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGA GTTAGAGTGGGAGCTACTACTGTTTACGACAGCTGGTTCGACCCCTGGGGCCAGGGAAC CCTGGTGACCGTCTCCTCA SEQ ID 209 CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA TGGGGGGTCCAGCCCATACTATGATAGTAGTGGTTTACTACCCTGGTACTTCGATCTCTG GGGCCGTGGCACCCTGGTCACCGTCTCCTCA SEQ ID 210 CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC TCCAGGGAAGGGACTGGAATATGTTTCAGCTATTAGTAGTAATGGGGGTAGCACATATT ATGCAAACTCTGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTTCAAATGGGCAGCCTGAGAGCTGAGGACATGGCTGTGTATTACTGTGCGAGAGC TAAGTTTTGGACATACTACTTTGACTACTGGGGCCAGGGAACCCTGGTGACCGTCTCCTC A SEQ ID 211 CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGCG GTGGTTCGGGGAGTTATTATAAGAGGTTCTTTGACTACTGGGGCCAGGGAACCCTGGTC ACCGTCTCCTCA SEQ ID 212 GAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAGGAAGCCTGGGGCCTCAGTGAAGG TCTCCTGCAAGGCTTCTGGTTACACATTTACCAGTTATGCCATCAGCTGGGTGCGACAGG CCCCTGGACAAGGGCTTGAGTGGATGGGGTGGATCAGCGCTTACGACGGTAACACAAAC TATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAG CCTACATGGAGGTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGA GATGGTACGGTCCGAAGGGTAGTGGGAGCTACTACCCCTGGAAACTTTGACTACAGGGG CCAGGGAACCCTGGTCACCGTCTCCTCA SEQ ID 213 GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACT ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA TCTGAATCGAGGATATTGTAGTGGTGGTAGCTGCTTTGGCTACTGGGGCCAGGGAACCC TGGTCACCGTCTCCTCA SEQ ID 214 CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTACAGCCGGGGGGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTACTACCATATACT ACGCAGACTCTGTGAAGGGCCGATTCACCGTCTCCAGAGACAATGCCAAGAACTCACTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGGGA TTATAGCAGCTCGGGGGAGTGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCT CCTCA SEQ ID 215 GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACT ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA TCAGGCAGCTATGGTAGGCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCT CCTCA SEQ ID 216 CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT CTCCTGTGCAGCCTCTGGATTCATCTTCAGTAACTATGCTATACACTGGGTCCGCCAGGC TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGGAC TTTTGCGGGGTATAGCAGCAAACTGGGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGT CACCGTCTCCTCA

[168] Exemplary VL amino acid sequences of CLEC2D antibodies of the disclosure are shown in Table 4 below. VL amino acid sequences having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100 % identity to the sequences listed in Table 4 are considered within the scope of the disclosure. Table 4. VL Amino Acid Sequences SEQ ID VL Amino Acid Sequence SEQ ID 217 ETTLTQSPATLSVSLGERATLSCRASQSIGSNLVWYQLKPGQGPRLVIYSATSRATGIPARFSGSG SGTEFILSISNLQSEDLAVYYCQQYGSSPPTTFGQGTRLEIKR SEQ ID 218 EIVMTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGRAPRLLIYGASNRATGIPDRFSGS GSGTDFTLIISRLEPEDFALYYCQQYGSSPGTFGQGTKVDIKR SEQ ID 219 DVVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGS GSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKLEIKR SEQ ID 220 EIVLTQSPDSLAVSLGERATITCKSSRNILYSGNNKNFLAWYQHKPGQPPKLLIYWASTRESGVP DRFSGSGSGTDFTLTINSLEAEDAATYYCHQSSSLPHTFGPGTKVDIKR SEQ ID 221 ETTLTQSPGTLSLSPGQRATLSCRASESVSKSYLLWYQQKPGQAPRLLIYGASTRASGIPNRFSGS GSGTDFTLTISRLEPEDSAVYYCQHYGSSRTFGQGTRLEIKR SEQ ID 222 ETTLTQSPGTLSLSPGERATLSCRASQSISSTYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGS GSGTDFTLSISRLEPEDFAVYYCQQYGNSPPGATFGQGTRLEIKR SEQ ID 223 DIQLTQSPSSLSASVGERVTITCRSSQALRNVVGLGDDLAWYQHTPGSAPKILIYSTSTLQSGVSS RFSGGKSGRDFTLTIDRLQPGDSATYYCLQHHDFPFTFGPGTKVEIKR SEQ ID 224 DVVMTQSPLSLPVTPGEPASISCRSSQSLLNSNGYNYLEWYLQKPGQSPQLLIYLGSNRASGVPD RFSGSGSGTDFTLKISRVEADDAGVYYCMQSLQTPLTFGGGTKLEIKR SEQ ID 225 ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSSPRITFGQGTRLEIKR SEQ ID 226 DVVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCQQYNNWPPMYTFGQGTKLEIKR SEQ ID 227 DVVMTQSPATLSVSPGERVTLSCRASQSVRDNVGWYKQKPGQPPRLVIYGASTRATGIPARISG SGSGTEFTLTISSLQSEDFAVYYCQQFNNWPYTFGQGTKLEIKR SEQ ID 228 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLHTGVPSRFSGSG SGTDFTLTISSLQPEDFATYYCQQSYSIPRTFGQGTKVEIKR SEQ ID 229 DVVMTQSPATLSVTPGERATLSCRASQSVNSNVAWYQQKPGQAPRLLIYDVSTRATDIPARFSG SGSGTDFTLTISRLDPEDFAVYYCQQCASSPPVTFGGGTKLEIKR SEQ ID 230 EIVMTQSPATLSLSPGERATLSCGASQSVSSSYLAWYQQKPGLAPRLLIYDASSRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSSPRVTFGGGTKVDIKR SEQ ID 231 DVVMTQSPGTLSLSPGERATLSCRASQSVSSSALAWFQQKPGQAPRLLIYDSSSRATGIPDSFSGS GSGTEFTLTISSLQPEDFATYYCQQFNTYPNTFGQGTKLEIKR SEQ ID 232 DIQMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWFLQKPGQSPRLLIYMGSSRASGVPER FSGSGSGTDFTLKISRVEAEDVGVYYCMQTLHTVTFGGGTKVEIKR SEQ ID 233 ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSSLLFGQGTRLEIKR SEQ ID 234 DIQLTQSPSFLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSG SGTDFTFTISSLQPEDIATYYCQQYDNLPPLTFGGGTKVEIKR SEQ ID 235 DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPD RFSGSGSGTDFTVKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIKR SEQ ID 236 EIVLTQSPLSLPVTLGQPASISCRSCQSLVYSDGNTYLNCFQQRPGQSPRRLIYKVSNRDSGVPDR FSGSGSGTDFTLEISRVEAEDVGIYFCMQGLQTPFTFGPGTKVDIKR SEQ ID 237 DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG SGSGTDFTLTISRLEPEDFAVYYCQQYGSSPALTFGGGTKLEIKR SEQ ID 238 EIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSTRASGVPDR FSGSGSGTDFTLKISRAEAEDVGVYYCMQALHTPWTFGLGTKVDIKR SEQ ID 239 DIQMTQSPATLSVSPGERATLFCRASEGLTTNLAWYQHKPGQAPRLLIYAASTRATGVPARFSG SGSGTDFTLTISSLQSEDSAVYYCQQYNHWPLYTFGQGTKVEIKR SEQ ID 240 DIQLTQSPSTLSLSPGERATLSCRASQSVSSYLAWYQQKSGQAPRLLIYDASNRATGIPARFSGSG SGTDFTLTISSLEPEDFAVYYCQQGSNWPLTFGGGTKVEIKR SEQ ID 241 DIVMTHTPLSSPVTLGQPASISCRSSQSLEHTDGNTYLSWLHQRPGQPPRLLIYKVSTRFSGVPDR FSGSGAGTDFTLKISRVEAEDVGVYYCVQATHYPRTFGHGTKVEIKR SEQ ID 242 EIVLTQSPGTLSLSPGERATLSCRASQSISGSYLAWYQQKRGQAPRLLIYDASSRAEGIPDRFIGSG SGTDFTLTISRLEPEDFAMYYCQQYGSSPIFTFGPGTKVDIKR SEQ ID 243 EIVLTQSPDSLPVTPGEPASISCRSSQSLLHSNGNNYLDWYLQKPGQSPQLLIYLGSNRASGVPDR FSGSGSGTDFTLKLSRVEAEDVGVYYCMQGLQIPITFGPGTKVDIKR SEQ ID 244 DIQMTQSPSSVSASVGDRVTITCRASQNIRHWLVWYQQKLGQAPKLLIYAASNLQSGVPSRFSG SGSGTEFTLTINSLQAEDFATYYCLQHNSYPWTFGQGTKVEIKR SEQ ID 245 EIVLTQSPDFQSVTPKQKVTITCRASQSIGGSLHWYQQKPGQSPKLIIKYASQSFSGVPSRFSGSGS GTDFTLTIDSLEAEDAATYYCHQSISLPLTFGGGTKVDIKR SEQ ID 246 ETTLTQSPGTLSLSPGEGATLSCRASQSVTSNYLAWYQQKPGQAPRLLIYGASYRATGIPDRFSG SGSGTDFTLTISRLEPEDFAVYYCQQYASSVTFGQGTRLEIKR SEQ ID 247 DVVMTQSPATLSVSPGERATLSCRASQSISSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKLEIKR SEQ ID 248 DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASARESGV PDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQFYSPPRTFGQGTKVEIKR SEQ ID 249 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSSPPGTFGGGTKVDIKR SEQ ID 250 EIVLTQSPGTLSLSPGERATLSCRASQSLSTNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSG SGTEFTLTITSLQSEDFAVYYCQQYHNWPPYTFGQGTKVEIKR SEQ ID 251 DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGS GSGTEFTLTISSLQPDDFATYYCQQYNSYWTFGQGTKVEIKR SEQ ID 252 ETTLTQSPGTLSLSPGEGATLSCRASHSVGANYIAWYQQKPGQAPRLLIHTASKRATGVPERFSG SGSGTDFTLSISRLEPEDFAVYHCQQYAAAPITFGQGTRLEIKR SEQ ID 253 EIVMTQSPSSLSASVGDRVIITCRASQGIANYLAWYQQKPGKGPKLLIYASSTLQSGVPSRFSGSG SGTDFTLTISGLQPEDVATYYCQKYNSVPLTFGGGTKVDIKR SEQ ID 254 DVVMTQSPVSLAVSLGERATINCKSSQSVLYRTNNKNYLAWYQQKPGQPPKLLIYWASTRESG VPDRFSGSGSGTDFTLTISSLQPEDVAVYYCQQYYNLPRSFGQGTKLEIKR SEQ ID 255 DIVMTHTPDSLAVSLGERATINCKSNRSVLYSPNNQNYLGWYQQKPGQPPKLLIYWASTRDSG APDRFSGSGSGTDFTLTINSLQAEDVAVYYCQQYASTPYTFGQGTKVEIKR SEQ ID 256 DVVMTQSPATLSLSPGERATLSCRASESVNSNFLAWYQQKPGQAPRLLIYAASTRATGIPARFSG SGSGTEFTLIITSLQSEDFAVYYCQQYNNWPLTFGGGTKLEIKR SEQ ID 257 DVVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGS GSGTDFTLTISSLEPEDFAVYYCQQRSNWSLTFGGGTKLEIKR SEQ ID 258 ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASTRATGIPDRFSGS GSGTDFTLTIGRLEPEDFAVYYCQHYGPSRRITFGQGTRLEIKR SEQ ID 259 ETTLTQSPDTLSVSPGGRATLSCRASQSIGSNLAWYQQKPGQSPRLLIYDASTRATGIPARFSGSG SGTEFTLTISSLESEDFVLYYCQQHGEWPTFGQGTRLEIKR SEQ ID 260 DVVMTQSPATLSLSPGERATLSCRASQSVGNSLAWYQQKPGQAPRLLIYDASNRATGIPARFSG SGSGTDFTLTITSLEPEDFAIYYCQQRGTWPPLTFGGGTKLEIKR SEQ ID 261 DVVMTQSPSSLSASVGDTVTITCRASQSITNWLAWYQQKPGKAPKRLIYGASSLQSGVPSRFSGS GSGTEFTLTISSLQPEDFATYYCQQYTNYPRTFGQGTKLEIKR SEQ ID 262 DIQMTQSPSTLSASVGDRVTITCRARQSISNRLAWYQQKPGRAPNVLIYKASTLANGVPSRFSGS GSGTEFTLTISSLQPDDFATYYCQQYQSYWTFGPGTKVEIKR SEQ ID 263 DIQLTQSPATLSLSPGERATLSCKASQSVSSYLAWYQQKLGQAPRLLIYDASNRATGIPARFSAS GSGTDFTLTISSLQPEDVATYYCQKYNSPPRTFGQGTKVEIKR SEQ ID 264 ETTLTQSPGTLSLSPGERVSLSCRASQNVYSNFLAWYQQRPGQAPSLLIYGASSRAAGVPDRFSG SGSGTDFALTISRVEPEDFAVYYCQQYGTSPITFGQGTRLEIKR SEQ ID 265 EIVLTQSPRSSPVTLGQPASISCRSSQSLEHGDGNTYLSWLQQRPGQPPRLLIYKVSNRLSGVPDR FSGSGAGTDFTLKISRVEAEDVGVYYCMQGIYWPRTFGQGTRLEIKR SEQ ID 266 ETTLTQSPVTLSLSPGDRATLSCRASQSVSSTSLAWYQHKPGQAPRLLIYGASRRATGIPDRFSGS GSGTDFTLTINRLEPEDFAVYYCQHYGSSPPITFGQGTRLEIKR SEQ ID 267 ETTLTQSPATLSVSPGERATLSCRASQSVGSKLAWYQQKPGQAPRLLIYGASTRATGVPVRFSGS GSGTEFTLTISSLQSEDFAVYYCQQYNNWPPITFGQGTRLEIKR SEQ ID 268 EIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDR FSGSGSGTDFTLKISRVEAEDVGVYYCMQTLQTPLTFGGGTKVDIKR SEQ ID 269 DVVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESG VPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSSTPYTFGQGTKLEIKR SEQ ID 270 DIVMTHTPLSLSVTPGQPASISCKSSQSLLGGDGKTYLYWYLQKPGQPPQLLLYEVSNRFSGVPD RFSGSGAATDFTLKISRVEAEDVGVYYCMQSTQFPWTFGQGTKVEIKR SEQ ID 271 ETTLTQSPGTLSLSAGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYAASYRATGIPDRFSG RGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPITFGQGTRLEIKR SEQ ID 272 DVVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYDASTRATGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCQHYNNWPHTFGQGTKLEIKR SEQ ID 273 ETTLTQSPGTLSLSPGERATLSCRASQSVSSNSLAWYQQKPGQAPRLLIYGASSRASGIPDRFNGS GSGTDFTLTINRLEPEDFAVYYCQQYGNSQTFGQGTRLEIKR SEQ ID 274 DVVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKLEIKR SEQ ID 275 DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVP DRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPRTFGGGTKLEIKR SEQ ID 276 DIQMTQSPSTLSASVGDRVTITCRASQSISRWLAWYQQKPGKAPKLLIYKASTIKSGVPSRFSAS GSGTEFTLTISSLQPEDFATYYCQHYKSDSRTFGQGTKVEIKR SEQ ID 277 DVVMTQSPSSLAASVGDRITITCRPSQDIGTYLNWYQQKAGEAPKLLIYAASNLHSGVSSRFRG VGSGTQFTLTISSLQPEDFATYYCHQSYGPRTFGQGTKLEIKR SEQ ID 278 ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCQQYNNWPPITFGQGTRLEIKR SEQ ID 279 DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG SGSGTDFTLTISRLEPEDFAVYYCQQYGSSGYTFGQGTKLEIKR SEQ ID 280 ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSSFGQGTRLEIKR SEQ ID 281 EIVLTQSPSTLSASVGDRVTITCRASQSISSCLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSG SGTEFTLTISTLQPEDFATYYCQQLNSYPQTFGQGTKVDIKR SEQ ID 282 DIVMTHTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQPPQLLIYEVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCMQSIQLPLTFGGGTKVEIKR SEQ ID 283 DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG SGSGTDFTLTISRLEPEDFAVYYCQQYNNWPLTFGGGTKLEIKR SEQ ID 284 DIQLTQSPDSLAVSLGERATINCTSSQSVLYSSNNKNYIAWYQQKPGQPPKLLIYWASTRESGVP DRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYYIPRTFGQGTKVEIKR SEQ ID 285 DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRAPGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTRTFGQGTKLEIKR SEQ ID 286 ETTLTQSPGTLSLSPGERATLSCRASQSLTSSYLAWYQQKPGQAPRLLIYRASSRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSSPNTFGQGTRLEIKR SEQ ID 287 EIVLTQSPLSLPVTLGQPASISCRSSQSLVHSNGHTYLSWFQQRPGQSPRRLIYEVSNRDSGVPDR FSGSGSGTDFTLRISRVEAEDVGVYYCLQGTHWPPLTVGGGTKVDIKR SEQ ID 288 DVVMTQSPATLSLSPGERATLSCRASQSVGSDLAWYQQKPGQAPRLLIYRASTRAAGIPARFSG SGSGTDFTLTISRLEPEDFAVFYCQQYGRSPYTSGQGTKLEIKR SEQ ID 289 DIVMTHTPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGV PDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIKR SEQ ID 290 EIVMTQSPLSLSVTPGEPASISCRSSQSLLHSSGYNYLDWYLQKPGQSPQLLIYLGSTRASGVPDR FSGSGSGTDFTLKISRVEAEDVGVYYCMQGLQIPLTFGGGTKVDIKR SEQ ID 291 DIVMTHTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQPPQLLIYEVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGVYYCMQSIQLPWTFGQGTKVEIKR SEQ ID 292 ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCQQYNNWPRFGQGTRLEIKR SEQ ID 293 DVVMTQSPSTLSASVGDRVTITCRASQTINSWLAWYQQKPGKAPKLLISRASRLESGVPSRFSGS ASGTEYILTINSLQPDDFAMYFCHQYNSYSPTFGQGTKLEIKR SEQ ID 294 ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPARFSGS GSGTDFTLTISSLEPEDFAVYYCQQRYNWPITFGQGTRLEIKR SEQ ID 295 EIVLTQSPATLSLSPGETATLSCRASQTIGPKSFGWYQQRPGQAPRLLIYDSNRATGIPARFSGSGS GTDFTLTISSLEPEDFAVYYCQQRSRWPLTFGPGTKVDIKR SEQ ID 296 DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLYWFQQRAGQSPRRLIYKVSKRDSGVP DRFSGSGSGTDFTLKISRVEAEDVGIYYCVQGRHWPYTLGQGTKLEIKR SEQ ID 297 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGS GSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVDIKR SEQ ID 298 DVVMTQSPSTLSASVGDRVTITCRASQSITTWLAWSQQQPGKAPKLLIYKASSLTSGVPSRFSGS GSGTEFTLTISSLQPDDFASYYCHHYNGASRMFGQGTKLEIKR SEQ ID 299 ETTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGS GSGTDFTLTISSLEPEDFAVYYCQQRSNWPFFGQGTRLEIKR SEQ ID 300 ETTLTQSPATLTLSPGERVTLSCRASQSIGTYVAWYQQKPGQAPRFLIYDSSNRATGIPARFSGSG SGTDFTLTISSLEPEDFAFYYCQQRAEWPLTFGQGTRLEIKR SEQ ID 301 DVVMTQSPGTLSLSPGERATLSCRASQSVNSGYLAWYQQKPGQPPRLLISGVSTRATGIPDRFSG SGSGTDFTLTISRLEPEDFAVYYCQEYGNSAMYNFGQGTKLEIKR SEQ ID 302 ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGS GSGTEFTLTISSLQSEDFAVYYCQQYNNWPPFTFGQGTRLEIKR SEQ ID 303 DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLGWYQQKSGQAPRLLIYGASSRATDIPDRFSG SGSGTDFTLTISKLEAEDSAVYYCQQYGISPLAFGQGTKLEIKR SEQ ID 304 ETTLTQSPATLSVSPGERATLSCRASQSISNNLAWYQQKPGQAPRLLIYGTSTRATGIPARFSGSG SGTEFTLTISSLQSEDFAVYYCQQYNFWPSITFGQGTRLEIKR SEQ ID 305 ETTLTQSPGTLSLSPGERATLSCRASQSVSSSSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSSQTFGQGTRLEIKR SEQ ID 306 DVVMTQSPLSLPVSLGQPASISCRSNQSLVYSDGGTYLNWFQQRAGQSPRRLVYKVSNRDSGVP DRFSGSGSGTDFTLRISRVEAEDVGVYYCMQGTHWPYTFGQGTKLEIKR SEQ ID 307 DIQLTQSPSSLSASVGDRVTVTCRASQSISSYLNWYQQKPGKAPQLLIYDASNLETGVPSRFSGS GSGTDFTFTISSLQPEDFATYYCQQFDNVPVTFGGGTKVEIKR SEQ ID 308 EIVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDR FSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPRTFGQGTKLEIKR SEQ ID 309 DVVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS GSGTDFTLTINRLEPEDFAVYYCQQYGSSSMYTFGQGTKLEIKR SEQ ID 310 DVVMTQSPSSLSASVGDSVAITCRASQSISNYLNWYQQRPGKAPKLLIFAASSLQSGVPSRFSGS GSGTDFTLTISSLQPEDFATYSCQQSYITPWTFGQGTKLEIKR SEQ ID 311 DVVMTQSPGTLSLSPGERATLSCRASQSVSTLLAWYQQKPGQAPRLLIYDASNRATGIPGRFSAS GSGTDFSLTISSLETEDSAVYYCQHRYVWPFTFGGGTKLEIKR SEQ ID 312 DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGS GSGTEFTLTIRSLQPEDFATYYCLQHNSYPRTFGQGTKVEIKR SEQ ID 313 DVVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGS GSGTDFTLTISSLEPEDFAVYYCQQRSNWPWTFGQGTKLEIKR SEQ ID 314 DVVMTQSPLSLPVTLGQAASISCRSSHSLTTTDGRTYVAWFQQRPGQSPRRLLYEVSKRDSGAP DRFSGSGSGTDFTLKISRVEADDVGIYHCMQGTHGPHTFGQGTKLEIKR SEQ ID 315 ETTLTQSPATLSVSPGERATLSCRASQSVTSNLAWYQQKPGQAPRLLIYGASNRATGIPARFSVS GSGTDFTLTISRLEPEDFAVYYCQQYGSPPPTTFGQGTRLEIKR SEQ ID 316 DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG SGSGTDFTLTISRLEPEDFAVYYCQQYGSSRRTFGQGTKLEIKR SEQ ID 317 ETTLTQSPGTLSLSPGERATLSCRASQSVFNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSG GGSGTDFTLTISRLEPEDFAVYCCQQYGSSPITFGQGTRLEIKR SEQ ID 318 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSG SGTDFTLTISRLEPEDFAVYYCQQYGSSLRYTFGQGTKLEIKR SEQ ID 319 EIVLTQSPDSLAVSLGERATINCKSSQSVLYDSNSKNYLSWYQQKPGQPPKLLISWASTRGSGVP DRFSGSGSGTDFTLTISSLQAEDVAVYYCQQFYGIPHFGQGTRLEIKR SEQ ID 320 DVVMTQSPATLSLSPGERATLSCRASQSVGTNLAWYQQKPGQAPRLLIYDASNRATGIPARFSG SGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPITFGGGTKLEIKR SEQ ID 321 DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDR FSGSGAGTDFTLKISRVEAEDVGVYYCMQGTQFPQTFGQGTKLEIKR SEQ ID 322 EIVLTQSPGTLSLSPGERATLSCRASQSVISRYLAWYQQKPGQAPRLLIHGASTRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKVEIKR SEQ ID 323 DIQLTQSPSTLAASVGDRVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLESGVPSRFSGS GSGTEFTLTISSLQPDDFATYYCQQYNSYSGTFGQGTKVEIKR SEQ ID 324 DVVMTQSPAILSVSPGERATLSCRASQSVSSSLAWYQQKPGQPPRLLIYGASTRATAIPARFSGS GSGTEFTLTISSLQSEDFAVYYCQRYDNWPPLFGQGTKLEIKR

[169] A VL amino acid sequence of the disclosure may be encoded by a polynucleotide shown in Table 5 below. Table 5. VL DNA Sequences SEQ ID VL DNA Sequence SEQ ID 325 GAAACGACACTCACGCAGTCTCCAGCCACCCTATCTGTGTCTCTAGGAGAAAGAGCCACCC TTTCTTGCAGGGCCAGTCAGAGTATTGGCAGCAACTTAGTCTGGTACCAGCTGAAACCTGGC CAGGGTCCCAGGCTCGTCATATATAGTGCAACCTCTAGGGCCACTGGAATCCCAGCCAGGT TCAGCGGCAGTGGGTCTGGGACAGAGTTCATTCTCTCCATCAGCAACCTGCAGTCTGAAGAT CTTGCAGTTTATTACTGTCAGCAGTATGGTAGTTCACCTCCGACCACCTTCGGCCAAGGGAC ACGACTGGAGATTAAACGT SEQ ID 326 GAAATTGTGATGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAAAAACCT GGCCGGGCTCCCAGGCTCCTCATCTATGGCGCATCCAACAGGGCCACAGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCATCATCAGCAGACTGGAGCCTGA AGATTTTGCCTTGTATTACTGTCAGCAGTATGGAAGCTCACCGGGAACGTTCGGCCAAGGG ACCAAAGTGGATATCAAACGT SEQ ID 327 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCGGACGTTCGGCCAAGGGACCAA GCTGGAGATCAAACGT SEQ ID 328 GAAATTGTGTTGACGCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CACCTGCAAGTCCAGCCGGAATATTTTATACAGCGGCAACAATAAAAACTTCTTGGCTTGGT ATCAGCACAAACCAGGACAGCCTCCTAAGTTGCTCATTTACTGGGCATCTACCCGGGAATCC GGGGTCCCTGACCGATTTAGTGGCAGCGGGTCTGGGACAGATTTCACCCTCACCATCAATA GCCTGGAAGCTGAAGATGCTGCAACGTATTACTGTCATCAGAGTAGTAGTTTACCTCACACT TTCGGCCCTGGGACCAAAGTGGATATCAAACGT SEQ ID 329 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGCAAAGAGCCACCC TCTCCTGCAGGGCCAGTGAGAGTGTTAGCAAGAGCTACTTACTCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCACCAGGGCCAGTGGCATCCCAAAC AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG AAGATTCTGCAGTGTATTACTGTCAGCACTATGGCAGCTCTCGCACCTTCGGCCAAGGGACA CGACTGGAGATTAAACGT SEQ ID 330 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTATTAGCAGCACCTACTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCAGCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAACTCACCTCCGGGAGCCACCTTCGGCC AAGGGACACGACTGGAGATTAAACGT SEQ ID 331 GACATCCAGTTGACCCAGTCTCCTTCCTCCCTGTCTGCATCTGTGGGAGAAAGAGTCACCAT CACTTGCCGGTCCAGCCAGGCCCTGCGAAATGTTGTCGGCCTTGGCGATGATTTAGCCTGGT ATCAACACACGCCAGGCAGCGCCCCCAAGATCCTGATCTACTCTACATCGACTTTACAAAGT GGAGTCTCATCAAGATTCAGCGGCGGAAAGTCTGGGAGAGACTTCACTCTCACGATCGATC GTCTGCAGCCTGGAGATTCTGCAACTTATTACTGTCTCCAGCACCATGATTTCCCTTTCACTT TCGGCCCTGGGACCAAGGTGGAAATCAAACGT SEQ ID 332 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGAATAGTAATGGATACAACTATTTGGAGTGGTACC TGCAGAAGCCGGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG TGGAGGCTGACGATGCTGGTGTTTATTACTGCATGCAGTCTCTACAAACTCCTCTCACTTTC GGCGGTGGGACCAAGCTGGAGATCAAACGT SEQ ID 333 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG AAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCCCGGATCACCTTCGGCCAA GGGACACGACTGGAGATTAAACGT SEQ ID 334 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCTATGTACACTTTTGGCCAGGG GACCAAGCTGGAGATCAAACGT SEQ ID 335 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGTCACACT CTCCTGCAGGGCCAGTCAGAGTGTTAGAGACAACGTAGGTTGGTACAAGCAGAAACCTGGC CAACCTCCCAGGCTCGTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGAT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGTTTAATAATTGGCCTTACACTTTTGGCCAGGGGACCAA GCTGGAGATCAAACGT SEQ ID 336 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT CACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGG AAAGCCCCTAACCTCCTGATCTATGCTGCATCCAGTTTGCACACTGGGGTCCCATCAAGGTT CAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATT TTGCAACTTACTACTGTCAACAGAGTTACAGTATTCCTCGAACGTTCGGCCAAGGGACCAAG GTGGAAATCAAACGT SEQ ID 337 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGGGAAAGGGCCACCCT CTCCTGCAGGGCCAGTCAAAGTGTTAACAGCAACGTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGTATCCACCAGGGCCACTGATATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTTGACCCTGAAGAT TTTGCAGTGTATTACTGTCAGCAGTGTGCTAGCTCACCTCCTGTCACTTTCGGCGGAGGGAC CAAGCTGGAGATCAAACGT SEQ ID 338 GAAATTGTGATGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCGGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCTGGCGCCCAGGCTCCTCATCTATGATGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCGGGTCACTTTCGGCGGAG GGACCAAAGTGGATATCAAACGT SEQ ID 339 GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCGCCTTAGCCTGGTTCCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCTATGATTCATCCAGCAGGGCCACTGGCATCCCAGACA GCTTCAGCGGCAGTGGATCTGGGACAGAATTCACACTCACAATCAGTAGCCTGCAGCCTGA AGATTTTGCAACTTATTACTGTCAACAGTTTAATACCTACCCCAACACTTTTGGCCAGGGGA CCAAGCTGGAGATCAAACGT SEQ ID 340 GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTTCC TGCAGAAGCCAGGGCAGTCTCCACGGCTCCTGATCTATATGGGTTCTAGTCGGGCCTCCGGG GTCCCTGAGAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG TGGAGGCTGAGGATGTTGGGGTCTATTACTGCATGCAAACTTTACACACTGTCACTTTCGGC GGCGGGACCAAGGTGGAAATCAAACGT SEQ ID 341 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG AAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACTCCTCTTCGGCCAAGGGACA CGACTGGAGATTAAACGT SEQ ID 342 GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTTGGAGACAGAGTCACCAT CACTTGCCGGGCCAGTCAGGGCATTAGCAGTTCTTTGGCCTGGTATCAGCAAAAGCCAGGG AAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTT CAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGAT ATTGCAACATATTACTGTCAACAGTATGATAATCTCCCTCCTCTCACTTTCGGCGGAGGGAC CAAGGTGGAAATCAAACGT SEQ ID 343 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTCACAGTGAAAATCAGCAGAG TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCGTACACTTTT GGCCAGGGGACCAAGCTGGAGATCAAACGT SEQ ID 344 GAAATTGTGTTGACGCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT CTCCTGCAGGTCTTGTCAAAGCCTCGTATACAGTGATGGCAACACCTACTTGAATTGCTTTC AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAGGTTTCTAACCGGGACTCTGG GGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACAGATTTTACACTGGAAATCAGCAGA GTGGAGGCTGAGGATGTTGGGATTTATTTCTGCATGCAAGGTCTACAAACTCCATTCACTTT CGGCCCTGGGACCAAAGTGGATATCAAACGT SEQ ID 345 GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTGCGCTCACTTTCGGCGGAG GGACCAAGCTGGAGATCAAACGT SEQ ID 346 GAAATTGTGATGACGCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTACTCGGGCCTCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGACTTTACACTGAAAATCAGCAGAG CGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACACACTCCGTGGACGTTC GGCCTAGGGACCAAAGTGGATATCAAACGT SEQ ID 347 GACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGGGCCACCC TCTTTTGCCGGGCCAGTGAAGGTCTTACCACCAACTTAGCCTGGTACCAGCACAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGCTGCCTCCACCAGGGCCACTGGTGTCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT TCCGCAGTTTATTACTGTCAGCAGTATAATCACTGGCCTCTCTACACTTTTGGCCAGGGGAC CAAGGTGGAAATCAAACGT SEQ ID 348 GACATCCAGTTGACCCAGTCTCCTTCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAATCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGGGTAGCAACTGGCCGCTCACTTTCGGCGGAGGGACCAA GGTGGAAATCAAACGT SEQ ID 349 GATATTGTGATGACCCACACTCCACTCTCCTCACCTGTCACCCTTGGACAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAAAGCCTCGAACACACTGATGGAAACACCTACTTAAGTTGGCTTC ACCAGAGGCCAGGCCAGCCCCCAAGACTGTTAATTTATAAGGTTTCTACCCGGTTCTCTGGG GTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATCAGCAGGG TGGAGGCTGAGGATGTCGGCGTTTATTACTGCGTGCAGGCTACACACTATCCTCGGACGTTC GGCCATGGGACCAAGGTGGAGATCAAACGT SEQ ID 350 GAAATTGTGCTGACTCAGTCTCCAGGCACCCTGTCCTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTATTAGCGGCAGTTACTTAGCCTGGTACCAGCAGAAACGT GGCCAGGCTCCCAGGCTCCTCATCTATGATGCGTCCAGCAGGGCCGAAGGCATCCCAGACA GGTTCATTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGACTTTGCTATGTATTACTGTCAGCAGTATGGTAGCTCACCAATATTCACTTTCGGCCCTG GGACCAAAGTGGATATCAAACGT SEQ ID 351 GAAATTGTGCTGACTCAGTCTCCAGACTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGAAACAACTATTTGGATTGGTACC TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAACTCAGCAGAG TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTCTACAAATCCCTATCACTTTC GGCCCTGGGACCAAAGTGGATATCAAACGT SEQ ID 352 GACATCCAGATGACCCAGTCTCCATCTTCTGTGTCTGCATCTGTGGGAGACAGAGTCACCAT CACTTGTCGGGCGAGTCAGAACATTCGCCACTGGTTAGTCTGGTATCAGCAAAAATTAGGG CAAGCCCCTAAACTCCTGATCTATGCTGCGTCCAATTTGCAAAGTGGGGTCCCGTCAAGGTT CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAACAGCCTGCAGGCTGAAGAT TTTGCAACCTATTACTGTCTACAGCATAACAGTTACCCGTGGACGTTCGGCCAAGGGACCAA GGTGGAAATCAAACGT SEQ ID 353 GAAATTGTGTTGACGCAGTCTCCAGACTTTCAGTCTGTGACTCCAAAGCAGAAAGTCACCAT CACCTGCCGGGCCAGTCAGAGCATTGGTGGTAGCTTACACTGGTACCAGCAGAAACCAGGT CAGTCTCCAAAGCTCATCATCAAGTATGCTTCCCAGTCCTTCTCAGGGGTCCCCTCGAGGTT CAGTGGCAGTGGATCTGGGACAGATTTCACCCTCACCATCGATAGCCTGGAGGCTGAAGAT GCTGCAACGTACTATTGTCATCAGAGTATCAGTTTACCGCTCACTTTCGGCGGAGGGACCAA AGTGGATATCAAACGT SEQ ID 354 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAGGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTACCAGCAACTACTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCTACAGGGCCACTGGCATCCCTGACA GGTTCAGCGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAGCAGTATGCTAGCTCAGTCACCTTCGGCCAAGGGACAC GACTGGAGATTAAACGT SEQ ID 355 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTATTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCCTCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTAGAACGTTCGGCCAAGGGACCAA GCTGGAGATCAAACGT SEQ ID 356 GACATCCAGTTGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTGCCCGGGAATC CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAAC AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATTTTATAGTCCTCCTCGGAC GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGT SEQ ID 357 GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCCCCGGGCACTTTCGGCGGAG GGACCAAAGTGGATATCAAACGT SEQ ID 358 GAAATTGTGCTGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTTTAAGTACCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGCACAGAGTTCACTCTCACCATCACCAGCCTGCAGTCTGAAGATT TTGCAGTTTATTACTGTCAGCAGTATCATAACTGGCCTCCGTACACTTTTGGCCAGGGGACC AAGGTGGAGATCAAACGT SEQ ID 359 GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT CACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCAGGG AAAGCCCCTAAGCTCCTGATCTATAAGGCGTCTAGTTTAGAAAGTGGGGTCCCATCAAGGTT CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGAT TTTGCAACTTATTACTGCCAACAGTATAATAGTTATTGGACGTTCGGCCAAGGGACCAAGGT GGAAATCAAACGT SEQ ID 360 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAGGCGCCACCC TCTCCTGCAGGGCCAGTCACAGTGTTGGCGCCAACTACATAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTTATCCATACTGCATCCAAAAGGGCCACTGGCGTCCCAGAG AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCAGTATCAGCAGACTGGAGCCTG AAGACTTTGCCGTGTATCACTGTCAGCAGTATGCTGCCGCACCGATTACCTTCGGCCAAGGG ACACGACTGGAGATTAAACGT SEQ ID 361 GAAATTGTGATGACACAGTCTCCATCCTCCCTGTCTGCATCTGTGGGGGACAGAGTCATCAT CACTTGCCGGGCGAGTCAGGGCATTGCCAATTATTTAGCCTGGTATCAGCAGAAACCAGGG AAAGGTCCTAAACTCCTGATCTATGCTTCATCTACTTTGCAATCAGGGGTCCCATCTCGGTT CAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGGCCTGCAGCCTGAAGAT GTTGCAACTTATTACTGTCAGAAGTATAACAGTGTCCCTCTCACTTTCGGCGGAGGGACCAA AGTGGATATCAAACGT SEQ ID 362 GATGTTGTGATGACTCAGTCTCCAGTCTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGAACCAACAATAAGAACTACTTGGCTTGG TATCAGCAGAAACCAGGACAGCCTCCTAAGTTGCTCATTTACTGGGCATCTACCCGGGAATC CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC AGCCTGCAGCCTGAGGATGTGGCAGTGTACTACTGTCAGCAATATTACAATCTTCCTCGATC TTTTGGCCAGGGGACCAAGCTGGAGATCAAACGT SEQ ID 363 GATATTGTGATGACCCACACTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCAAGTCCAACCGGAGTGTTTTATACAGCCCCAACAATCAGAACTACTTAGGTTGGT ACCAGCAGAAGCCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGACTC CGGGGCCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAAC AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATGCAAGTACTCCATACAC TTTTGGCCAGGGGACCAAGGTGGAGATCAAACGT SEQ ID 364 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTGAGAGTGTTAATAGCAACTTCTTAGCCTGGTACCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCTATGCTGCATCCACCAGGGCCACTGGTATCCCAGCCAG GTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCATCATCACCAGCCTGCAGTCTGAAG ATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCGCTCACTTTCGGCGGAGGGACC AAGCTGGAGATCAAACGT SEQ ID 365 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGTCGCTCACTTTCGGCGGAGGGACCAA GCTGGAGATCAAACGT SEQ ID 366 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAACAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCTTCCACCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACGGACTTCACTCTCACCATCGGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAACACTATGGTCCCTCACGTCGGATCACCTTCGGCCAAG GGACACGACTGGAGATTAAACGT SEQ ID 367 GAAACGACACTCACGCAGTCTCCAGACACCCTGTCTGTGTCTCCAGGGGGAAGAGCCACCC TCTCCTGTAGGGCCAGTCAGAGCATTGGGAGCAATTTAGCCTGGTACCAACAGAAACCTGG CCAGTCTCCCAGGCTCCTCATCTATGATGCATCCACCAGGGCCACGGGAATCCCAGCCAGGT TCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGGAGTCTGAAGA TTTTGTACTTTATTACTGTCAGCAGCATGGTGAATGGCCCACCTTCGGCCAAGGGACACGAC TGGAGATTAAACGT SEQ ID 368 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTCGGTAACTCCTTAGCCTGGTACCAGCAGAAGCCTGGC CAGGCTCCCCGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCCGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCACCAGCCTAGAGCCTGAAGAT TTTGCAATTTATTACTGTCAACAACGTGGCACCTGGCCTCCCCTCACTTTCGGCGGAGGGAC CAAGCTGGAGATCAAACGT SEQ ID 369 GATGTTGTGATGACTCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACACAGTCACCAT CACTTGCCGGGCCAGTCAGAGTATAACTAACTGGTTGGCCTGGTATCAGCAGAAACCAGGG AAAGCCCCCAAGCGCCTGATCTATGGTGCGTCCAGTTTGCAGAGTGGGGTCCCATCAAGGT TCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGA TTTTGCAACTTATTACTGTCAACAGTATACTAATTACCCTCGTACGTTCGGCCAAGGGACCA AGCTGGAGATCAAACGT SEQ ID 370 GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT CACTTGTCGGGCCAGGCAGAGCATCAGTAACCGGTTGGCCTGGTATCAGCAGAAACCAGGG AGAGCCCCTAATGTCCTGATCTATAAGGCGTCTACTTTAGCAAATGGGGTCCCATCAAGGTT CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGAC TTTGCAACTTATTACTGCCAACAGTATCAAAGTTACTGGACGTTCGGCCCAGGGACCAAGGT GGAAATCAAACGT SEQ ID 371 GACATCCAGTTGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAAGGCCAGTCAGAGTGTTAGTAGCTACTTAGCCTGGTACCAACAGAAACTTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGCCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGAT GTTGCAACTTATTACTGTCAAAAGTATAACAGTCCCCCTCGGACGTTCGGCCAGGGGACCA AGGTGGAAATCAAACGT SEQ ID 372 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGGGTCAGCC TTTCCTGCAGGGCCAGTCAGAATGTTTACAGCAATTTCTTAGCCTGGTATCAACAGAGACCT GGCCAGGCTCCCAGTCTCCTCATCTATGGTGCCTCCAGCAGGGCCGCTGGCGTCCCAGACAG GTTCAGTGGCAGTGGGTCTGGGACAGACTTCGCTCTCACCATCAGCAGAGTGGAGCCTGAA GATTTTGCAGTCTATTACTGTCAACAATATGGAACCTCACCGATCACCTTCGGCCAAGGGAC ACGACTGGAGATTAAACGT SEQ ID 373 GAAATTGTGCTGACTCAGTCTCCACGCTCCTCACCCGTCACCCTTGGACAGCCGGCCTCCAT CTCCTGTAGGTCTAGTCAAAGTCTCGAACACGGTGATGGAAACACGTACTTGAGTTGGCTTC AGCAGAGGCCAGGCCAGCCTCCAAGACTCCTGATTTATAAGGTTTCTAACCGGTTGTCTGGG GTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACTGATTTCACACTGAAAATCAGCAGGG TGGAAGCTGAGGATGTCGGGGTTTATTACTGCATGCAAGGTATATACTGGCCTCGAACCTTC GGCCAAGGGACACGACTGGAGATTAAACGT SEQ ID 374 GAAACGACACTCACGCAGTCTCCAGTCACCCTGTCTTTGTCTCCAGGGGACAGAGCCACCCT CTCTTGCAGGGCCAGTCAGAGTGTTAGCAGCACCTCCTTAGCCTGGTACCAGCACAAACCTG GCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGGAGGGCCACTGGCATCCCAGACAG GTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAACAGACTGGAGCCTGAA GATTTTGCAGTGTATTACTGTCAGCACTATGGTAGTTCACCTCCAATCACCTTCGGCCAAGG GACACGACTGGAGATTAAACGT SEQ ID 375 GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTGGCAGCAAATTAGCCTGGTACCAGCAGAAACCTGG CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTGTCCCAGTCCGGT TCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCCCCGATCACCTTCGGCCAAGGGA CACGACTGGAGATTAAACGT SEQ ID 376 GAAATTGTGTTGACGCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG TGGAGGCTGAGGATGTTGGGGTGTATTACTGCATGCAAACTCTTCAAACTCCGCTCACTTTC GGCGGAGGGACCAAAGTGGATATCAAACGT SEQ ID 377 GATGTTGTGATGACTCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATC CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTAGTACTCCGTA CACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGT SEQ ID 378 GATATTGTGATGACCCACACTCCCCTCTCTCTGTCCGTCACCCCTGGACAGCCGGCCTCCAT CTCCTGCAAGTCTAGTCAGAGCCTCCTGGGTGGTGATGGAAAGACCTATTTGTATTGGTACC TGCAGAAGCCAGGCCAGCCTCCACAGCTCCTGCTCTATGAAGTTTCCAACCGATTCTCTGGA GTGCCAGATAGGTTCAGTGGCAGCGGGGCAGCGACAGATTTCACACTGAAAATCAGCAGGG TGGAAGCTGAGGATGTCGGGGTTTATTACTGCATGCAATCTACACAATTTCCGTGGACGTTC GGCCAAGGGACCAAGGTGGAGATCAAACGT SEQ ID 379 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTGCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGCTGCATCCTACAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCCGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGA AGATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCCATCACCTTCGGCCAAG GGACACGACTGGAGATTAAACGT SEQ ID 380 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT TTTGCAGTTTATTACTGTCAGCACTATAATAACTGGCCTCATACCTTCGGCCAAGGGACCAA GCTGGAGATCAAACGT SEQ ID 381 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTCCTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCTCTGGCATCCCAGACA GGTTCAATGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAATAGGCTGGAGCCTGA AGACTTTGCAGTGTATTACTGTCAGCAGTATGGTAACTCACAGACCTTCGGCCAAGGGACA CGACTGGAGATTAAACGT SEQ ID 382 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCCCGGACGTTCGGCCAAGGGACCAA GCTGGAGATCAAACGT SEQ ID 383 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAAAGCCTCGTATACAGTGATGGAAACACCTACTTGAATTGGTTTC AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAGGTTTCTAACCGGGACTCTGG GGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGG GTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTACACATTGGCCTCGGACTTT CGGCGGAGGGACCAAGCTGGAGATCAAACGT SEQ ID 384 GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT CACTTGCCGGGCCAGTCAGAGTATTAGTAGGTGGTTGGCCTGGTATCAGCAGAAGCCAGGG AAAGCCCCTAAGCTCCTGATCTATAAGGCGTCTACTATAAAAAGTGGGGTCCCATCAAGAT TCAGCGCCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGA TTTTGCAACTTATTACTGCCAACACTATAAAAGTGATTCCCGGACGTTCGGCCAAGGGACCA AGGTGGAAATCAAACGT SEQ ID 385 GATGTTGTGATGACTCAGTCTCCATCCTCCCTCGCTGCATCTGTTGGAGACAGAATTACCAT CACTTGCCGGCCAAGTCAGGACATAGGCACTTATTTAAATTGGTATCAACAGAAGGCAGGG GAAGCCCCTAAGCTCCTCATCTATGCTGCCTCCAATCTGCACAGTGGCGTCTCATCAAGGTT CAGAGGCGTTGGGTCTGGGACACAATTCACTCTCACCATCAGCAGTCTGCAACCTGAGGAT TTTGCAACTTACTACTGTCATCAGAGTTACGGTCCTCGGACATTCGGCCAAGGGACCAAGCT GGAGATCAAACGT SEQ ID 386 GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGCATCCCAGCCAGGT TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCGATCACCTTCGGCCAAGGGA CACGACTGGAGATTAAACGT SEQ ID 387 GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCAGGGTACACTTTTGGCCAGGGGA CCAAGCTGGAGATCAAACGT SEQ ID 388 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG AAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCGTTCGGCCAAGGGACACGACTG GAGATTAAACGT SEQ ID 389 GAAATTGTGTTGACACAGTCTCCTTCCACCCTGTCTGCATCTGTAGGGGACAGAGTCACCAT CACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGCTTGGCCTGGTATCAGCAGAAACCAGGG AAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTT CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCACCCTGCAGCCTGAAGAT TTTGCAACTTATTACTGTCAACAGCTTAATAGTTACCCTCAGACGTTCGGCCAAGGGACCAA AGTGGATATCAAACGT SEQ ID 390 GATATTGTGATGACCCACACTCCACTCTCTCTGTCCGTCACCCCTGGACAGCCGGCCTCCAT CTCCTGCAAGTCTAGTCAGAGCCTCCTGCATAGTGATGGAAAGACCTATTTGTATTGGTACC TGCAGAAGCCAGGCCAGCCTCCACAGCTCCTGATCTATGAAGTTTCCAACCGGTTCTCTGGA GTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGACAGATTTCACACTGAAAATCAGCCGGG TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAAGTATACAGCTTCCGCTCACTTTC GGCGGAGGGACCAAGGTGGAGATCAAACGT SEQ ID 391 GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAGCAGTATAATAACTGGCCTCTCACTTTCGGCGGAGGGA CCAAGCTGGAGATCAAACGT SEQ ID 392 GACATCCAGTTGACCCAGTCTCCCGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCACGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACATAGCTTGGT ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATC CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATTATATTCCTCGGAC GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGT SEQ ID 393 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCCCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCGGACATTCGGC CAAGGGACCAAGCTGGAGATCAAACGT SEQ ID 394 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTCTTACCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCAGGCTCCCAGACTCCTCATCTATCGTGCATCCAGCAGGGCCACTGGCATCCCAGACC GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTTTATTACTGTCAGCAGTATGGTAGTTCACCTAACACCTTCGGCCAAGGGA CACGACTGGAGATTAAACGT SEQ ID 395 GAAATTGTGTTGACACAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAAAGCCTCGTACACAGTAATGGACACACCTACTTGAGTTGGTTTC AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTCATTTATGAGGTTTCTAACCGGGACTCTGG TGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTAAGAATCAGCAGG GTGGAGGCTGAGGATGTTGGGGTTTATTACTGCTTGCAAGGAACACACTGGCCCCCCCTCAC TGTCGGCGGAGGGACCAAAGTGGATATCAAACGT SEQ ID 396 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTGGCAGCGACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTACCGTGCATCCACCAGGGCCGCTGGTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGAT TTTGCAGTGTTTTACTGTCAGCAGTATGGTAGATCACCGTACACTTCTGGCCAGGGGACCAA GCTGGAGATCAAACGT SEQ ID 397 GATATTGTGATGACCCACACTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATC CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTACTCCGCTCAC TTTCGGCGGAGGGACCAAGGTGGAGATCAAACGT SEQ ID 398 GAAATTGTGATGACGCAGTCTCCACTCTCCCTGTCCGTCACCCCTGGAGAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAGAGCCTCCTACATAGTAGTGGATACAACTATTTGGATTGGTACC TGCAGAAGCCAGGCCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTACTCGGGCCTCCGGG GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG TGGAGGCTGAGGATGTTGGGGTTTATTATTGCATGCAAGGTCTACAAATTCCGCTCACTTTC GGCGGAGGGACCAAAGTGGATATCAAACGT SEQ ID 399 GATATTGTGATGACCCACACTCCACTCTCTCTGTCCGTCACCCCTGGACAGCCGGCCTCCAT CTCCTGCAAGTCTAGTCAGAGCCTCCTGCATAGTGATGGAAAGACCTATTTGTATTGGTACC TGCAGAAGCCAGGCCAGCCTCCACAGCTCCTGATCTATGAAGTTTCCAACCGGTTCTCTGGA GTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGACAGATTTCACACTGAAAATCAGCCGGG TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAAGTATACAGCTTCCGTGGACGTTC GGCCAAGGGACCAAGGTGGAGATCAAACGT SEQ ID 400 GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGCATCCCAGCCAGGT TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCGGTTCGGCCAAGGGACACGAC TGGAGATTAAACGT SEQ ID 401 GATGTTGTGATGACTCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGGGACAGAGTCACCAT CACTTGCCGGGCCAGTCAGACTATTAATAGTTGGTTGGCCTGGTATCAGCAGAAACCAGGG AAGGCCCCTAAGCTCCTCATCTCTAGGGCGTCTCGTTTAGAAAGTGGGGTCCCATCAAGGTT CAGCGGCAGTGCATCTGGCACAGAATACATTCTCACCATCAACAGCCTGCAGCCTGATGAT TTTGCAATGTACTTCTGCCATCAATATAATAGTTATTCTCCCACTTTTGGCCAGGGGACCAA GCTGGAGATCAAACGT SEQ ID 402 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGCCA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGA AGATTTTGCAGTTTATTACTGTCAGCAGCGTTACAACTGGCCTATCACCTTCGGCCAAGGGA CACGACTGGAGATTAAACGT SEQ ID 403 GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCGGGGGAAACAGCCACCCT CTCCTGCAGGGCCAGTCAGACTATTGGTCCCAAGTCCTTCGGCTGGTACCAACAGAGACCTG GCCAGGCTCCCAGGCTCCTCATCTATGACTCCAACAGGGCCACTGGCATCCCAGCCAGGTTC AGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATT TTGCAGTTTATTACTGTCAGCAGCGTAGCAGGTGGCCTCTCACTTTCGGCCCTGGGACCAAA GTGGATATCAAACGT SEQ ID 404 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAAAGCCTCGTGTACAGTGATGGAAACACCTACTTGTATTGGTTTC AGCAGAGGGCAGGCCAATCTCCAAGGCGCCTGATTTATAAGGTTTCTAAGCGGGACTCTGG GGTCCCAGACAGGTTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGG GTGGAGGCTGAGGATGTTGGAATTTATTACTGCGTGCAAGGTAGACACTGGCCGTACACTC TTGGCCAGGGGACCAAGCTGGAGATCAAACGT SEQ ID 405 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCA GGTTCAGTGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGA TGATTTTGCAACTTATTACTGCCAACAGTATAATAGTTATTCAAGGACGTTCGGCCAGGGGA CCAAAGTGGATATCAAACGT SEQ ID 406 GATGTTGTGATGACTCAGTCTCCTTCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCAT CACTTGCCGGGCCAGTCAGAGTATTACTACCTGGTTGGCCTGGTCTCAGCAGCAACCAGGG AAAGCCCCTAAGCTCCTCATCTATAAGGCCTCTAGTTTAACAAGTGGGGTCCCATCAAGGTT CAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGCCTGATGAT TTTGCAAGTTATTACTGCCATCATTATAATGGTGCTTCTCGTATGTTCGGCCAAGGGACCAA GCTGGAGATCAAACGT SEQ ID 407 GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGG CCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGT TCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTTTCTTCGGCCAAGGGACACGAC TGGAGATTAAACGT SEQ ID 408 GAAACGACACTCACGCAGTCTCCAGCCACCCTGACTTTGTCTCCAGGGGAAAGAGTCACCC TCTCCTGCAGGGCCAGTCAGAGTATTGGCACTTACGTCGCCTGGTATCAGCAGAAACCTGGC CAGGCTCCCAGATTCCTCATCTATGATTCATCGAATAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGTAGTGGGTCTGGGACAGACTTCACTCTCACGATCAGCAGCCTGGAGCCTGAAGAT TTTGCATTTTATTACTGTCAACAGCGTGCCGAGTGGCCTCTCACCTTCGGCCAAGGGACACG ACTGGAGATTAAACGT SEQ ID 409 GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACTCT CTCCTGCAGGGCCAGTCAGAGTGTTAATAGCGGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCAACCTCCCAGACTCCTCATCTCTGGTGTTTCCACCAGGGCCACTGGCATCCCAGACAG GTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAA GATTTTGCAGTGTATTACTGTCAGGAGTATGGTAACTCAGCTATGTACAATTTTGGCCAGGG GACCAAGCTGGAGATCAAACGT SEQ ID 410 GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGT TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCCTTCACCTTCGGCCAAGGGA CACGACTGGAGATTAAACGT SEQ ID 411 GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGGCTGGTATCAGCAGAAATCC GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGACATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAAACTGGAGGCAGA AGATTCTGCAGTGTATTACTGTCAGCAGTATGGTATCTCACCTCTCGCGTTCGGCCAAGGGA CCAAGCTGGAGATCAAACGT SEQ ID 412 GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAGAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTATTAGCAACAACTTAGCCTGGTACCAGCAGAAACCTGG CCAGGCTCCCAGGCTCCTCATCTATGGTACATCCACCAGGGCCACTGGTATCCCAGCCAGGT TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA TTTTGCAGTTTATTACTGTCAGCAGTATAATTTCTGGCCTTCGATCACCTTCGGCCAAGGGAC ACGACTGGAGATTAAACGT SEQ ID 413 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTCCTTAGCCTGGTACCAGCAGAAACC TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG AAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACAGACCTTCGGCCAAGGGAC ACGACTGGAGATTAAACGT SEQ ID 414 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCTCCCTTGGACAGCCGGCCTCCATC TCCTGCAGGTCTAATCAAAGCCTCGTATACAGTGATGGAGGCACCTACTTGAATTGGTTTCA GCAGAGGGCAGGCCAGTCTCCAAGGCGCCTAGTTTATAAGGTTTCTAACCGGGACTCTGGG GTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTGAGAATCAGCAGGG TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGGACACACTGGCCGTACACTTTT GGCCAGGGGACCAAGCTGGAGATCAAACGT SEQ ID 415 GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCGT CACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGG AAAGCCCCTCAACTCCTGATCTACGATGCATCCAATTTGGAAACAGGGGTCCCCTCAAGGTT CAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATT TTGCAACATATTACTGTCAGCAGTTTGATAATGTCCCAGTCACTTTCGGCGGAGGGACCAAG GTGGAAATCAAACGT SEQ ID 416 GAAATTGTGCTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAAAGCCTCGTATACAGTGATGGAAACACCTACTTGAATTGGTTTC AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAGGTTTCTAACCGGGACTCTGG GGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGG GTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTACACACTGGCCTCGAACGT TCGGCCAAGGGACCAAGCTGGAGATCAAACGT SEQ ID 417 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAACAGACTGGAGCCTGAAGAT TTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCATCCATGTACACTTTTGGCCAGGGGAC CAAGCTGGAGATCAAACGT SEQ ID 418 GATGTTGTGATGACTCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGGGACAGCGTCGCCAT CACTTGCCGGGCAAGTCAGAGCATTAGCAACTATTTAAATTGGTATCAGCAGAGACCAGGG AAAGCCCCTAAGCTCCTGATCTTTGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTT CAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATT TTGCAACTTACTCCTGTCAACAGAGTTACATTACCCCGTGGACGTTCGGCCAAGGGACCAAG CTGGAGATCAAACGT SEQ ID 419 GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCACCCTCTTAGCCTGGTACCAACAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGGCAGGTT CAGTGCCAGTGGGTCTGGGACAGACTTCAGTCTCACCATCAGCAGCCTAGAGACTGAAGAT TCTGCAGTTTATTACTGTCAGCACCGTTACGTGTGGCCGTTCACTTTCGGCGGAGGGACCAA GCTGGAGATCAAACGT SEQ ID 420 GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGG AAAGCCCCTAAGCGTCTGATCTATGGTGCATCCAGTTTGCAAAGTGGAGTCCCATCAAGGTT CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGGAGCCTGCAGCCTGAAGAT TTTGCAACTTATTATTGTCTACAGCATAATTCCTACCCTCGAACATTCGGCCAAGGGACCAA GGTGGAAATCAAACGT SEQ ID 421 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCGTGGACGTTCGGCCAAGGGACCA AGCTGGAGATCAAACGT SEQ ID 422 GATGTTGTGATGACTCAGTCTCCGCTCTCCCTGCCCGTCACCCTTGGACAGGCGGCCTCCAT CTCCTGCAGGTCTAGTCATAGCCTCACAACTACTGATGGACGTACTTACGTGGCTTGGTTTC AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTTCTTTATGAGGTTTCTAAGCGGGACTCTGG GGCCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACTCTGAAAATCAGCAGG GTGGAGGCTGACGATGTTGGAATTTATCATTGCATGCAAGGAACACATGGGCCTCACACGT TCGGCCAAGGGACCAAGCTGGAGATCAAACGT SEQ ID 423 GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAAAGTGTTACCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAGGGCCACTGGTATCCCAGCCAGGT TCAGTGTCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGA TTTTGCAGTGTATTACTGTCAGCAGTATGGTAGTCCACCTCCGACCACCTTCGGCCAAGGGA CACGACTGGAGATTAAACGT SEQ ID 424 GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACGTCGGACGTTCGGCCAAGGGA CCAAGCTGGAGATCAAACGT SEQ ID 425 GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCCTTGTCTCCAGGGGAAAGAGCCACCC TCTCCTGCAGGGCCAGTCAGAGTGTTTTCAACAACTACTTAGCCTGGTACCAACAGAGACCT GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCGGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGATTTCGCAGTGTATTGCTGTCAGCAGTATGGTAGTTCACCGATCACCTTCGGCCAAGGGA CACGACTGGAGATTAAACGT SEQ ID 426 GAAATTGTGCTGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGAT TTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACTCAGGTACACTTTTGGCCAGGGGAC CAAGCTGGAGATCAAACGT SEQ ID 427 GAAATTGTGCTGACTCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT CAACTGCAAGTCCAGCCAGAGTGTTTTATATGATTCCAACAGTAAGAACTACTTAAGTTGGT ATCAGCAGAAACCAGGCCAGCCTCCTAAGTTGCTCATTTCCTGGGCGTCTACCCGGGGGTCC GGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCA GCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATTTTATGGTATTCCCCACTTC GGCCAAGGGACACGACTGGAGATTAAACGT SEQ ID 428 GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTGGTACCAATTTAGCCTGGTACCAGCAGAAACCTGGC CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT TTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCGATAACTTTCGGCGGAGGGAC CAAGCTGGAGATCAAACGT SEQ ID 429 GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT CTCCTGCAGGTCTAGTCAAAGCCTCGTATACAGTGATGGAAACACCTACTTGAGTTGGCTTC AGCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTATAAGATTTCTAACCGGTTCTCTGGG GTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATCAGCAGGG TGGAAGCTGAGGATGTCGGGGTTTATTACTGCATGCAAGGTACACAATTTCCTCAAACGTTC GGCCAAGGGACCAAGCTGGAGATCAAACGT SEQ ID 430 GAAATTGTGCTGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTAATAAGCAGGTACTTAGCCTGGTATCAGCAGAAACCT GGCCAGGCTCCCAGGCTCCTCATCCATGGTGCATCCACCAGGGCCACTGGCATCCCAGACA GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA AGACTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCCGTACACTTTTGGCCAGG GGACCAAGGTGGAAATCAAACGT SEQ ID 431 GACATCCAGTTGACCCAGTCTCCTTCCACCCTGGCTGCATCTGTAGGAGACAGAGTCACCAT CACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCAGGG AAAGCCCCTAAGGTCCTGATCTATAAGGCGTCTAGTTTAGAAAGTGGGGTCCCATCAAGGT TCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGA TTTTGCAACTTATTACTGCCAACAGTATAATAGTTATTCGGGGACGTTCGGCCAAGGGACCA AGGTGGAAATCAAACGT SEQ ID 432 GATGTTGTGATGACTCAGTCTCCAGCCATCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT CTCCTGCAGGGCCAGTCAGAGTGTTAGTAGCAGCTTAGCCTGGTACCAGCAGAAACCTGGC CAGCCTCCCAGGCTCCTCATCTATGGTGCCTCCACCAGGGCCACTGCTATCCCAGCCAGGTT CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT TTTGCAGTTTATTACTGTCAGCGCTATGATAACTGGCCTCCCCTTTTTGGCCAGGGGACCAA GCTGGAGATCAAACGT

[170] Exemplary CDR amino acid sequences of CLEC2D antibodies of the disclosure are shown in Table 6 below. Table 6. CDR Amino Acid Sequences VH VL SEQ ID CDRH1 SEQ ID CDRH2 SEQ ID CDRH3 SEQ ID CDRL1 SEQ ID CDR L2 SEQ ID CDRL 3 SEQ ID 433 GYTFT SYAM H SEQ ID 486 WINAGNG NTKYSQKF QG SEQ ID 547 GSLSRSGWY AGLFDY SEQ ID 654 ASQSIGS NLVW SEQ ID 727 SAT SRA TG SEQ ID 784 YGSS PPTT F SEQ ID 434 GFTFS SYSMN SEQ ID 487 IISDDGSKS YYADSVQ G SEQ ID 548 DRGTKWNQ LNDVFDM SEQ ID 655 ASQSVSS SYLAW SEQ ID 728 GAS NRA TG SEQ ID 785 YGSS PGTF SEQ ID 435 GYTFT SYYM H SEQ ID 488 IINPSGGST SYAQKFQ G SEQ ID 549 GRGYSSSRL YYFDY SEQ ID 656 ASQSVSS YLAW SEQ ID 729 DAS NRA TG SEQ ID 786 RSN WPRT F SEQ ID 436 GFTFS DPYM D SEQ ID 489 RITNKRTG YATTYAA SVKD SEQ ID 550 DVSGSFAAY SEQ ID 657 SSRNILYS GNNKNFL AW SEQ ID 730 WAS TRE SG SEQ ID 787 SSSLP HTF SEQ ID 437 GFTFS SYAM H SEQ ID 490 WINAGNG NTKYSQKF QG SEQ ID 551 EGGAVAGTV Y SEQ ID 658 ASESVSK SYLLW SEQ ID 731 GAS TRA SG SEQ ID 788 YGSS RTF SEQ ID 438 GFTFS NAWM S SEQ ID 491 RIKSKTDG GTTDYAA PVKG SEQ ID 552 DEYFY SEQ ID 659 ASQSISST YLAW SEQ ID 732 GAS TRA TG SEQ ID 789 YGNS PPGA TF SEQ ID 439 GGSFS GYYW S SEQ ID 492 EINHSGST NYNPSLKS SEQ ID 553 VNPGSYTRE VSNFDY SEQ ID 660 SSQALRN VVGLGD DLAW SEQ ID 733 STS TLQ SG SEQ ID 790 HHDF PFTF SEQ ID 440 GDSVS SNSVT WN SEQ ID 493 RTYYRSQ WYYNYAV SVKS SEQ ID 554 RGHNYGVD Y SEQ ID 661 SSQSLLN SNGYNYL EW SEQ ID 734 LGS NRA SG SEQ ID 791 SLQT PLTF SEQ ID 441 GYTFA AYYL H SEQ ID 494 RIKSKTDG ETTDYAAP VKG SEQ ID 555 GVGWSPFQY SEQ ID 662 ASQSVSS NLAW SEQ ID 735 GAS SRA TG SEQ ID 792 YGSS PRITF SEQ ID 442 GFTFS SHLM H SEQ ID 495 FIRSKAYG GTTEYAAS VKG SEQ ID 556 DDKIAAAGF TYWYFDL SEQ ID 663 ASQSVRD NVGW SEQ ID 736 AAS SLH TG SEQ ID 793 YNN WPP MYTF SEQ ID 443 GGSISS GGYS WS SEQ ID 496 RISPGNGV TSYAQKFQ G SEQ ID 557 EAADDPFDH SEQ ID 664 ASQSISSY LNW SEQ ID 737 DVS TRA TD SEQ ID 794 FNN WPYT F SEQ ID 444 GDSVS NNRA AWN SEQ ID 497 VISYDGTS KYYGDSV KG SEQ ID 558 ADYKYD SEQ ID 665 ASQSVNS NVAW SEQ ID 738 DAS SRA TG SEQ ID 795 SYSIP RTF SEQ ID 445 GYTFT SYGIS SEQ ID 498 YIYHSGST YYNPSLKS SEQ ID 559 HRRPIYDILT GFDY SEQ ID 666 ASQSVSS SALAW SEQ ID 739 DSS SRA TG SEQ ID 796 CASS PPVT F SEQ ID 446 GYSFT SYWIG SEQ ID 499 YISSSGSYT NYADSVK G SEQ ID 560 EDTMVRGVI P SEQ ID 667 SSQSLLH SNGYNYL DW SEQ ID 740 MGS SRA SG SEQ ID 797 YGSS PRVT F SEQ ID 447 GYSFT SYWIA SEQ ID 500 WISAYNG NTNYAQK LQG SEQ ID 561 DRRYYDSSG YYPAYYFDY SEQ ID 668 ASQGISSS LAW SEQ ID 741 AAS TLQ SG SEQ ID 798 FNTY PNTF SEQ ID 448 GFTFT DAWM N SEQ ID 501 IIYPGDSDT RYSPSFQG SEQ ID 562 DGGYDSSGF HFDY SEQ ID 669 SCQSLVY SDGNTYL NC SEQ ID 742 KVS NRD SG SEQ ID 799 TLHT VTF SEQ ID 449 GFTFS NNWM T SEQ ID 502 WIIPIFGIA NYAQKFQ G SEQ ID 563 LPSSGYLQD HHYYGMDV SEQ ID 670 ASEGLTT NLAW SEQ ID 743 LGS TRA SG SEQ ID 800 YGSS LLF SEQ ID 450 GFTFS SYGM H SEQ ID 503 VIYPGDSD TRYSPSFQ G SEQ ID 564 AAVGDGYSY GRLD SEQ ID 671 SSQSLEH TDGNTYL SW SEQ ID 744 AAS TRA TG SEQ ID 801 YDNL PPLT F SEQ ID 451 GFTFD DYAM H SEQ ID 504 RVKNKAD GETTDYA APVKG SEQ ID 565 LPSYYYDSS GYFTWYFDL SEQ ID 672 ASQSISGS YLAW SEQ ID 745 KVS TRF SG SEQ ID 802 ALQT PYTF SEQ ID 452 GFTFS NYVM S SEQ ID 505 NIKQDGTE KHYVDSV KG SEQ ID 566 ELYNYGSKD YFDY SEQ ID 673 SSQSLLH SNGNNYL DW SEQ ID 746 DAS SRA EG SEQ ID 803 GLQT PFTF SEQ ID 453 GFTFS SYAMS SEQ ID 506 VISYDGSN KYYADSV KG SEQ ID 567 GGTWDTAM VTGFDY SEQ ID 674 ASQNIRH WLVW SEQ ID 747 AAS NLQ SG SEQ ID 804 YGSS PALT F SEQ ID 454 GYTFT SYDIN SEQ ID 507 AISGSGGS TYYADSV KG SEQ ID 568 PHYDILTGSR APFDY SEQ ID 675 ASQSIGG SLHW SEQ ID 748 YAS QSF SG SEQ ID 805 ALHT PWTF SEQ ID 455 GYTFT DYAIH SEQ ID 508 YISSTSSTI YYADSVK G SEQ ID 569 ARVESKDGY FDY SEQ ID 676 ASQSVTS NYLAW SEQ ID 749 GAS YRA TG SEQ ID 806 YNH WPLY TF SEQ ID 456 GFTVS SNYMS SEQ ID 509 AISGIGDTT YYADSVK G SEQ ID 570 DLRLSTWDA YDF SEQ ID 677 ASQSISSN LAW SEQ ID 750 WAS ARE SG SEQ ID 807 GSN WPLT F SEQ ID 457 GGTFS SYAIS SEQ ID 510 WMNPNSG NTGYAQK FQG SEQ ID 571 NSQRSFDY SEQ ID 678 SSQSVLY SSNNKNY LAW SEQ ID 751 TAS KRA TG SEQ ID 808 ATHY PRTF SEQ ID 458 GFTFS SYAIS SEQ ID 511 WINAGDG GTKSSREF QG SEQ ID 572 DLGDPRGGIL NY SEQ ID 679 ASQSLST NLAW SEQ ID 752 ASS TLQ SG SEQ ID 809 YGSS PIFTF SEQ ID 459 GFTFS SYAIH SEQ ID 512 VIYSGGST YYADSVK G SEQ ID 573 SSPWGELSL YQGAFDI SEQ ID 680 ASQSISS WLAW SEQ ID 753 WAS TRD SG SEQ ID 810 GLQI PITF SEQ ID 460 GYTFT SSDIN SEQ ID 513 GIIPIFGTA NYAQKFQ G SEQ ID 574 DNDFWSGKV FDY SEQ ID 681 ASHSVGA NYIAW SEQ ID 754 DAS TRA TG SEQ ID 811 HNSY PWTF SEQ ID 461 GDSVS SNSAA WN SEQ ID 514 GIIPMYGT ANYAQKF QG SEQ ID 575 EGGSGWRHY FDY SEQ ID 682 ASQGIAN YLAW SEQ ID 755 GAS SLQ SG SEQ ID 812 SISLP LTF SEQ ID 462 GDSVS SNNAA WN SEQ ID 515 WMNPNSG NTGYAEK FQG SEQ ID 576 DYCSSTSCQ NWFDP SEQ ID 683 SSQSVLY RTNNKN YLAW SEQ ID 756 KAS TLA NG SEQ ID 813 YASS VTF SEQ ID 463 GFSLS TSGVG VG SEQ ID 516 RTYYRSK WYNDYAV SVKS SEQ ID 577 GRVAGDAFD I SEQ ID 684 SNRSVLY SPNNQNY LGW SEQ ID 757 GAS SRA AG SEQ ID 814 YNN WPRT F SEQ ID 464 GGSISS YYWS SEQ ID 517 RTFYRSK WYNDYAV SVKS SEQ ID 578 DQGAAAGTL GYFDY SEQ ID 685 ASESVNS NFLAW SEQ ID 758 KVS NRL SG SEQ ID 815 FYSP PRTF SEQ ID 465 GFTFS SSAMH SEQ ID 518 LIYWDDD KRYSPSLK S SEQ ID 579 GIYDSSGSSN PFDS SEQ ID 686 ASQSIGS NLAW SEQ ID 759 GAS RRA TG SEQ ID 816 YGSS PPGT F SEQ ID 466 GDSVS SDSAV WT SEQ ID 519 YIYYTGST NYNPSLKS SEQ ID 580 GYCSGGSCP GTDFDY SEQ ID 687 ASQSVGN SLAW SEQ ID 760 EVS NRF SG SEQ ID 817 YHN WPPY TF SEQ ID 467 GFTFS TYPM H SEQ ID 520 MIWHDES KKYYADS VKG SEQ ID 581 DGVGGRDG YNFDY SEQ ID 688 ASQSITN WLAW SEQ ID 761 AAS YRA TG SEQ ID 818 YNSY WTF SEQ ID 468 GFTFA AYNIN SEQ ID 521 RTYYKSK WYNDYAA SVKS SEQ ID 582 APLAADGYF DY SEQ ID 689 ARQSISN RLAW SEQ ID 762 GAS SRA SG SEQ ID 819 YAA APITF SEQ ID 469 GFTFS SYGM T SEQ ID 522 VISYDGRN EYYADSV KG SEQ ID 583 ARGLQYLIW YFDL SEQ ID 690 ASQNVYS NFLAW SEQ ID 763 KAS TIKS G SEQ ID 820 YNSV PLTF SEQ ID 470 GYTFT GYYM H SEQ ID 523 FISYDGSN KYYADSV KG SEQ ID 584 PGMVRGVIT APLDY SEQ ID 691 SSQSLEH GDGNTY LSW SEQ ID 764 AAS NLH SG SEQ ID 821 YYNL PRSF SEQ ID 471 GYTLT ELSMH SEQ ID 524 FIRANADS GTTEYAAS VKG SEQ ID 585 EAKWGMYY FDY SEQ ID 692 ASQSVSS TSLAW SEQ ID 765 LGS NRA PG SEQ ID 822 YAST PYTF SEQ ID 472 GFTFS DQYM D SEQ ID 525 TISGNGVG TYYPDSVK D SEQ ID 586 GGGASYTDS SEQ ID 693 ASQSVGS KLAW SEQ ID 766 RAS SRA TG SEQ ID 823 YNN WPLT F SEQ ID 473 GFTFG DYAM S SEQ ID 526 WINPNSGG TNYAQKF QG SEQ ID 587 KGGYVGYSY GPFGGY SEQ ID 694 SSQSLLG GDGKTY LYW SEQ ID 767 EVS NRD SG SEQ ID 824 RSN WSLT F SEQ ID 474 GFNFS GYEM N SEQ ID 527 GFDPEDGE TIYAQKFQ G SEQ ID 588 GGTMVRGFG FNY SEQ ID 695 ASQSVSS NSLAW SEQ ID 768 RAS TRA AG SEQ ID 825 YGPS RRITF SEQ ID 475 RFTFS DAWM S SEQ ID 528 RVRNKAN SYTTEYAA SVKG SEQ ID 589 ARRAMIGPL PRLVGYFDL SEQ ID 696 SSQSLVY SDGNTYL NW SEQ ID 769 RAS RLE SG SEQ ID 826 HGE WPTF SEQ ID 476 GFTFS TYGM H SEQ ID 529 AISSNGGS TYYADSV KG SEQ ID 590 GRPAPSWVK TRNWFDP SEQ ID 697 ASQSISR WLAW SEQ ID 770 DSN RAT G SEQ ID 827 RGT WPPL TF SEQ ID 477 GISFR DYWM H SEQ ID 530 YVSTSGST RYYADSV KG SEQ ID 591 EASSGWN SEQ ID 698 PSQDIGT YLNW SEQ ID 771 KVS KRD SG SEQ ID 828 YTNY PRTF SEQ ID 478 GDSVS SKSAA WN SEQ ID 531 GISGSGGS TYYADSV KG SEQ ID 592 GGRYTKGGY FDD SEQ ID 699 ASQSISSC LAW SEQ ID 772 KAS SLT SG SEQ ID 829 YQSY WTF SEQ ID 479 GDSVS SGSAA WN SEQ ID 532 RIKSKISGG TTDYAAP VQG SEQ ID 593 RLDSSGRGG YFDY SEQ ID 700 SSQSLLH SDGKTYL YW SEQ ID 773 DSS NRA TG SEQ ID 830 YNSP PRTF SEQ ID 480 EFTLR NYGVS SEQ ID 533 RTYYRSK WYNDYAV SLKS SEQ ID 594 ELVGTSSPYY YYYYGMDV SEQ ID 701 SSQSVLY SSNNKNY IAW SEQ ID 774 GVS TRA TG SEQ ID 831 YGTS PITF SEQ ID 481 GGSVS GYYW S SEQ ID 534 LISYDGSK KYYANSV KG SEQ ID 595 DYYYGSGSS P SEQ ID 702 ASQSLTS SYLAW SEQ ID 775 GAS SRA TD SEQ ID 832 GIYW PRTF SEQ ID 482 GDSVS SNTAT WN SEQ ID 535 WINAGNG NTKYSEKF EG SEQ ID 596 GRPYCSSTSC YPEWFDP SEQ ID 703 SSQSLVH SNGHTYL SW SEQ ID 776 GTS TRA TG SEQ ID 833 YGSS PPITF SEQ ID 483 GDSVS GNSAA WN SEQ ID 536 RINPDGSS TSYADSVK G SEQ ID 597 LRGIDYYDSS GYQRGFDY SEQ ID 704 ASQSVGS DLAW SEQ ID 777 DAS NLE TG SEQ ID 834 YNN WPPI TF SEQ ID 484 GYTFT SYAIS SEQ ID 537 RTYYRSK WNNDYAL SVKS SEQ ID 598 GGRGDGAAF DI SEQ ID 705 SSQSLLH SSGYNYL DW SEQ ID 778 AAS SLQ SG SEQ ID 835 TLQT PLTF SEQ ID 485 GFIFSN YAIH SEQ ID 538 RTYYRAK WYNEYAG SVKS SEQ ID 599 PPDGGNSGR WYFDL SEQ ID 706 ASQTINS WLAW SEQ ID 779 EVS KRD SG SEQ ID 836 YYSS TPYT F SEQ ID 539 GMSGSGY STYYADSV KG SEQ ID 600 DKNVRKHD YGDHPYGGY FDY SEQ ID 707 ASQTIGP KSFGW SEQ ID 780 WAS TRG SG SEQ ID 837 STQF PWTF SEQ ID 540 EIHHSGST NYNPSLKS SEQ ID 601 VAGATSLWY SEQ ID 708 SSQSLVY SDGNTYL YW SEQ ID 781 KIS NRF SG SEQ ID 838 YNN WPHT F SEQ ID 541 RTYYRSK WYKDNAL SVKS SEQ ID 602 LANSDGVDV SEQ ID 709 ASQSITT WLAW SEQ ID 782 KAS SLE SG SEQ ID 839 YGNS QTF SEQ ID 542 LIYSDGRT NYADSVK G SEQ ID 603 GVTRTFDY SEQ ID 710 ASQSIGT YVAW SEQ ID 783 GAS TRA TA SEQ ID 840 GTH WPRT F SEQ ID 543 AISSNGGS TYYANSV KG SEQ ID 604 GNGPFDP SEQ ID 711 ASQSVNS GYLAW SEQ ID 841 YKSD SRTF SEQ ID 544 WISAYDG NTNYAQK LQG SEQ ID 605 RDTPLVGVSI Y SEQ ID 712 ASQSVSS SYLGW SEQ ID 842 SYGP RTF SEQ ID 545 YISSSGTTI YYADSVK G SEQ ID 606 RAGYGDYRH FQH SEQ ID 713 ASQSISN NLAW SEQ ID 843 YGSS GYTF SEQ ID 546 VIWYDGS NKYYADS VKG SEQ ID 607 TGDRFQEFD Y SEQ ID 714 ASQSVSS SSLAW SEQ ID 844 YGSS F SEQ ID 608 DDRGRGDDF DY SEQ ID 715 SNQSLVY SDGGTYL NW SEQ ID 845 LNSY PQTF SEQ ID 609 HGRAGINWY FDL SEQ ID 716 ASQSISN YLNW SEQ ID 846 SIQLP LTF SEQ ID 610 GGGLWAFDI SEQ ID 717 ASQSVST LLAW SEQ ID 847 YYYI PRTF SEQ ID 611 DKIGSCPY SEQ ID 718 ASQGIRN DLGW SEQ ID 848 ALQT RTF SEQ ID 612 RPDSSSQCFD Y SEQ ID 719 SSHSLTT TDGRTYV AW SEQ ID 849 YGSS PNTF SEQ ID 613 SSGWSLPED Y SEQ ID 720 ASQSVTS NLAW SEQ ID 850 GTH WPPL TV SEQ ID 614 DVNPELLGA GFDY SEQ ID 721 ASQSVFN NYLAW SEQ ID 851 YGRS PYTS SEQ ID 615 SLNSGGYRC FHH SEQ ID 722 SSQSVLY DSNSKNY LSW SEQ ID 852 YYST PLTF SEQ ID 616 APRGVVPAA MRGGY SEQ ID 723 ASQSVGT NLAW SEQ ID 853 GLQI PLTF SEQ ID 617 LVGNSGSYY PFGY SEQ ID 724 SSQSLVY SDGNTYL SW SEQ ID 854 SIQLP WTF SEQ ID 618 GRSLPYRGL APRSFGGYY FDY SEQ ID 725 ASQSVIS RYLAW SEQ ID 855 YNN WPRF SEQ ID 619 GRTHWGPQD FDY SEQ ID 726 ASQSVSS SLAW SEQ ID 856 YNSY SPTF SEQ ID 620 GGMYYYGS GSSYFDY SEQ ID 857 RYN WPIT F SEQ ID 621 KIAAAGKQP VDY SEQ ID 858 RSRW PLTF SEQ ID 622 RKVYDYVW GSYRLPGSVS YYFDY SEQ ID 859 GRH WPYT L SEQ ID 623 LPGRAARPD Y SEQ ID 860 YNSY SRTF SEQ ID 624 GPGAVAGTK PKYYFDY SEQ ID 861 YNG ASRM F SEQ ID 625 ATYYYDSSG YRFDY SEQ ID 862 RSN WPFF SEQ ID 626 RNLGY SEQ ID 863 RAE WPLT F SEQ ID 627 ARYYDSSGY IAPSGYFDY SEQ ID 864 YGNS AMY NF SEQ ID 628 DGPAVDGAE YFQH SEQ ID 865 YNN WPPF TF SEQ ID 629 LASGSPPPGD Y SEQ ID 866 YGIS PLAF SEQ ID 630 GPIVGATMD Y SEQ ID 867 YNF WPSI TF SEQ ID 631 WYGDYGLD Y SEQ ID 868 YGSS QTF SEQ ID 632 VAKYYYESG GYRASNWFD P SEQ ID 869 GTH WPYT F SEQ ID 633 APPPTVGWY APVFDY SEQ ID 870 FDNV PVTF SEQ ID 634 VTGRRVGAH DY SEQ ID 871 YGSS SMYT F SEQ ID 635 AQPGAETLN FDL SEQ ID 872 SYITP WTF SEQ ID 636 QVAGGMDV SEQ ID 873 RYV WPFT F SEQ ID 637 GSVYSGSYY MLIDY SEQ ID 874 HNSY PRTF SEQ ID 638 QDKDNTRYS GLGV SEQ ID 875 RSN WPW TF SEQ ID 639 GPRMWSSGI DAFDI SEQ ID 876 GTHG PHTF SEQ ID 640 RDWAGKRV SEQ ID 877 YGSP PPTT F SEQ ID 641 GRAGIAAFDI SEQ ID 878 YGSS RRTF SEQ ID 642 GALQGEWRR FDY SEQ ID 879 YGSS PITF SEQ ID 643 TNQGYGGNS GVFDY SEQ ID 880 YGSS LRYT F SEQ ID 644 IVGGAVDC SEQ ID 881 FYGI PHF SEQ ID 645 VRVGATTVY DSWFDP SEQ ID 882 GTQF PQTF SEQ ID 646 DGGSSPYYD SSGLLPWYF DL SEQ ID 883 YGSS PPYT F SEQ ID 647 AKFWTYYFD Y SEQ ID 884 YNSY SGTF SEQ ID 648 GGGSGSYYK RFFDY SEQ ID 885 YDN WPPL F SEQ ID 649 DGTVRRVVG ATTPGNFDY SEQ ID 650 DLNRGYCSG GSCFGY SEQ ID 651 DYSSSGECFD Y SEQ ID 652 DQAAMVGY FDY SEQ ID 653 TFAGYSSKL GYFDL Table 7. Heavy Chain CDR DNA Sequences SEQ ID CDRH1 DNA Seq SEQ ID CDRH2 DNA Seq SEQ ID CDRH3 DNA Seq SEQ ID 1004 GGGGACAGTGTCTCTAG CAACACTGCTACTTGGA AC SEQ ID 1062 AGGACATACTACAGGTCCAAG TGGTATAAGGATAATGCACTGT CTGTGAAAAGT SEQ ID 1127 GCCCGGCGGGCTATGATAGGGCCGC TTCCGCGACTTGTCGGGTACTTCGA TCTC SEQ ID 1005 GGATTCACCTTCAGTTCC CATCTTATGCAC SEQ ID 1063 GTTATATCATATGATGGAACTA GTAAATATTACGGAGACTCCGT GAAGGGC SEQ ID 1128 GGCCGCCCCGCCCCATCCTGGGTTA AAACCCGTAACTGGTTCGACCCC SEQ ID 1006 GGGGACAGTGTCTCTAG CGGCAGTGCTGCTTGGA AC SEQ ID 1064 AGGACATATTATAGGGCCAAG TGGTATAATGAATATGCAGGG TCTGTGAAAAGC SEQ ID 1129 GGAGGAATGTATTACTATGGTTCGG GGAGCTCGTACTTTGACTAC SEQ ID 1007 GGTTACACCTTTACCAGC TACGGTATCAGC SEQ ID 1065 TGGATCAGCGCTTACAATGGTA ACACAAACTATGCACAGAAGC TCCAGGGC SEQ ID 1130 AGGAAGGTGTATGATTACGTTTGGG GGAGTTATCGCCTCCCCGGGTCGGT ATCGTACTACTTTGACTAC SEQ ID 1008 GGATTCACCTTCAGTAG CTATGCTATACAC SEQ ID 1066 CTCATTTATTGGGATGATGATA AGCGCTACAGCCCATCTCTGAA GAGC SEQ ID 1131 AAGGGGGGCTACGTCGGATACAGCT ATGGACCTTTTGGGGGCTAC SEQ ID 1009 GGGTTCTCACTCAGCACT AGTGGAGTGGGTGTGGG C SEQ ID 1067 TGGATGAACCCTAACAGTGGT AACACCGGCTATGCAGAGAAG TTCCAGGGC SEQ ID 1132 GGTCGGGCTGGTATTGCCGCTTTTG ATATC SEQ ID 1010 GGATACACCTTCACCAG TTCTGATATCAAC SEQ ID 1068 GTTATATCATATGATGGAAGTA ATAAATACTACGCAGACTCCGT GAAGGGC SEQ ID 1133 GCAGATTATAAATATGACT SEQ ID 1011 GGATTCACCTTCAGTAG CTATGCTATGCAC SEQ ID 1069 ACTATTAGTGGTAATGGTGTTG GCACATACTACCCAGACTCCGT GAAGGAC SEQ ID 1134 AGCAGTGGCTGGTCACTGCCTGAAG ACTAC SEQ ID 1012 GGATTCACCTTTAGCAG CTATGGCATGACG SEQ ID 1070 GTTATATGGTATGATGGAAGTA ATAAATACTATGCAGACTCCGT GAAGGGC SEQ ID 1135 CAAGACAAAGACAACACGAGATAT TCCGGTTTGGGCGTC SEQ ID 1013 GGATACACCTTCGCCGC CTATTATTTACAC SEQ ID 1071 CGGATCAGCCCTGGTAACGGT GTCACAAGTTATGCACAGAAA TTTCAGGGC SEQ ID 1136 GCCGCGGTGGGGGATGGATACAGCT ATGGTCGGCTCGATT SEQ ID 1014 GGATACACCTTCACCGG CTACTATATGCAC SEQ ID 1072 TGGATCAACCCTAACAGTGGT GGCACAAACTATGCACAGAAG TTTCAGGGC SEQ ID 1137 GATCAGGCAGCTATGGTAGGCTACT TTGACTAC SEQ ID 1015 GGATACACCTTCACCAG TTATGATATCAAC SEQ ID 1073 TGGATGAACCCTAACAGTGGT AACACAGGCTATGCACAGAAG TTCCAGGGC SEQ ID 1138 GGCCGGCCATATTGTAGTAGTACCA GCTGCTACCCAGAGTGGTTCGACCC C SEQ ID 1016 GGATTCATCTTCAGTAAC TATGCTATACAC SEQ ID 1074 CGTGTTAAAAACAAAGCTGAT GGTGAGACAACGGACTACGCT GCACCCGTCAAAGGC SEQ ID 1139 AGATTGGATAGCAGTGGCCGTGGTG GTTACTTTGACTAC SEQ ID 1017 GGATTCACTTTCACTGAT GCCTGGATGAAC SEQ ID 1075 GCTATTAGTGGTAGTGGTGGTA GCACATACTATGCAGACTCCGT GAAGGGC SEQ ID 1140 GACAAGAACGTCCGAAAACATGAC TACGGTGACCACCCCTACGGGGGGT ACTTTGACTAC SEQ ID 1018 GGTGGGTCCGTCAGTGG TTACTACTGGAGC SEQ ID 1076 GAAATCCATCATAGTGGAAGC ACCAACTACAACCCGTCCCTCA AGAGT SEQ ID 1141 GAGTTGGTGGGTACCAGCTCTCCTT ATTACTACTACTACTACGGTATGGA CGTC SEQ ID 1019 GGATTCAACTTCAGTGG ATATGAAATGAAC SEQ ID 1077 TACGTCAGTACTAGTGGTAGTA CCAGATACTACGCAGACTCTGT GAAGGGC SEQ ID 1142 GGTGGGGGTGCGAGCTATACTGACT CC SEQ ID 1020 GGGGACAGTGTCTCTAG CAACAGTGTTACTTGGA AC SEQ ID 1078 AGGACTTACTACCGGTCCCAGT GGTATTATAATTATGCGGTGTC TGTGAAAAGT SEQ ID 1143 TCGAGCCCCTGGGGGGAGTTATCGT TATACCAGGGGGCTTTTGATATC SEQ ID 1021 GGATTCACCTTCAGCAG CTATGCTATGCAC SEQ ID 1079 CGTATTAATCCTGATGGGAGTA GCACAAGCTACGCGGACTCCG TGAAGGGC SEQ ID 1144 GTGGCGGGAGCTACTTCCCTATGGT AC SEQ ID 1022 GGAATCAGCTTCAGAGA TTACTGGATGCAC SEQ ID 1080 TGGATCAACGCTGGCAATGGT AACACAAAATATTCACAGAAG TTCCAGGGC SEQ ID 1145 CATGGTAGGGCCGGAATAAACTGGT ACTTCGATCTC SEQ ID 1023 GGATACACCTTCACTAG CTATGCTATGCAT SEQ ID 1081 CTTATTTATAGTGATGGTCGCA CAAACTATGCAGACTCCGTGA AGGGC SEQ ID 1146 GCGCCCCCTCCGACTGTTGGCTGGT ACGCCCCCGTCTTTGACTAC SEQ ID 1024 GGGTTCACCGTCAGTAG CAACTACATGAGC SEQ ID 1082 AACATAAAGCAAGATGGAACT GAGAAACACTATGTGGACTCT GTGAAGGGC SEQ ID 1147 GACTATTACTATGGTTCGGGGAGTT CTCCC SEQ ID 1025 GGATTCACCTTTAGTAAC AATTGGATGACC SEQ ID 1083 GGTATGAGTGGTAGTGGTTATA GTACATACTACGCAGACTCCGT GAAGGGC SEQ ID 1148 GATCTGAATCGAGGATATTGTAGTG GTGGTAGCTGCTTTGGCTAC SEQ ID 1026 GAATTCACCCTTAGGAA CTATGGCGTGAGC SEQ ID 1084 GCTATTAGTAGTAATGGGGGT AGCACATACTACGCAGACTCA GTGAAGGGC SEQ ID 1149 GCCCAGCCGGGCGCTGAGACGTTGA ACTTCGATCTC SEQ ID 1027 GGTTACACATTTACCAGT TATGCCATCAGC SEQ ID 1085 TGGATCAGCGCTTACGACGGT AACACAAACTATGCACAGAAG CTCCAGGGC SEQ ID 1150 CCGGGTATGGTTCGGGGAGTTATTA CTGCCCCGCTTGACTAC SEQ ID 1028 GGATTCACCTTCAGTACC TATCCCATGCAC SEQ ID 1086 GTTATATCATATGATGGACGTA ATGAATACTACGCAGACTCCGT GAAGGGC SEQ ID 1151 GGGGGGACTATGGTTCGGGGTTTCG GATTTAACTAC SEQ ID 1029 GGATTCACCTTTGATGAT TATGCCATGCAC SEQ ID 1087 GCTATTAGTGGTAGTGGTGGTA GCACATACTACGCAGACTCCGT GAAGGGC SEQ ID 1152 GCCACGTATTACTATGATAGTAGTG GTTATAGGTTTGACTAC SEQ ID 1030 GGGGACAGTGTCTCTAA CAACAGGGCTGCTTGGA AC SEQ ID 1088 AGGACATACTACAGGTCCAAG TGGTATAATGAATATGCAGTCT CTGTGAAAAGT SEQ ID 1153 GAGGCTGCCGACGACCCGTTTGACC AT SEQ ID 1031 GGATTCACCTTCAGTGA CCCCTACATGGAC SEQ ID 1089 CGAATTACAAATAAGCGTACC GGTTACGCCACAACATATGCC GCGTCTGTGAAGGAC SEQ ID 1154 GGCCCCGGGGCAGTGGCTGGTACTA AGCCAAAGTACTACTTTGACTAC SEQ ID 1032 GGATTCACTTTCAGTAAC GCCTGGATGAGC SEQ ID 1090 CGTATTAAAAGCAAAACTGAT GGTGGGACAACAGACTACGCT GCACCCGTGAAAGGC SEQ ID 1155 GACAAGATCGGCAGCTGTCCTTAC SEQ ID 1033 GGGGACAGTGTCTCTAG CAACAGTGCTGCTTGGA AC SEQ ID 1091 AGGACATACTACAGGTCCAAG TGGTATAATGATTATGCAGTAT CTGTGAAAAGT SEQ ID 1156 GGAATCTATGATAGTAGTGGTTCTT CCAATCCCTTTGACTCC SEQ ID 1034 GGATTCACCTTCAGTAG CTATGCTATGCAT SEQ ID 1092 TACATCTATCATAGTGGGAGCA CCTACTACAACCCGTCCCTCAA GAGT SEQ ID 1157 ACTTTTGCGGGGTATAGCAGCAAAC TGGGGTACTTCGATCTC SEQ ID 1035 GGTGGCTCCATCAGCAG TGGTGGTTACTCCTGGA GC SEQ ID 1093 AGGACTTACTACAGGTCCAAG TGGTATAATGATTATGCAGTAT CTCTGAAAAGT SEQ ID 1158 GCCCGAGTGGAATCCAAGGATGGGT ACTTTGACTAC SEQ ID 1036 GGGGACAGTGTCTCTGG CAACAGTGCTGCTTGGA AC SEQ ID 1094 TTCATTAGAGCCAACGCTGATA GTGGGACAACAGAGTACGCCG CGTCTGTGAAAGGC SEQ ID 1159 GACCTGCGACTTTCTACGTGGGATG CTTATGATTTC SEQ ID 1037 GGATTCACCTTTGCTGCT TATAATATCAAC SEQ ID 1095 AGGACATACTACAGGTCCAAG TGGTATAATGATTATGCAGTAT CTGTGAAGAGT SEQ ID 1160 GGATCGGTATATAGTGGGAGCTACT ATATGCTCATTGACTAC SEQ ID 1038 GGGGACAGTGTCTCTAG CAACAATGCTGCTTGGA AC SEQ ID 1096 AGGACATTCTACAGGTCCAAG TGGTATAATGACTATGCAGTTT CTGTGAAAAGT SEQ ID 1161 CGGGATTGGGCAGGAAAAAGGGTC SEQ ID 1039 GGTTACACCTTTACCAGC TATGGTATCAGC SEQ ID 1097 TGGATCATCCCTATCTTTGGTA TAGCAAACTACGCACAGAAGT TCCAGGGC SEQ ID 1162 GATGGGGGGTCCAGCCCATACTATG ATAGTAGTGGTTTACTACCCTGGTA CTTCGATCTC SEQ ID 1040 GGATTCACCTTTAGCAG CTATGCCATGAGC SEQ ID 1098 TGGATCAACGCTGGCAATGGT AACACAAAATATTCAGAGAAG TTCGAAGGC SEQ ID 1163 GGCAATGGGCCGTTCGACCCC SEQ ID 1041 GGATTCACCTTTAGCAA CTATGTCATGAGC SEQ ID 1099 TACATCAGTAGTACTAGTAGTA CCATATACTACGCAGACTCCGT GAAGGGC SEQ ID 1164 GGACGGACTCACTGGGGCCCCCAGG ACTTTGACTAC SEQ ID 1042 GGATTCACCTTCAGCAG CTCTGCCATGCAC SEQ ID 1100 GCTATTAGTGGTATTGGTGATA CTACATACTACGCGGACTCCGT GAAGGGC SEQ ID 1165 AGGGGACATAACTACGGTGTAGATT AC SEQ ID 1043 GGAGGCACCTTCAGCAG CTATGCTATCAGC SEQ ID 1101 AGGACATATTACAGGTCCAAG TGGTATAATGATTATGCAGTAT CTGTGAAAAGT SEQ ID 1166 GATTATTGTAGTAGTACCAGCTGCC AGAACTGGTTCGACCCC SEQ ID 1044 GGATACAGCTTTACCAG CTACTGGATCGCC SEQ ID 1102 ATGATTTGGCATGATGAGAGT AAGAAATACTATGCAGACTCC GTGAAGGGC SEQ ID 1167 TGGTACGGTGACTACGGCCTTGACT AC SEQ ID 1045 CGATTCACTTTCAGTGAC GCCTGGATGAGC SEQ ID 1103 GGGATCATCCCTATCTTTGGTA CAGCAAACTACGCACAGAAGT TCCAGGGC SEQ ID 1168 GTTACGGGACGGAGAGTGGGAGCC CATGACTAC SEQ ID 1046 GGATTCACCTTCAGTACC TATGGCATGCAC SEQ ID 1104 GTCATCTATCCTGGTGACTCTG ATACCAGATACAGCCCGTCCTT CCAAGGC SEQ ID 1169 GGCTCCTTGTCCCGAAGTGGCTGGT ACGCCGGACTCTTTGACTAC SEQ ID 1047 GGATTCACCGTCAGTAG CAACTACATGAGC SEQ ID 1105 CGTATTAAAAGCAAAATAAGT GGTGGGACAACAGACTACGCT GCACCCGTGCAAGGC SEQ ID 1170 GGGGCCCTACAGGGCGAATGGCGG AGATTTGACTAC SEQ ID 1048 GGATTCACCTTCAGTAG CTATAGCATGAAC SEQ ID 1106 GCTATTAGTAGTAATGGGGGT AGCACATATTATGCAAACTCTG TGAAGGGC SEQ ID 1171 AACAGTCAACGTTCGTTTGACTAC SEQ ID 1049 GGGGACAGTGTCTCTAG CGACAGTGCTGTTTGGA CC SEQ ID 1107 GGTATTAGTGGTAGTGGTGGTA GCACATACTACGCAGACTCCGT GAAGGGC SEQ ID 1172 GGGCCCCGAATGTGGAGCAGTGGC ATTGATGCTTTTGATATC SEQ ID 1050 GGATTCACCTTTGGTGAT TATGCTATGAGC SEQ ID 1108 CTTATATCATATGATGGAAGTA AAAAATACTATGCAAACTCCG TGAAGGGC SEQ ID 1173 CGGGCGGGTTACGGTGACTACAGAC ACTTCCAGCAC SEQ ID 1051 GGATTCACCTTCAGTAGT TATAGCATGAAC SEQ ID 1109 GTTATTTATAGCGGTGGTAGCA CATACTACGCAGACTCCGTGA AGGGC SEQ ID 1174 CATAGACGCCCAATTTACGATATTT TGACTGGTTTTGACTAC SEQ ID 1052 GGATACACCTTCACTGA TTATGCTATACAT SEQ ID 1110 TACATTAGTAGTAGTGGTAGTT ACACAAACTACGCAGACTCTG TGAAGGGC SEQ ID 1175 GATGGTACGGTCCGAAGGGTAGTGG GAGCTACTACCCCTGGAAACTTTGA CTAC SEQ ID 1053 GGTGGCTCCATCAGTAG TTACTACTGGAGC SEQ ID mi CGTATTAAAAGCAAAACTGAT GGTGAGACAACAGACTACGCT GCACCCGTGAAAGGC SEQ ID 1176 CGGGATACACCTTTGGTTGGGGTTT CGATATAC SEQ ID 1054 GGATTCACCTTCAGTAG CTATGGCATGCAC SEQ ID 1112 AGGACATACTACAAGTCGAAG TGGTATAATGATTATGCAGCAT CTGTGAAAAGT SEQ ID 1177 GATAACGATTTTTGGAGTGGGAAAG TCTTTGACTAC SEQ ID 1055 GGATTCACCTTCAGTGA CCAGTACATGGAC SEQ ID 1113 TTCATTAGAAGCAAAGCTTATG GTGGGACAACAGAATACGCCG CGTCTGTGAAAGGC SEQ ID 1178 GGCCGGTCCCTTCCCTACCGGGGGT TGGCTCCTAGATCTTTCGGAGGATA CTACTTTGACTAC SEQ ID 1056 GGTGGGTCCTTCAGTGG TTACTACTGGAGC SEQ ID 1114 TACATTAGTAGTAGTGGTACTA CCATATACTACGCAGACTCTGT GAAGGGC SEQ ID 1179 TTGCCTAGTAGTGGTTATCTACAGG ACCACCACTACTACGGTATGGACGT C SEQ ID 1057 GGATTCACCTTCAGCAG CTATGCTATCAGC SEQ ID 1115 ATTATATCAGATGATGGAAGT AAGAGTTACTACGCAGACTCC GTGCAGGGC SEQ ID 1180 GATGTCAGTGGGTCCTTCGCGGCCT AC SEQ ID 1058 GGATACACCTTCACCAG CTACTATATGCAC SEQ ID 1116 TGGATCAACGCTGGCGATGGT GGCACAAAAAGTTCACGGGAG TTCCAGGGC SEQ ID 1181 GACGAGTATTTCTAC SEQ ID 1059 GGGGACAGTGTCTCTAG CAAAAGTGCTGCTTGGA AC SEQ ID 1117 TATATCTATTACACTGGGAGCA CCAACTACAACCCCTCCCTCAA GAGC SEQ ID 1182 GAGGCTAGCAGTGGCTGGAAC SEQ ID 1060 GGATACAGCTTTACCAG CTACTGGATCGGC SEQ ID 1118 GTTATATCATATGATGGAAGTA ATAAATACTATGCAGACTCCGT GAAGGGC SEQ ID 1183 GAGGGCGGAGCAGTGGCTGGTACT GTCTAC SEQ ID 1061 GGATACACCCTCACTGA ATTATCCATGCAC SEQ ID 1119 CGTGTTAGAAACAAAGCTAAC AGTTACACCACAGAATACGCC GCGTCTGTGAAAGGC SEQ ID 1184 GATCGGCGTTACTATGATAGTAGTG GTTATTATCCCGCCTACTACTTTGAC TAC SEQ ID 1120 GAAATCAATCATAGTGGAAGC ACCAACTACAACCCGTCCCTCA AGAGT SEQ ID 1185 GGCGGTACTTGGGATACAGCTATGG TTACGGGCTTTGACTAC SEQ ID 1121 GGGATCATCCCTATGTATGGTA CAGCAAACTACGCACAGAAGT TCCAGGGC SEQ ID 1186 ATAGTGGGAGGTGCCGTTGACTGC SEQ ID 1122 ATAATCAACCCTAGTGGTGGTA GCACAAGCTACGCACAGAAGT TCCAGGGC SEQ ID 1187 GAGGATACTATGGTTCGGGGAGTTA TTCCC SEQ ID 1123 AGGACATACTACAGGTCCAAA TGGAATAATGATTATGCATTAT CTGTGAAAAGT SEQ ID 1188 TTGGCGAGTGGTTCCCCCCCTCCGG GGGACTAC SEQ ID 1124 ATCATCTATCCTGGTGACTCTG ATACCAGATACAGCCCGTCCTT CCAAGGC SEQ ID 1189 GTTAGAGTGGGAGCTACTACTGTTT ACGACAGCTGGTTCGACCCC SEQ ID 1125 TTTATATCATATGATGGAAGTA ATAAATACTACGCAGACTCCGT GAAGGGC SEQ ID 1190 GATGATCGGGGTCGGGGAGATGACT TTGACTAC SEQ ID 1126 GGTTTTGATCCTGAAGATGGTG AAACAATCTACGCACAGAAGT TCCAGGGC SEQ ID 1191 CTAGCTAATTCCGACGGTGTGGACG TC SEQ ID 1192 GGCGGTGGTTCGGGGAGTTATTATA AGAGGTTCTTTGACTAC SEQ ID 1193 GGGGGAAGATATACCAAGGGAGGG TACTTTGACGAC SEQ ID 1194 GAACTATACAACTATGGTTCAAAGG ACTACTTTGACTAC SEQ ID 1195 GATGGCCCCGCCGTTGATGGTGCTG AATACTTCCAGCAC SEQ ID 1196 GTCGCCAAATATTATTACGAGAGTG GTGGTTATCGGGCCTCCAACTGGTT CGACCCC SEQ ID 1197 GAAGGGGGCAGTGGCTGGCGCCAC TACTTTGACTAC SEQ ID 1198 GATCAAGGGGCAGCAGCTGGTACCC TGGGGTACTTTGACTAC SEQ ID 1199 GGGCGCGTGGCGGGGGATGCTTTTG ATATC SEQ ID 1200 ACCAACCAGGGATACGGTGGTAACT CCGGGGTATTTGACTAC SEQ ID 1201 CCCCCCGACGGTGGTAACTCCGGTC GCTGGTACTTCGATCTC SEQ ID 1202 GCCCGGGGGCTACAGTACCTAATCT GGTACTTCGATCTC SEQ ID 1203 GCTCGTTACTATGATAGTAGTGGTT ATATTGCCCCATCGGGTTACTTTGA CTAC SEQ ID 1204 GATGGTGTAGGAGGGAGAGATGGC TACAATTTTGACTAC SEQ ID 1205 CCCCATTACGATATTTTGACTGGTTC CCGGGCGCCCTTTGACTAC SEQ ID 1206 CGAAACTTAGGCTAC SEQ ID 1207 GCTAAGTTTTGGACATACTACTTTG ACTAC SEQ ID 1208 AAAATAGCAGCAGCTGGTAAGCAA CCTGTTGACTAC SEQ ID 1209 GGCCCTATAGTGGGAGCGACTATGG ACTAC SEQ ID 1210 AGACCGGATAGCAGCAGTCAATGTT TTGACTAC SEQ ID 1211 GCCCCCCTAGCAGCAGATGGCTACT TTGACTAC SEQ ID 1212 GACGGGGGCTATGATAGTAGTGGTT TTCACTTTGACTAC SEQ ID 1213 GGGGTGGGATGGTCGCCCTTCCAAT AC SEQ ID 1214 GGTGTAACCCGGACCTTTGACTAC SEQ ID 1215 GACGACAAAATAGCAGCAGCTGGA TTCACATACTGGTACTTCGATCTC SEQ ID 1216 GATTATAGCAGCTCGGGGGAGTGCT TTGACTAC SEQ ID 1217 TTAAGGGGTATAGATTACTATGATA GTAGTGGTTACCAACGGGGGTTTGA CTAC SEQ ID 1218 GCGCCGAGGGGTGTAGTACCAGCTG CTATGCGGGGGGGCTAC SEQ ID 1219 GACAGGGGAACTAAATGGAACCAA TTGAATGATGTTTTTGATATG SEQ ID 1220 GGATATTGTAGTGGTGGTAGCTGCC CAGGAACGGATTTTGACTAC SEQ ID 1221 GGTGGGAGGGGGGATGGGGCCGCT TTTGACATC SEQ ID 1222 GATTTAGGGGATCCCCGGGGTGGTA TTTTGAACTAC SEQ ID 1223 AGTCTCAATAGTGGGGGCTACCGAT GCTTCCATCAC SEQ ID 1224 GTAAATCCGGGGAGTTATACGAGGG AGGTGAGCAACTTTGACTAC SEQ ID 1225 CTCCCGGGGAGAGCAGCTCGTCCAG ACTAC SEQ ID 1226 GAAGCTAAGTGGGGAATGTACTACT TTGACTAC SEQ ID 1227 GGCCGAGGGTATAGCAGCAGTCGG CTCTACTACTTTGACTAC SEQ ID 1228 TTGGTGGGCAATAGTGGGAGCTACT ATCCGTTTGGGTAC SEQ ID 1229 CAAGTCGCGGGCGGTATGGACGTC SEQ ID 1230 GGGGGAGGGCTTTGGGCTTTTGATA TC SEQ ID 1231 CTCCCCTCGTATTACTATGATAGTA GTGGTTACTTTACCTGGTACTTCGAT CTC SEQ ID 1232 ACAGGGGACCGCTTCCAAGAGTTTG ACTAC SEQ ID 1233 GATGTGAACCCGGAGCTACTGGGGG CGGGATTTGACTAC Table 8. Light Chain CDR DNA Sequences SEQ ID CDRL1 DNA Seq SEQ ID CDRL2 DNA Seq SEQ ID CDRL3DNASeq SEQ ID 1234 GCCAGTCAGAGTGTCGGTAACTCCTTA GCCTGG SEQ ID 1308 GGTGCGTCCAGTTTGCAG AGTGGG SEQ ID 1373 CAACGTGGCACCTGGCCT CCCCTCACTTTC SEQ ID 1235 GCCAGTCAGAGTATAACTAACTGGTTG GCCTGG SEQ ID 1309 AGGGCGTCTCGTTTAGAA AGTGGG SEQ ID 1374 CAGTATACTAATTACCCTC GTACGTTC SEQ ID 1236 GCCAGTCAGACTATTAATAGTTGGTTG GCCTGG SEQ ID 1310 GGTGCTTCCACCAGGGCC ACTGGC SEQ ID 1375 CAAAGTATACAGCTTCCG TGGACGTTC SEQ ID 1237 GCAAGTCAGGGCATTAGAAATGATTTA GGCTGG SEQ ID 1311 GGTGCATCCAGTTTGCAA AGTGGA SEQ ID 1376 CAATATAATAGTTATTCTC CCACTTTT SEQ ID 1238 GCAAGTCAGAGCATTAGCAGCTATTTA AATTGG SEQ ID 1312 GCTGCATCCAGTTTGCAC ACTGGG SEQ ID 1377 CACTATGGTCCCTCACGTC GGATCACCTTC SEQ ID 1239 TCCAGCCAGAGTGTTTTATACAGCTCC AACAATAAGAACTACATAGCTTGG SEQ ID 1313 GCTGCATCCACTTTGCAA AGTGGG SEQ ID 1378 CAGCATAATTCCTACCCTC GAACATTC SEQ ID 1240 GCCAGTCAGGGCATTAGCAGTTCTTTG GCCTGG SEQ ID 1314 GCTGCATCCACCAGGGCC ACTGGT SEQ ID 1379 CAGAGTTACAGTATTCCTC GAACGTTC SEQ ID 1241 GCCAGTGAGAGTGTTAATAGCAACTTC TTAGCCTGG SEQ ID 1315 GGTGCCTCCAGCAGGGCC GCTGGC SEQ ID 1380 CAATATTATTATATTCCTC GGACGTTC SEQ ID 1242 GCCAGTCAGAGTGTTGGCAGCAAATTA GCCTGG SEQ ID 1316 GCTGCATCCTACAGGGCC ACTGGC SEQ ID 1381 CAGTATGGTAGCTCATCC ATGTACACTTTT SEQ ID 1243 GCCAGTCAGAATGTTTACAGCAATTTC TTAGCCTGG SEQ ID 1317 AAGGTTTCTAACCGGTTG TCTGGG SEQ ID 1382 CAGTATGATAATCTCCCTC CTCTCACTTTC SEQ ID 1244 TCTAGTCAAAGTCTCGAACACGGTGAT GGAAACACGTACTTGAGTTGG SEQ ID 1318 GATGCATCCACCAGGGCC ACTGGT SEQ ID 1383 CAGTATAATAACTGGCCG CTCACTTTC SEQ ID 1245 TCTAGTCAGAGCCTCCTGCATAGTAAT GGAAACAACTATTTGGATTGG SEQ ID 1319 GGTACATCCACCAGGGCC ACTGGT SEQ ID 1384 CAGTATAATAGTTATTCGG GGACGTTC SEQ ID 1246 GCCAGTCAGAGTATTAGCAACAACTTA GCCTGG SEQ ID 1320 GGTGCATCCAGGAGGGC CACTGGC SEQ ID 1385 CAGTATAATAACTGGCCC CCGATCACCTTC SEQ ID 1247 GCCAGTCAGAGTGTTAGCAGCACCTCC TTAGCCTGG SEQ ID 1321 AAGATTTCTAACCGGTTC TCTGGG SEQ ID 1386 CAATATGGAACCTCACCG ATCACCTTC SEQ ID 1248 TCTAGTCAAAGCCTCGTATACAGTGAT GGAAACACGTACTTGAGTTGG SEQ ID 1322 GATGCATCCACCAGGGCC ACGGGA SEQ ID 1387 CAGTATAATAACTGGCCT CCCATCACCTTC SEQ ID 1249 TCTAATCAAAGCCTCGTATACAGTGAT GGAGGCACCTACTTGAATTGG SEQ ID 1323 AAGGTTTCTAAGCGGGAC TCTGGG SEQ ID 1388 CAAGGTATATACTGGCCT CGAACCTTC SEQ ID 1250 TCCAGCCAGAGTGTTTTATACAGAACC AACAATAAGAACTACTTGGCTTGG SEQ ID 1324 GACTCCAACAGGGCCACT GGC SEQ ID 1389 CAGCGTAGCAACTGGTCG CTCACTTTC SEQ ID 1251 GCCAGTCAGAGCATTGGGAGCAATTTA GCCTGG SEQ ID 1325 GAAGTTTCCAACCGGTTC TCTGGA SEQ ID 1390 CAAGGTCTACAAATCCCT ATCACTTTC SEQ ID 1252 TCTAGTCAAAGCCTCGTGTACAGTGAT GGAAACACCTACTTGTATTGG SEQ ID 1326 GGTGCCTCCACCAGGGCC ACTGCT SEQ ID 1391 CACTATAATAACTGGCCTC ATACCTTC SEQ ID 1253 GCCAGTCAGAGTGTTAGAGACAACGTA GGTTGG SEQ ID 1327 GCTGCCTCCACCAGGGCC ACTGGT SEQ ID 1392 CAGTATGGTAGCTCGTTC SEQ ID 1254 GCCAGTCAGACTATTGGTCCCAAGTCC TTCGGCTGG SEQ ID 1328 TTGGGTTCTAATCGGGCC TCCGGG SEQ ID 1393 CAGTATAATTTCTGGCCTT CGATCACCTTC SEQ ID 1255 TCTAGTCAGAGCCTCCTGCATAGTGAT GGAAAGACCTATTTGTATTGG SEQ ID 1329 GGTGCATCCTACAGGGCC ACTGGC SEQ ID 1394 CACTATGGTAGTTCACCTC CAATCACCTTC SEQ ID 1256 GCCAGTCAGAGTGTTAGTAGCAGCTTA GCCTGG SEQ ID 1330 AGTGCAACCTCTAGGGCC ACTGGA SEQ ID 1395 CAAGGTACACAATTTCCTC AAACGTTC SEQ ID 1257 GCCAGTGAAGGTCTTACCACCAACTTA GCCTGG SEQ ID 1331 AAGGTTTCTACCCGGTTC TCTGGG SEQ ID 1396 CAAGGGACACACTGGCCG TACACTTTT SEQ ID 1258 GCCAGTCAGAGTGTTAGCACCCTCTTA GCCTGG SEQ ID 1332 GCTGCATCCAGTTTGCAA AGTGGG SEQ ID 1397 CAATATTACAATCTTCCTC GATCTTTT SEQ ID 1259 GCCAGTCAGAGTGTTTTCAACAACTAC TTAGCCTGG SEQ ID 1333 GCTGCCTCCAATCTGCAC AGTGGC SEQ ID 1398 CAGCATGGTGAATGGCCC ACCTTC SEQ ID 1260 TCTAGTCAAAGCCTCGTATACAGTGAT GGAAACACCTACTTGAATTGG SEQ ID 1334 GATGTATCCACCAGGGCC ACTGAT SEQ ID 1399 CAAGGTAGACACTGGCCG TACACTCTT SEQ ID 1261 TCTAGTCAGAGCCTCCTACATAGTAGT GGATACAACTATTTGGATTGG SEQ ID 1335 AAGGCGTCTACTATAAAA AGTGGG SEQ ID 1400 CAGTTTAATAATTGGCCTT ACACTTTT SEQ ID 1262 TCTAGTCAGAGCCTCCTGAATAGTAAT GGATACAACTATTTGGAGTGG SEQ ID 1336 GCTGCGTCCAATTTGCAA AGTGGG SEQ ID 1401 CAGCGTAGCAGGTGGCCT CTCACTTTC SEQ ID 1263 GCCAGTCAGAGTGTTACCAGCAACTAC TTAGCCTGG SEQ ID 1337 TGGGCATCTACCCGGGAA TCCGGG SEQ ID 1402 CAAAGTATACAGCTTCCG CTCACTTTC SEQ ID 1264 GCCAGTCAGAGTGTTAGCAGCAGCTCC TTAGCCTGG SEQ ID 1338 GGTGCATCCACCAGGGCC ACTGGC SEQ ID 1403 CAGTATGGTAGCTCACCC CCGGGCACTTTC SEQ ID 1265 GCCAGTCAGAGTATTGGCAGCAACTTA GTCTGG SEQ ID 1339 AAGGCGTCTACTTTAGCA AATGGG SEQ ID 1404 CGCTATGATAACTGGCCTC CCCTTTTT SEQ ID 1266 TCTAGTCAAAGCCTCGAACACACTGAT GGAAACACCTACTTAAGTTGG SEQ ID 1340 GGTGCATCCACCAGGGCC AGTGGC SEQ ID 1405 CAGTATAATCACTGGCCTC TCTACACTTTT SEQ ID 1267 GCAAGTCAGAGCATTAGCAACTATTTA AATTGG SEQ ID 1341 GATTCATCCAGCAGGGCC ACTGGC SEQ ID 1406 CAGGGTAGCAACTGGCCG CTCACTTTC SEQ ID 1268 CCAAGTCAGGACATAGGCACTTATTTA AATTGG SEQ ID 1342 GGTGCATCCAACAGGGCC ACTGGT SEQ ID 1407 CAAGGTACACACTGGCCT CGAACGTTC SEQ ID 1269 GCCAGTCAAAGTGTTAACAGCAACGTA GCCTGG SEQ ID 1343 GATGCATCCAGCAGGGCC ACTGGC SEQ ID 1408 CACCGTTACGTGTGGCCGT TCACTTTC SEQ ID 1270 GCCAGTCAGAGTGTTGGTACCAATTTA GCCTGG SEQ ID 1344 GATTCATCGAATAGGGCC ACTGGC SEQ ID 1409 CAGTATGGTAGTTCACCG ATCACCTTC SEQ ID 1271 GCCAGTCAGAGTATTAGTAGGTGGTTG GCCTGG SEQ ID 1345 GGTGCATCCAGCAGGGCC TCTGGC SEQ ID 1410 CAAGGTACACATTGGCCT CGGACTTTC SEQ ID 1272 GCGAGTCAGAACATTCGCCACTGGTTA GTCTGG SEQ ID 1346 TGGGCGTCTACCCGGGGG TCCGGG SEQ ID 1411 CAAGGTCTACAAATTCCG CTCACTTTC SEQ ID 1273 TCCAGCCGGAATATTTTATACAGCGGC AACAATAAAAACTTCTTGGCTTGG SEQ ID 1347 AAGGTTTCTAACCGGGAC TCTGGG SEQ ID 1412 CAGTCTCTACAAACTCCTC TCACTTTC SEQ ID 1274 GCCAGTCAGAGTATTAGCAGCACCTAC TTAGCCTGG SEQ ID 1348 GGTGCATCCAGCAGGGCC ACTGAC SEQ ID 1413 CAGTATGCTAGCTCAGTC ACCTTC SEQ ID 1275 GCCAGGCAGAGCATCAGTAACCGGTTG GCCTGG SEQ ID 1349 TATGCTTCCCAGTCCTTCT CAGGG SEQ ID 1414 CAGTATAATAACTGGCCT CCCTTCACCTTC SEQ ID 1276 GCCAGTGAGAGTGTTAGCAAGAGCTAC TTACTCTGG SEQ ID 1350 TGGGCATCTGCCCGGGAA TCCGGG SEQ ID 1415 CAGTATGGTAGCTCACAG ACCTTC SEQ ID 1277 GCCAGTCAGAGTGTTAGCAGCAGCGCC TTAGCCTGG SEQ ID 1351 GGTGCCTCCACCAGGGCC ACTGGT SEQ ID 1416 CAGTATGGTAGTTCACCTC CGACCACCTTC SEQ ID 1278 GCCAGTCAAAGTGTTACCAGCAACTTA GCCTGG SEQ ID 1352 GAGGTTTCTAAGCGGGAC TCTGGG SEQ ID 1417 CAGCGTAGCAACTGGCCG TGGACGTTC SEQ ID 1279 GCCAGTCAGAGTATTGGCACTTACGTC GCCTGG SEQ ID 1353 GAAGTTTCCAACCGATTC TCTGGA SEQ ID 1418 CAGGCTACACACTATCCTC GGACGTTC SEQ ID 1280 GCCAGTCAGAGTGTTAGCAGCAACTCC TTAGCCTGG SEQ ID 1354 GCTTCATCTACTTTGCAA TCAGGG SEQ ID 1419 CAGAGTTACATTACCCCGT GGACGTTC SEQ ID 1281 TCCAGCCAGAGTGTTTTATATGATTCC AACAGTAAGAACTACTTAAGTTGG SEQ ID 1355 AAGGCCTCTAGTTTAACA AGTGGG SEQ ID 1420 CAGAGTTACGGTCCTCGG ACATTC SEQ ID 1282 GCCAGTCAGAGTGTTAGTAGCTACTTA GCCTGG SEQ ID 1356 AAGGCGTCTAGTTTAGAA AGTGGG SEQ ID 1421 CAGTGTGCTAGCTCACCTC CTGTCACTTTC SEQ ID 1283 TCTTGTCAAAGCCTCGTATACAGTGAT GGCAACACCTACTTGAATTGC SEQ ID 1357 TTGGGTTCTACTCGGGCC TCCGGG SEQ ID 1422 CAGTATAATAACTGGCCT CCGATAACTTTC SEQ ID 1284 GCCAGTCAGAGTGTTAGCAGCAGCTAC TTAGGCTGG SEQ ID 1358 GGTGTTTCCACCAGGGCC ACTGGC SEQ ID 1423 CACTATAAAAGTGATTCC CGGACGTTC SEQ ID 1285 GCCAGTCAGAGCATTGGTGGTAGCTTA CACTGG SEQ ID 1359 ACTGCATCCAAAAGGGCC ACTGGC SEQ ID 1424 CAGCATAACAGTTACCCG TGGACGTTC SEQ ID 1286 TCCAGCCAGAGTGTTTTATACAGCTCC AACAATAAGAACTACTTAGCTTGG SEQ ID 1360 ATGGGTTCTAGTCGGGCC TCCGGG SEQ ID 1425 CAATATTATAGTACTCCGC TCACTTTC SEQ ID 1287 GCCAGTCAGAGTATTAGCAGCAACTTA GCCTGG SEQ ID 1361 GGTGCATCCAGCAGGGCC ACTGGC SEQ ID 1426 CAGTATGGTAGCTCACTCC TCTTC SEQ ID 1288 TCTAGTCATAGCCTCACAACTACTGAT GGACGTACTTACGTGGCTTGG SEQ ID 1362 GGTGCATCCACCAGGGCC ACTGGT SEQ ID 1427 CAGAGTAGTAGTTTACCTC ACACTTTC SEQ ID 1289 TCTAGTCAGAGCCTCCTGGGTGGTGAT GGAAAGACCTATTTGTATTGG SEQ ID 1363 GAGGTTTCTAACCGGGAC TCTGGT SEQ ID 1428 CAGTATGGTAACTCACCTC CGGGAGCCACCTTC SEQ ID 1290 GCGAGTCAGGGCATTGCCAATTATTTA GCCTGG SEQ ID 1364 GGCGCATCCAACAGGGC CACAGGC SEQ ID 1429 CAGTATCAAAGTTACTGG ACGTTC SEQ ID 1291 GCCAGTCAGAGTATTACTACCTGGTTG GCCTGG SEQ ID 1365 GATGCGTCCAGCAGGGCC GAAGGC SEQ ID 1430 CACTATGGCAGCTCTCGC ACCTTC SEQ ID 1292 GCCAGTCAGAGTATTAGTAGCTGGTTG GCCTGG SEQ ID 1366 CGTGCATCCAGCAGGGCC ACTGGC SEQ ID 1431 CAGTTTAATACCTACCCCA ACACTTTT SEQ ID 1293 GCCAGTCAGAGTGTTAATAGCGGCTAC TTAGCCTGG SEQ ID 1367 TCTACATCGACTTTACAA AGTGGA SEQ ID 1432 CAGTATGGTAGCTCACCT GCGCTCACTTTC SEQ ID 1294 GCCAGTCACAGTGTTGGCGCCAACTAC ATAGCCTGG SEQ ID 1368 TGGGCATCTACCCGGGAC TCCGGG SEQ ID 1433 CAGTATGGTAGTCCACCTC CGACCACCTTC SEQ ID 1295 TCTAGTCAGAGCCTCCTGCATAGTAAT GGATACAACTATTTGGATTGG SEQ ID 1369 GATGCATCCAACAGGGCC ACTGGC SEQ ID 1434 CAGTATGGTAGCTCACCTC GGGTCACTTTC SEQ ID 1296 GCCAGTCAGAGTGTTAGCAGCAACTTA GCCTGG SEQ ID 1370 CGTGCATCCACCAGGGCC GCTGGT SEQ ID 1435 CAGCGTGCCGAGTGGCCT CTCACCTTC SEQ ID 1297 GCCAGTCAGAGTGTAATAAGCAGGTAC TTAGCCTGG SEQ ID 1371 GATGCATCCAATTTGGAA ACAGGG SEQ ID 1436 CAGTATGGTAGCTCACGT CGGACGTTC SEQ ID 1298 TCTAGTCAAAGCCTCGTACACAGTAAT GGACACACCTACTTGAGTTGG SEQ ID 1372 TTGGGTTCTAATCGGGCC CCCGGG SEQ ID 1437 CAGTATGGTAGCTCAGGG TACACTTTT SEQ ID 1299 GCCAGTCAGAGTGTTAGCAGCAGCTAC TTAGCCTGG SEQ ID 1438 CAGTATGGTAACTCACAG ACCTTC SEQ ID 1300 GCCAGTCAGAGTTTAAGTACCAACTTA GCCTGG SEQ ID 1439 CAATTTTATGGTATTCCCC ACTTC SEQ ID 1301 GCCAGTCAGAGTATTAGCGGCAGTTAC TTAGCCTGG SEQ ID 1440 AAGTATAACAGTCCCCCT CGGACGTTC SEQ ID 1302 GCCAGTCAGAGTCTTACCAGCAGCTAC TTAGCCTGG SEQ ID 1441 CAAGGTCTACAAACTCCA TTCACTTTC SEQ ID 1303 TCCAGCCAGGCCCTGCGAAATGTTGTC GGCCTTGGCGATGATTTAGCCTGG SEQ ID 1442 CAGCGTAGCAACTGGCCT TTCTTC SEQ ID 1304 TCCAACCGGAGTGTTTTATACAGCCCC AACAATCAGAACTACTTAGGTTGG SEQ ID 1443 CAGTATGGTATCTCACCTC TCGCGTTC SEQ ID 1305 GCCAGTCAGAGTGTTAGCAGCTACTTA GCCTGG SEQ ID 1444 CAGAGTATCAGTTTACCG CTCACTTTC SEQ ID 1306 GCCAGTCAGAGTGTTGGCAGCGACTTA GCCTGG SEQ ID 1445 CAATTTTATAGTCCTCCTC GGACGTTC SEQ ID 1307 GCCAGTCAGAGTATTAGTAGCTGCTTG GCCTGG SEQ ID 1446 CAGTATAATAACTGGCCT AGAACGTTC SEQ ID 1447 CAAGGAACACATGGGCCT CACACGTTC SEQ ID 1448 CAATCTACACAATTTCCGT GGACGTTC SEQ ID 1449 AAGTATAACAGTGTCCCT CTCACTTTC SEQ ID 1450 CATTATAATGGTGCTTCTC GTATGTTC SEQ ID 1451 CAGTATAATAGTTATTGG ACGTTC SEQ ID 1452 CAAGCTCTACACACTCCGT GGACGTTC SEQ ID 1453 CAGTATAATAGTTATTCAA GGACGTTC SEQ ID 1454 CAGTATGGTAGCTCACTC AGGTACACTTTT SEQ ID 1455 CAGTATAATAACTGGCCT CGGTTC SEQ ID 1456 GAGTATGGTAACTCAGCT ATGTACAATTTT SEQ ID 1457 CAGTATAATAACTGGCCT CTCACTTTC SEQ ID 1458 CAGTATGCTGCCGCACCG ATTACCTTC SEQ ID 1459 CAAACTTTACACACTGTCA CTTTC SEQ ID 1460 CAGTATGGTAGCTCACCC CGGATCACCTTC SEQ ID 1461 CAGTATAATAACTGGCCC CGGACGTTC SEQ ID 1462 CAGTATAATAACTGGCCT CCTATGTACACTTTT SEQ ID 1463 CAGTATGGTAGCTCACCTC CGTACACTTTT SEQ ID 1464 CAAACTCTTCAAACTCCGC TCACTTTC SEQ ID 1465 CAAGGAACACACTGGCCC CCCCTCACTGTC SEQ ID 1466 CAGTATGGAAGCTCACCG GGAACGTTC SEQ ID 1467 CAGTATCATAACTGGCCTC CGTACACTTTT SEQ ID 1468 CAATATTATAGTAGTACTC CGTACACTTTT SEQ ID 1469 CAGTATGGTAGCTCACCA ATATTCACTTTC SEQ ID 1470 CAGTATGGTAGTTCACCTA ACACCTTC SEQ ID 1471 CAGCACCATGATTTCCCTT TCACTTTC SEQ ID 1472 CAGCGTTACAACTGGCCT ATCACCTTC SEQ ID 1473 CAATATGCAAGTACTCCA TACACTTTT SEQ ID 1474 CAGCGTAGCAACTGGCCT CGGACGTTC SEQ ID 1475 CAGTATGGTAGATCACCG TACACTTCT SEQ ID 1476 CAGTTTGATAATGTCCCAG TCACTTTC SEQ ID 1477 CAGCTTAATAGTTACCCTC AGACGTTC SEQ ID 1478 CAAGCTCTACAAACTCCG TACACTTTT SEQ ID 1479 CAGTATAATAACTGGCCT CCGATCACCTTC SEQ ID 1480 CAAGCTCTACAAACTCGG ACATTC

[171] In some embodiments, a nucleotide sequence encoding an antibody, antibody fragment, VH domain, VL domain or CDR of the disclosure is a wild type sequence. In some embodiments, the nucleotide sequence is codon optimized for expression in mammalian cells. In some embodiments, the nucleotide sequence is codon optimized for expression in human cells.

[172] In some embodiments, the invention relates to an antibody that is capable ofbinding to CLEC2D and that blocks the interaction between CLEC2D and CD161 (FIG. 1). In some embodiments, the anti-CLEC2D antibody as disclosed herein, is a monoclonal antibody. In some embodiments, the anti-CLEC2D antibody as disclosed herein, is a polyclonal antibody.

[173] In some embodiments, the invention relates to an antibody that is capable ofbinding to CLEC2D and that blocks the interaction between CLEC2D and CD161, which is capable of removing CLEC2D-expressing cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC) and / or by complement-dependent cytotoxicity (CDC). In some embodiments, the invention relates to an antibody that is capable ofbinding to CLEC2D and that blocks the interaction between CLEC2D and CD161, that is capable of stimulating the cytokine production and the cytotoxicity mediated by NK cells.

[174] In some embodiments, the anti-CLEC2D antibody as disclosed herein, is a humanized antibody. In some embodiments, the anti-CLEC2D antibody as disclosed herein, is of human IgG1, IgG1 N296A, IgG2 , IgG3 or IgG4 isotype. In some embodiments, the anti-CLEC2D antibody is a mouse IgG1, IgG2a, IgG2b or IgG3 isotype.

[175] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100 % identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-108.

[176] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) comprising an amino acid sequence having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100 % identity to an amino acid sequence selected from the group consisting of SEQ ID NOs. 217-324.

[177] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100 % identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-108; and a variable light chain (VL) comprising an amino acid sequence having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100 % identity to an amino acid sequence selected from the group consisting ofSEQ ID NOs: 217-324.

[178] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 109-216.

[179] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) comprising an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 325-432.

[180] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 109-216; and a variable light chain (VL) comprising an amino acid sequence encoded by a nucleic acid selected from the group consisting ofSEQ ID NOs: 325-432.

[181] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence selected from the group consisting ofSEQ ID NOs: 1-108.

[182] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) comprising an amino acid sequence selected from the group consisting ofSEQ ID NOs:217-324.

[183] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-108, and a variable light chain (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 217-324.

[184] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO 44and a VL comprising an amino acid sequence according to SEQ ID NO: 260.

[185] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:45, and a VL comprising an amino acid sequence according to SEQ ID NO:261.

[186] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:42, and a VL comprising an amino acid sequence according to SEQ ID NO: 258.

[187] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:1, and a VL comprising an amino acid sequence according to SEQ ID NO: 217.

[188] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:73, and a VL comprising an amino acid sequence according to SEQ ID NO:289.

[189] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:21, and a VL comprising an amino acid sequence according to SEQ ID NO:237.

[190] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:35, and a VL comprising an amino acid sequence according to SEQ ID NO:251.

[191] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:58, and a VL comprising an amino acid sequence according to SEQ ID NO: 274.

[192] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:7, and a VL comprising an amino acid sequence according to SEQ ID NO:223.

[193] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a Variable heavy chain (VH) complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 433-485.

[194] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a Variable heavy chain (VH) complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 486-546.

[195] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a Variable heavy chain (VH) complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 547-653.

[196] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 654-726.

[197] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 727-783.

[198] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 784-885.

[199] In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a Variable heavy chain (VH) complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 433-485, a VH complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 486-546, and a VH complementarity determining region 3 (CDR3) comprising a...

Claims

1. An isolated anti-CLEC2D antibody or antigen-binding fragment thereof comprising aheavy chain variable domain (VH) and a light chain variable domain (VL), wherein the antibody or antigen-binding fragment thereof comprises:a) a VH comprising complementarity determining regions (CDR) CDR1, CDR2, and CDR3 of SEQ ID NOs: 433, 486, and 547, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 654, 727, and 784, respectively;b) a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 439, 492, and 590, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 688, 755, and 828, respectively;c) a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 439, 492, and 589, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 687, 729, and 827, respectively;d) a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 466, 521, and 603, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 662, 732, and 814, respectively; ore) a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 439, 492, and 553, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 660, 733, and 790, respectively.

2. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein theantibody or antigen-binding fragment thereof comprises a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 433, 486, and 547, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 654, 727, and 784, respectively, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence at least 90% identical to SEQ ID NO: 1, and a VL amino acid sequence at least 90% identical to SEQ ID NO:217, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence of SEQ ID NO: 1, and a VL amino acid sequence of SEQ ID NO:217, and optionallywherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 1481, 1913, 2129, or 2345, and the light chain comprises an amino acid sequence of SEQ ID NO:1589.2020222891   17 Jun 20263.     The isolated antibody or antigen-binding fragment thereof of claim 1, wherein theantibody or antigen-binding fragment thereof comprises a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 439, 492, and 590, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 688, 755, and 828, respectively, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence at least 90% identical to SEQ ID NO: 45, and a VL amino acid sequence at least 90% identical to SEQ ID NO:261, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence of SEQ ID NO: 45, and a VL amino acid sequence of SEQ ID NO:261, and optionally wherein the heavy chain comprises an amino acid sequence of SEQ ID NO:1525, 1957, 2173, or 2389, and the light chain comprises an amino acid sequence of SEQ ID NO:1633.

4. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein theantibody or antigen-binding fragment thereof comprises a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 439, 492, and 589, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 687, 729, and 827, respectively, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence at least 90% identical to SEQ ID NO: 44, and a VL amino acid sequence at least 90% identical to SEQ ID NO:260, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence of SEQ ID NO: 44, and a VL amino acid sequence of SEQ ID NO:260, and optionallywherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 1524, 1956, 2172, or 2388, and the light chain comprises an amino acid sequence of SEQ ID NO:1632.

5. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein theantibody or antigen-binding fragment thereof comprises a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 466, 521, and 603, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 662, 732, and 814, respectively, optionally2020222891   17 Jun 2026wherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence at least 90% identical to SEQ ID NO: 58, and a VL amino acid sequence at least 90% identical to SEQ ID NO:274, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence of SEQ ID NO: 58, and a VL amino acid sequence of SEQ ID NO:274, and optionallywherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 1538, 1970, 2186, or 2402, and the light chain comprises an amino acid sequence of SEQ ID NO:1646.

6. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein theantibody or antigen-binding fragment thereof comprises a VH comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 439, 492, and 553, respectively, and a VL comprising CDR1, CDR2, and CDR3 of SEQ ID NOs: 660, 733, and 790, respectively, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence at least 90% identical to SEQ ID NO: 7, and a VL amino acid sequence at least 90% identical to SEQ ID NO:223, optionallywherein the antibody or antigen-binding fragment thereof comprises a VH amino acid sequence of SEQ ID NO: 7, and a VL amino acid sequence of SEQ ID NO:223, and optionallywherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 1487, 1919, 2135, or 2351, and the light chain comprises an amino acid sequence of SEQ ID NO:1595.

7. The isolated antibody or antigen-binding fragment thereof of any one of claims 1-6,wherein the antibody is afucosylated.

8. The isolated antibody or antigen-binding fragment thereof of any one of claims 1-7,wherein the antibody comprises an IgG1 Fc region, an IgG2 Fc region, an IgG4 Fc region, or an IgG1 Fc region comprising an N297A substitution.

9. The isolated antibody or antigen-binding fragment thereof of any one of claims 1-8,wherein:2020222891   17 Jun 2026the antibody or antigen-binding fragment thereof recognizes and binds to conformational epitope of CLEC2D antigen, comprised of amino acids positions overlapping and / or nonoverlapping with CD161 receptor interacting amino acid residues,the antibody or antigen-binding fragment thereof comprises a variable heavy chain sequence and a variable light chain sequence, that inhibit or abrogate or compete with another antibody that recognizes and binds to conformational epitope of CLEC2D antigen, comprised of amino acids positions either overlapping and / or non-overlapping with CD161 receptor interacting amino acid residues,the antibody or antigen-binding fragment thereof comprises a variable heavy chain sequence and a variable light chain sequence that bind to conformational epitope of CLEC2D antigen comprising any of the amino acid positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 or a combination thereof of SEQ ID NOs: 886-920 and 930-1003,the antibody or antigen-binding fragment thereof comprises a variable heavy chain sequence and a variable light chain sequence that inhibit or abrogate or competes with, the binding of another antibody to conformational epitope of CLEC2D antigen comprising any of the amino acid positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 or a combination thereof of SEQ ID NOs: 886-920 and 930-1003,the antibody or antigen-binding fragment thereof comprises a variable heavy chain sequence and a variable light chain sequence that bind to conformational epitope of CLEC2D antigen comprising at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-920 and 930-1003, constituting non-linear scaffolds for CD161 receptor interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors,the antibody or antigen-binding fragment thereof comprises a variable heavy chain sequence and a variable light chain sequence that bind to conformational epitope of CLEC2D2020222891   17 Jun 2026antigen comprising at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-920 and 930-1003, constituting allosteric and non-linear scaffolds for CD161 receptor non-interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors, orthe antibody or antigen-binding fragment thereof comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-920 and 930-1003, bind to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, independently or in combination to induce tumour killing or cytotoxicity.

10. A bispecific antibody comprising:the VH and the VL of the antibody or antigen-binding fragment thereof of any one of claims 1-9 that binds to CLEC2D, anda VH and a VL of an antibody or antigen-binding fragment thereof that binds to a second antigen, optionally wherein the second antigen is an immune checkpoint protein or a tumor antigen.

11. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1-9, or the bispecific antibody of claim 10, and a pharmaceutically acceptable excipient.

12. An isolated nucleic acid comprising a polynucleotide sequence that encodes the isolated antibody or antigen-binding fragment thereof of any one of claims 1-9 or the bispecific antibody of claim 10.

13. An expression vector comprising the isolated nucleic acid of claim 12.2020222891   17 Jun 202614. A host cell comprising the isolated nucleic acid of claim 12 or the expression vector of claim 13, wherein the cell is a eukaryotic cell.

15. Use of the isolated antibody or antigen-binding fragment thereof of any one of claims 19, the bispecific antibody of claim 10, or the pharmaceutical composition of claim 11, in the manufacture of a medicament for treating a cancer, modulating the activation of an immune response, increasing the cytotoxicity of a natural killer cell, or eliciting anti-tumour response in a subject in need thereof, wherein the cancer expresses CLEC2D.

16. A method of treating cancer, the method comprising administering a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof of any one of claims 1-9, the bispecific antibody of claim 10, or the pharmaceutical composition of claim 11, to a subject in need thereof, wherein the cancer expresses CLEC2D.

17. A combination therapy comprising the antibody or antigen-binding fragment thereof of any one of claims 1-9, the bispecific antibody of claim 10, or the pharmaceutical composition of claim 11, and an adoptive cell therapy comprising a chimeric antigen receptor T cell (CAR-T) or a chimeric antigen receptor NK cell (CAR-NK) directed against a second antigen.

18. An antibody library comprising at least about 108 unique monoclonal antibody clones, wherein the antibody library comprises an isolated antibody or antigen-binding fragment thereof of any one of claims 1-9, and wherein at least about 80% of the antibody clones detectably and specifically bind a CLEC2D antigen.

19. A method of screening a high diversity antibody gene library for antibodies that bind to a CLEC2D antigen, comprising:a) inserting a library of antibody genes into a phage protein gene and transforming a plurality of phages to produce a phage library, wherein the phages in the phage library display the library of antibody genes on the surface of the phages;2020222891   17 Jun 2026b) panning the phage library with a CLEC2D antigen for individual phages that bind to the CLEC2D antigen, thereby producing an enriched phage library that is enriched for antibody genes that encode antibodies that bind to the CLEC2D antigen;c) repeating step (b) at least once or at least twice;d) transferring the antibody genes from the enriched phage library to a yeast surface display library;e) isolating individual yeast cells that bind to the CLEC2D antigen from the yeast surface display library;f) culturing the isolated individual yeast cells that bind to the CLEC2D antigen to produce yeast surface display library clones; andg) sequencing the yeast surface display library clones;thereby isolating antibody genes that bind to the CLEC2D antigen,wherein the antibody genes comprise the amino acid sequence of the isolated antibody or antigen-binding fragment thereof of any one of claims 1-9.

20. A method of making a composition comprising an anti-CLEC2D antibody or antigenbinding fragment thereof, comprisinga) transforming mammalian cells with a vector comprising a sequence encoding a promoter and a sequence encoding an anti-CLEC2D antibody or antigen-binding fragment thereof, wherein the sequence encoding the promoter and the anti-CLEC2D antibody or antigenbinding fragment thereof are operably linked;b) culturing the mammalian cells under conditions suitable for the expression of the anti-CLEC2D antibody or antigen-binding fragment thereof; andc) obtaining the anti-CLEC2D antibody or antigen-binding fragment thereof from the cultured mammalian cells to produce a supernatant,wherein the anti-CLEC2D antibody or antigen-binding fragment thereof comprises the isolated antibody or antigen-binding fragment thereof of any one of claims 1-9.

21. Use of the isolated antibody or antigen-binding fragment thereof of any one of claims 19, the bispecific antibody of claim 10, or the pharmaceutical composition of claim 11, in the2020222891   17 Jun 2026manufacture of a medicament for treating a cancer in a subject in need thereof, wherein the subject has an aberrant or differential cellular expression of CLEC2D.

22. A method of treating a cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof of any one of claims 1-9, the bispecific antibody of claim 10, or the pharmaceutical composition of claim 11, wherein the subject has an aberrant or differential cellular expression of CLEC2D.

23. The use of claim 21 or the method of claim 22, wherein the isolated antibody or antigenbinding fragment thereof is in combination with an immune checkpoint inhibitor for treating cancer, an autoimmune disorder, or an inflammatory disorder in a subject in need thereof,optionally wherein the immune checkpoint inhibitor is selected from the group consisting of PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, TIM-3 inhibitors, and LAG-3 inhibitors, and optionally wherein:a) the PD-1 inhibitor is selected from the group consisting of Pembrolizumab, Nivolumab, and Cemiplimab;b) the PD-L1 inhibitor is selected from the group consisting of Atezolizumab, Avelumab, and Durvalumab;c) the CTLA-4 inhibitor is Ipilimumab; and / ord) the antibody is a bispecific antibody comprising a first specificity for CLEC2D and a second specificity for an immune checkpoint protein, for use in treating cancer, optionally wherein the immune checkpoint protein is selected from PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, TIGIT, OX40, CD137, or GITR, and optionallyfurther in combination with an adoptive cell therapy comprising a CAR-T cell or CAR-NK cell directed against the second antigen.

24. The use or method of any one of claims 15 or 21-23, wherein the cancer is selected from non-small cell lung cancer, melanoma, breast cancer, gastric cancer, prostate cancer, renal cell carcinoma, colorectal cancer, pancreatic cancer, lymphoma, urothelial cancer, or head and neck 9142020222891   17 Jun 2026squamous cell carcinoma.

25. The use or method of any one of claims 15 or 21-24, further in combination with at least one additional anti-cancer therapy selected from the group consisting of chemotherapeutics, targeted small molecules, cancer vaccines, adoptive cell therapies, and oncolytic viruses, optionally wherein the chemotherapeutic is selected from the group consisting of taxanes, platinum-based drugs, antimetabolites, and alkylating agents.

26. The use or method of any one of claims 23-25, wherein the autoimmune or inflammatory disorder is selected from rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, Sjogren’s syndrome, type 1 diabetes, autoimmune uveitis, and autoimmune thyroiditis.

Images